ANNUAL REPORT !"

MACFARLANE BURNET INSTI TUTE FOR MEDI CAL R ESEARCH AND PUB L I C H EALTH

page ! # Chairman’s Report INSIDE$ Director’s Report % Board of Directors & Patrons !' Burnet Institute’s new building !" Centre for Virology "' Centre for Immunology "$ Centre for Population Health (" Centre for International Health #' Corporate and Support Services 45 Where we work #$ Commercialisation #) Summary of income and expenditure #% Education and capacity building program *' Committee members *! Governance statement *# Our achievements )* In appreciation )8 Our organisational structure )& How you can support the Burnet Institute

Director: Brendan Crabb, BSc(Hons) PhD Deputy Directors: P Mark Hogarth, PhD; David Anderson, BSc(Hons), PhD Company Secretary: Peter Spiller, BBus, CPA

Cover: A live Plasmodium falciparum parasite (green), the cause of human malaria, inside a human red blood cell. Image taken at the "''% Burnet Institute DeltaVision RT High Resolution Microscope Workshop with thanks to Dr Tom Hope, Dr Candida da Fonseca Pereira, Dr Jenny Anderson and Dr Gilda Tachedjian. Parasites provided by Dr Paul Gilson and Tana Taechalertpaisarn. Photo Credits: Campbell Aitken, Jenny Anderson, Marion Brown, Gillian Chamberlain, Melissa Churchill, Helen Cox, Michael Desmond, Rod Escombe, Mary Garcia, Paul Gorry, Ian Haigh, Wendy Holmes, Chad Hughes, Gabriella Khoury, Rachel Lenders, Bruce Loveland, Johnson Mak, Amanda Morgan, Les O’Rourke, Paul Ramsland, Gilda Tachedjian, Koman Tam, Mike Toole, Zomkyi. Editorial Managers: Gillian Chamberlain, Tracy Routledge Design: Motion Print: Southern Colour The cost of preparing and printing this Annual Report has been generously donated to the Burnet Institute by an anonymous donor.

page " Our Vision and Mission Our Values

The unifying vision of all health, medical research and We are passionate in our commitment to working and growing development undertaken at the Burnet Institute is the linking together to create a healthier world. We value excellence, of laboratory and field research with practical public health innovation and social justice, and share a desire to extend the programs; with an emphasis on addressing the health needs boundaries of knowledge and understanding. of disadvantaged populations.

To achieve this vision, Burnet’s mission is to create a healthier INSIDE world by utilising our unique skills in infectious diseases, immunology and public health to produce health outcomes such as vaccines for infectious diseases and cancer, better strategies for the treatment and prevention of infection, and innovative public health programs both in Australia and throughout the world, especially in our region.

Burnet’s broad mission embraces all facets of its research and development work – from basic laboratory research and discovery through to clinical trials, public health, treatment and prevention, advocacy and policy development – and allows the Institute to develop unique cross-disciplinary programs to respond to the major global health problems of our time. The broad mission allows Burnet to be proactive in leading Australia’s and our region’s preparedness and responsiveness to the threat of emerging diseases, such as avian and swine influenza, while continuing to address long- term health priorities. These include: developing hepatitis C, HIV and cancer vaccines; novel treatment strategies and diagnostics for HIV, hepatitis, tuberculosis and malaria; understanding the pathogenesis of infectious diseases; and undertaking advocacy, capacity building and policy development in the international health arena.

page ( I am sure many of you reading this report are very well aware international funders. Burnet has improved its financial position that the Burnet Institute takes its name from one of Australia’s through increased infrastructure funding from the Victorian State greatest scientists, Sir Frank Macfarlane Burnet. His legacy to Government through the Department of Industry Innovation and us is a name that identifies the activities of the Burnet Institute Regional Development, and research funding through the Federal – addressing issues of infectious disease and immunity for the Government’s National Health and Medial Research Council, for benefit of the world’s most disadvantaged people. which we are most grateful. This increased level of funding is a strong indicator of Burnet’s innovative and translational approach The great scientist who lent us his name once expressed a belief to laboratory research and public health activity. In addition, that, with the advent of modern vaccines, infectious diseases as an accredited non-government organisation, the Institute could be beaten for all mankind. Of course this proved true for receives substantial funding for our international health programs some diseases; however for others, elimination remains a distant hope. through AusAID.

As I write, the world is gripped by two crises – the much-written- I would like to congratulate Professor Brendan Crabb on his about financial crisis but more recently a dramatic new outbreak first year as Director and CEO of the Institute. Brendan has of influenza. It is too early to say that what is clearly an epidemic demonstrated strong leadership over this period, beginning in Mexico is a worldwide pandemic. However, it appears that with a reorganisation of Burnet’s scientific and public health swine flu is a new strain of influenza which has the capacity programs into four centres of excellence: Virology; Immunology; for human-to-human infection. Nothing demonstrates more Population Health; and International Health. This reorganisation clearly the need for Australia to have, in the Burnet Institute, an represents Burnet’s key areas of research and public health organisation with a capacity to tackle infections in our region. strength, and is led by the Institute’s most experienced and In "''&, notwithstanding the continual medical progress made highly credentialed staff. In addition, four cross-functional units by research organisations globally, including Burnet, the world have been formed which work across these centres and focus is still confronted with a variety of new infectious diseases (for on Infectious Diseases; Vaccines, Diagnostics and Therapeutics; example, HIV affects (( million worldwide, and hepatitis C affects Disease Prevention and Education; and Capacity Building. This "'' million, and have both arisen in the last "* years), and reorganisation will enable the Institute to further progress its perennial killers such as malaria, tuberculosis and cholera. global mission of reducing the impact of infectious diseases and cancer. I am delighted to present this Annual Report to you, which highlights the outstanding achievements of the Burnet Institute I am delighted to report that the development of Burnet’s new over the past !" months. I am also pleased to present a new look building, currently under construction above the Alfred Centre, for the Institute in the form of a new logo. The Institute’s new look is on track for completion in "'!'. This $&' million project has been designed to highlight our mission to improve global represents an outstanding achievement for the Institute and is a health, combining world-class laboratory research with practical reflection of the hard work and dedication of a remarkable team frontline health programs across our region. It is also the final from Burnet and its AMREP partners. This is a significant financial step in the merger of the former Austin Research Institute with commitment and is currently being offset by a major fundraising the Burnet Institute reflecting the unification of two outstanding campaign. This new development will enhance the Institute’s organisations. The launch of the new logo in May "''& will ability to progress its laboratory-based research and public coincide with the relocation of the Austin campus staff to join health programs to a much greater capacity. their colleagues at the Alfred Medical Research and Education Burnet’s international presence continues to expand and we Precinct (AMREP) in Prahran, Melbourne. have recently opened regional offices in Bangkok and Suva, Burnet is well positioned despite the current financial crisis. increasing the Institute’s ability to support our country offices However we are not totally immune from the impact of the global and build stronger relationships with other NGOs and funding downturn. Like many other organisations, Burnet has noted a bodies operating within the South East Asia and Pacific regions. reduced level of funding available from some granting bodies I must also congratulate the staff of the Centre for International and private philanthropic sources; and fluctuating exchange Health for the outstanding role they played, and continue to play, rates have also impacted on the value of grants received from in Myanmar post Cyclone Nargis. Burnet’s long-term presence in

Chairman’s Report

page # Myanmar and the networks that our staff have developed have I would also like to take this opportunity to recognise the enabled the Institute to establish a Resource Centre for local enormous and lasting contribution to Burnet made by the late community groups to source funding in response to this disaster. Richard Pratt. Mr Pratt donated the funds needed to establish the Institute "" years ago. Without his generosity, Burnet would One of the major advantages of being located at AMREP is the not exist and the Institute honours his memory. Finally, I must ability to foster close working relationships with the other AMREP congratulate and thank the staff of the Burnet Institute for a most partners. Not only do these relationships result in collaborative successful year of research and public health endeavour. I do not research programs, they also reduce operating costs through know of an organisation that has such a talented and dedicated the sharing of facilities and resources. Over the past year Burnet group of scientists, public health professionals and support staff. has strengthened its ties with The Alfred hospital, Baker IDI and I look forward to the coming year with enthusiasm, confident that Monash University through the joint animal house facility and with their continued dedication and confidence our contribution shared imaging service. Now in association with Baker IDI, Burnet to humanity will grow and develop even further. is collaborating internationally in Fiji and Alice Springs on joint public health initiatives.

I would like to acknowledge and thank the members of the Board who over the past year have made a significant contribution to the Institute both in time spent attending meetings and serving on various board committees. I sincerely thank them for their guidance and advice. The financing and design development Alastair Lucas of the new building has been an exhausting task and Board Chair members have given up many weekends and late nights for committee meetings and teleconferences. Thank you!

There were a number of changes to the Board in "''%. I would like to thank Dr Tracey Batten and Mr Ian Wightwick for their support and outstanding contributions to the Board. Tracey served as a valuable member of the Intellectual Property and Commercialisation Committee providing significant counsel and advice. As Chair of the former Austin Research Institute Board, Ian was instrumental in ensuring the success of the merger with the Burnet Institute in "''$. He also made a substantial contribution as a member of the Intellectual Property and Commercialisation Committee. To Tracey and Ian, thank you. I also take this opportunity to welcome to the Board Dr Alan Finkel AO, Chancellor of Monash University, Mr Henry Lanzer, Managing Partner of Arnold Bloch Leibler and Ms Natasha Stott Despoja, former Senator for South Australia.

Critical to the Institute’s success are the donors and in-kind supporters who provide the much-needed funds and services that ensure that we can continue to improve the quality of the health of millions of people around the world. It enables us to provide innovative solutions to major health challenges faced by many of the disadvantaged and marginalised communities with whom we work. I know I speak for the Board and all staff at the Institute in thanking you for your continued support.

page * It is with great pleasure that I write this report, my first as Director. The next phase of Institute development will involve changes What a remarkable year of transformation for the Institute. In to our Corporate and Support Services arm. This is underway reading the pages ahead, it might appear as though we are with the appointment of the Institute’s first Chief Operating becoming a new and different Institute to the one you may have Officer, Geoff Drenkhahn. Geoff is well known to staff from his known over the past "" years. To a degree this is true, as we former position as the Deputy Director of the Institute’s Centre have suddenly grown into a diverse organisation comprising for International Health (CIH). His varied role influences much of nearly #'' staff and students. However, while some things are the Institute’s operations and he has already made a significant changing, others remain the same. The most important of which contribution, most notably overseeing much of the work on the is that in "''% the Burnet’s core mission of addressing the new building. health needs of Australia and the world’s most disadvantaged It was a fabulous year for our research and public health populations through a combination of research and public health programs. Burnet’s international health programs continue to programs, has been reinforced. This mission, and the culture of expand and prosper, for example in China with the ongoing excellence, compassion, community involvement and public good success of the Burnet Institute managed China-Australia Health that underpins it, defines our organisation. and HIV/AIDS Facility (CAHHF). This $(!.% million program aims Perhaps the most momentous achievement of the past year is to strengthen China’s health systems, protect its population the commencement of our new building at the AMREP campus. against emerging infectious diseases and halt and reverse the This project, a very significant mark in the history of the Burnet spread of HIV in this vast country. In response to Cyclone Nargis Institute, completes the "''$ merger with the Austin Research our program in Myanmar has dramatically expanded in both Institute – allowing staff from our Austin campus to join those in scale and scope. Our work to improve health in resource poor Prahran, working together in the one precinct. countries, particularly Papua New Guinea (PNG), Indonesia, Lao PDR and Mozambique, is also progressing well. The Institute’s Another major event this year was the restructure of the Institute’s Centre for International Health (CIH) is now one of the nation’s operations into four Centres of Excellence. These Centres largest global health centres with approximately !%' staff, !(' consolidated our major areas of activity and provided a strong of whom are employed overseas. In "''%, CIH incorporated leadership framework to better realise synergies and ways to our Centre for Harm Reduction, a move aimed at incorporating build capacity. This new structure is designed to provide an the principles of harm reduction into our wider public health environment that promotes bigger and better research programs activities, particularly our HIV prevention programs. and allows our staff to flourish. I am very grateful for the support, leadership and commitment of the newly-appointed Centre Much was also achieved in research in "''%. It was a stellar Heads; Suzanne Crowe (Virology), Mark Hogarth (Immunology), year for publications, where both quality and quantity reached Margaret Hellard and John Reeder (Population Health) and Mike record levels. The Institute published !!% peer-reviewed papers Toole (International Health). including publications in some of the world’s best scientific journals such as Nature, The New England Journal of Medicine An important part of the restructure was the recognition of and The Lancet. It was also a record year for the awarding of four major themes that cut across the specific disciplines competitive grants and fellowships, especially from the NHMRC. of the Centres. Like the Centres, these themes of Infectious In a remarkable achievement, Burnet was successful in five Disease, Disease Prevention, Business Development (Vaccines, fellowship applications doubling the number of prestigious Diagnostics and Immuno-therapeutics), Education and Capacity NHMRC Fellows at the Institute. Building also define what we do as an Institute. I have appointed senior staff David Anderson, Robert Power, Steve Gerondakis Our epidemiologists work on a range of health issues, with and Marion Brown, as spokespeople for these themes and, more tuberculosis (TB), hepatitis C transmission, sexually-transmitted importantly, to drive significant new Institute-wide initiatives. It is infections and alcohol research being particularly prominent. from here that we can expect new areas of activity and emphasis I would like to emphasise the high-profile work of Helen Cox to emerge. and her colleagues on the investigation of the emergence of

Director’s Report

page $ drug resistance in the bacteria responsible for TB. These studies The Institute is fortunate to be governed by a Board of immensely are hugely significant as they form part of an emerging global talented individuals who give a lot of time and energy to serve the story about how one of the most significant human pathogens Institute. I speak on behalf of all staff in expressing my gratitude in history is adapting to evade the few available therapies. Few to our Chairman Alastair Lucas and all Directors. people realise that TB is rivalled only by HIV and malaria as the Finally, the Burnet Institute does all its work through funds world’s most important single-cause infectious disease. These generated by competitive grants, generally from Governments, studies underscore the fact that we are a long way from solving and through donations by philanthropic individuals and groups. the worsening global TB catastrophe. We are enormously grateful to those who donate these funds and Investigation into hepatitis C virus transmission in Australia I can guarantee that this treasured support is managed wisely was also very significant and demonstrated a great strength of and stretched as far as possible to maximise its impact in the Burnet – the integration of field studies with high technology communities it is intended to serve. laboratory capacity. In work published in "''%, Margaret Hellard and Campbell Aitken from the Institute’s Centre for Population Health, teamed with molecular virologist Heidi Drummer and other colleagues, to complete a major study in understanding infection and re-infection amongst injecting drug users. Hepatitis C is a Brendan Crabb major global health problem amongst many groups of people. It Director and CEO has become a very important, cross-cutting theme of the Institute and we will see a great deal more emerge in this area, especially in vaccine development. Progress was also made in HIV research with Suzanne Crowe and David Anderson continuing to develop a radical, inexpensive point-of-care diagnostic test to measure CD# T-cell levels in HIV infected individuals. Such a procedure is central to the prospect of effective widespread antiviral therapy throughout the developing world.

It was a big year for events and awards. Professor Mike Toole was awarded the highest honour in the Institute, the Fenner Award, and in his lecture to mark the occasion Mike told us of the broader and innovative vision that underpinned his team’s HIV control efforts around the world. Paul Gorry was named a Victorian Young Tall Poppy by the Australian Institute of Policy and Science.

All Burnet achievements are owed to its staff. I did not have to be here long to recognise the special and deep culture that permeates the people who work here, an egalitarian culture that prizes excellence, innovation and compassion. Thank you to all staff, especially to the Institute’s Deputy Directors, Mark Hogarth and David Anderson; the Administrative and Corporate Affairs team led by Geoff Drenkhahn, Peter Spiller and Paul Rathbone, who lead teams that have so ably managed the Institute’s affairs; the Centre Heads and Principals, and my personal assistant, Valerie Skahill.

page ) Board of Directors (L-R) Back: Mr John Dowling, Associate Professor David Anderson, Mr Henry Lanzer, Professor James McCluskey, Mr Ross E Cooke, Professor Mark Hogarth. Front: Ms Denise Allen, Mr Alastair Lucas, Professor Brendan Crabb, Professor the Hon Barry O Jones AO, Mr Neil Edwards. Absent: Professor Peter Doherty AC, Dr Tracey Batten, Mrs Bronwyn Constance, Dr Alan Finkel AM, Mr Garry Hounsell, Mr Robert Milne, Mrs Maria Myers AO, Natasha Stott Despoja, Mr Ian Wightwick.

The Directors of the Burnet Institute, all of whom act in an honorary capacity, along with the Executive Director and Deputy Executive Directors, who receive remuneration as paid members of staff and who held office at any time during or since the end of the financial year are:

Mr Alastair Lucas, BCom, FCPA Associate Professor David Anderson, PhD Director since !&&%; Chair, Burnet Institute Board of Directors; Director since "''$; Deputy Executive Director, Burnet Institute Member, Investment Committee, Grant Committee, Fundraising NHMRC Senior Research Fellow; Member, IP and Committee, ACS" Project Committee, Burnet Institute; Vice Commercialisation Committee, Burnet Institute; Chief Scientific Chair and Managing Director, Goldman Sachs JBWere; Member, Officer, Select Vaccines Ltd; Associate Professor, Department Takeovers Panel; Member, Monash Dean’s Advisory Board of Microbiology and Immunology, University of Melbourne; Director, Hepitope Limited Professor Peter Doherty, AC, FAA, FRS Director since "''"; Member, Research Advisory Committee, Dr Tracey Batten, MBBS, MHA, FRACMA, FAICD, MBA Burnet Institute; Nobel Laureate, Department of Microbiology Director since "''# and resigned & December "''%; Member, and Immunology, University of Melbourne IP and Commercialisation Committee, Burnet Institute; CEO, Eastern Health Professor Brendan Crabb, PhD Executive Director and CEO, Burnet Institute since March "''%; Mrs Bronwyn Constance, FCPA, FAICD, FCIS Member, Research Advisory Committee, and ACS" Project Director since "''$ and resigned !* April "''%; Member, Audit, Committee, Burnet Institute; Adjunct Professor, University of Finance and Risk Committee, Burnet Institute; Director and Melbourne; Adjunct Professor, La Trobe University; Editor-in- Chair, Audit Committee for the Cooperative Research Centre for Chief, International Journal for Parasitology Advanced Automotive Technology; Director and Chair, Audit Committee, Plantic Technologies Ltd; Director and Member, Ms Denise Allen Audit Committee, Melbourne Markets Authority Director since "''$; Chair, Investment Committee, Burnet Institute; Director, Medical Research Commercialisation Fund Mr Ross E Cooke, BCom, ACA (MRCF); Former Chair and Managing Director, Legg Mason Director since !&&%; Chair, Audit, Finance and Risk Committee, Asset Management Australia Ltd; Director, Utilities of Australia; and Member, ACS" Project Committee and Grant Committee, Director, AvSuper Burnet Institute; Director, Paxton Partners; Director and President, Wintringham; Director and President, Wintringham Housing Ltd

Mr John K Dowling, FREI, FAPI Director since "'''; Member, Research Advisory Committee, Burnet Institute; Managing Partner, K L Dowling & Co Board of Directors

page % 

Mr Neil Edwards, BEcon (Hons), FAICD, FIPAA Mr Robert L Milne, BEng (Civ), FIE (Aust), CP Eng Director since "''$; Member, Audit, Finance and Risk Director since "'''; Member, IP and Commercialisation Committee, ACS" Project Committee, Burnet Institute; CEO, Committee, Chair, ACS" Project Committee, Burnet Institute; Chifley Business School; CEO, ETM Search and Selection Chair, Hooker Cockram; Director, Great Connections Chairman, Regional Channels Authority Mrs Maria Myers, AO, BA, BSW, LLB Dr Alan Finkel, AM, PhD, FTSE, BE(Hons) Director since "''#; Member, Fundraising Committee, Director since "''%; Chancellor, Monash University; Director, Burnet Institute Florey Neuroscience Institute; Chair, Child Abuse Research Australia Centre Ms Natasha Stott Despoja, BA Director since "''%; Former Senator for South Australia; Former Professor P Mark Hogarth, PhD Leader, Australian Democrats; Director, Beyond Blue; Honorary Director since "''$; Acting Executive Director, Burnet Institute Research Fellow, University of Adelaide; Member, Advertising – September "'') to March "''%; Deputy Executive Director, Standards Board Burnet Institute; NHMRC Senior Principal Research Fellow; Former Executive Director, Austin Research Institute; Adjunct Mr Ian Wightwick, ASTC (App Chem), BEcon, MAdmin, MAICD Professor, University of Melbourne; Adjunct Professor, Director since "''$ and resigned & December "''%; Member, Monash University; Director, IgAvax Pty Ltd; Member, IP and Commercialisation Committee, Burnet Institute; Former IP and Commercialisation Committee, Member ACS" Project Chair, Austin Research Institute; Former Managing Director, Committee, Burnet Institute PaperlinX; Chair and Director, Plantic Technologies Ltd

Mr Garry Hounsell, BBus, CPA Director since "''*; Chair, Fundraising Committee, Burnet Institute; Director, Qantas Airways Ltd and Chair, Qantas Audit Patrons Committee and Member, Qantas Nominations Committee; Director, Orica Ltd; Director, Nufarm Ltd; Deputy Chair, Mitchell PATRON-IN-CHIEF Communications Group; Former Senior Partner, Ernst & Young; Governor of Victoria, Professor David de Kretser, AC CEO, Arthur Andersen

PATRONS Professor, the Hon Barry O Jones, AO, FAA, FAHA, FTSE, FASSA, FRSA, FRSV, FAIM Professor Gordon Ada, AO, Australian National University Director since "'''; Chair, Vision "'"' Australia; Chair, Port Hon Steve Bracks, MP, Former Premier of Victoria Arthur Historic Site Management Authority; Professorial Fellow, Mr Nobby Clark, AO, Former Chief Executive Officer, National University of Melbourne; Former Vice Chancellor’s Fellow, Australia Bank University of Melbourne; Former Commonwealth Minister Dr John Connell, AM, Founder, John Connell and Associates for Science; Former Chair, Victorian Schools Innovation Mr Bryce Courtenay, AM, Author Commission Rt Hon Sir Zelman Cowen, AK, Former Governor General Mr Henry Lanzer, BCom, LLB of Australia Director since "''%; Member, Development Committee, Burnet Professor Allan Fels, AO, Former Chairman of ACCC and Dean of Institute; Managing Partner, Arnold Block Leibler; Director, the Australian & New Zealand School of Government Premier Investments; Director, The Just Group; President, Rt Hon Malcolm Fraser, AC, Former Prime Minister, Australia Mount Scopus Memorial College Foundation; Director, Professor David Ho, Director, The Aaron Diamond AIDS Tarrawarra Museum of Art Research Centre, New York Hon Michael Kirby, AC, CMG, Member of the International Professor James McCluskey, Bioethics Committee of UNESCO and Member of the UNAIDS BMedSc, MBBS, MD, FRACP, FRCPA Global Panel on Human Rights Director since !&&%; Chair, Research Advisory Committee, Burnet Institute; Professor and Associate Dean (Research) Professor Sir Peter Morris, AC, Royal College of Surgeons, Faculty of Medicine Dentistry and Health Sciences, University London of Melbourne Mr John So, Former Lord Mayor of Melbourne

page & Burnet Institute’s new building

Report by Chief Operating Officer, Geoff Drenkhahn

April "% "''% will prove to be a date of significance in the history Alfred hospital; key partners the ANZ Bank and Baulderstone, of the Burnet Institute. That date represents the ‘contract close’ and tenants including Monash University, La Trobe University for the Alfred Centre Stage " project (ACS"), with the signing of and the Baker IDI. the raft of legal and financial contracts and agreements governing The ‘new’ building is in fact a horizontal and vertical extension the construction and subsequent occupation of Burnet’s new of the existing Alfred Centre, with the four new floors delivering building at the AMREP campus. an additional !#,"''sqm of space. Burnet will lease out three of The Burnet team, led by Board Members Alastair Lucas and the four new floors in ACS" and occupy the seventh floor which Rob Milne and senior staff, Mark Hogarth and Janet Cameron is being fitted out for laboratories, including a PC( security level and their staff are to be congratulated for their vision, planning laboratory. This initiative has been developed to allow for the and persistence in bringing to fruition a complex arrangement future growth of the Institute as well as securing our financial involving Federal and State governments; project co-sponsor The future via leasing arrangements.

The Burnet Institute’s Level ) offices and laboratories, the upper floor with windows yet to be installed.

page !' The construction of the building has proceeded very smoothly and to date is on time and on budget. The building remains scheduled for completion and occupancy in April "'!'. As the accompanying photos show it is taking shape as an impressive new facility.

I would like to thank all those who have contributed to the project, both in the planning and construction stages, in particular Janet Cameron who co-ordinated the pre-contract close negotiations and arrangements and Bruce Loveland who has project-managed the construction phase of the project for Burnet. I would also like to thank our legal advisors Blake Dawson, our project co-sponsor Alfred Health and our building contractor Baulderstone who have all contributed to making this exciting project a reality.

Workmen completing the Level $ slab Associate Professor in March "''&. The Burnet Institute’s Bruce Loveland. existing building is to the left.

The fitout of mechanical and electrical services to the new floors commencing.

page !! CENTRE FOR

The mission of the Centre for VirologyVIRO is to achieve innovative solutions for viral LOGY diseases of global importance. Basic research underpins most major scientific discoveries. Within the Centre for Virology strong emphasis is placed on understanding how viruses manipulate their host cells in order to infect them. Burnet’s research in this area is vital in understanding how viruses infect cells causing disease and in developing strategies to block infection.

page !"!" CENTRE FOR VIRO LOGY

page !( Overview

It has been a productive year for the Centre for Virology (CV) In November "''%, Jenny Anderson and Gilda Tachedjian in furthering our goal to achieve innovative solutions for viral convened the ‘High Resolution Fluorescence Imaging Workshop diseases. To crystallise our mission statement and to develop featuring DeltaVison Deconvolution Microscopy’ at the Burnet strategic milestones, the Centre held its first retreat in November Institute. Professor Tom Hope from Northwestern University "''%, which was attended by laboratory heads. On the hepatitis Chicago, shared his expertise in visualising fluorescently labelled C virus (HCV) front, the Drummer/Poumbourios laboratory have viral particles in cells to ** participants during the one-day produced a new HCV vaccine candidate that elicits a more seminar and to eight individuals in the practical component of effective immune response compared to other candidates, while the three-day course. the Anderson/Crowe laboratories were awarded funding from We welcome several new recruits to our Centre. Dr Jenny Anderson the Bill and Melinda Gates Foundation CD# Initiative to develop from Northwestern University Chicago, who undertook her a rapid point-of-care CD#+ T-cell test for use in remote settings. postdoctoral training with Professor Tom Hope, and was awarded Underscoring our research excellence, the Tachedjian lab was an NHMRC Project grant to determine how host cell restriction awarded the Nick Crofts Award, for the top-rated publication from factors block HIV-! infection. Mr Gregor Lichtfuss from the Robert the Burnet Institute, for a study published in PloS Medicine on the Koch-Institut Berlin, is undertaking his PhD studies to delineate identification of a mutation that confers dual class HIV-! reverse the impact of HIV infection on signalling processes in human blood transcriptase inhibitor resistance. cells. CV also hosted international students who completed part Our NHMRC project grant successes continue. In "''% the Centre of their studies in the Mak Laboratory: Margarida Rodriguez, from was awarded four project grants ($".* million) and an NHMRC University of Lisbon, Portugal and Vera van Hoeven, a Masters Principal Research Fellowship to Professor Suzanne Crowe. We student from Utrecht University in The Netherlands. Professor achieved a ##% success rate for NHMRC Project Grants ($(." Roland Marquet from the University of Strasberg, an expert on RNA million) starting in "''&. In addition, Associate Professor Gilda biochemistry, completed an eight-month sabbatical at Burnet. Tachedjian and Professor Eric Gowans were awarded NHMRC In "''% we farewelled Professor Eric Gowans, who is now the Senior Research Fellowships, Associate Professor Paul Gorry and Executive Director of the Women’s & Children’s Health Research Dr Kate Cherry were successful in obtaining the highly competitive Institute in Adelaide. We are pleased that Eric remains part of CV NHMRC Career Development Awards and Dr Hilary Hoare was as a co-laboratory head. Others who have left the Centre include awarded an NHMRC Postdoctoral Fellowship. Our strength in Dr Nicole Webster (Crowe Laboratory) who is currently a Research translational research is exemplified by funding of an NHMRC Officer at the University of Melbourne and Lisa Morris, a Senior Development grant (Anderson/Crowe Laboratory) and nine grants Scientist in the Clinical Research Laboratory who is now taking ($!.# million) from the Australian Centre for HIV and Hepatitis care of her new-born baby. Virology Research. We congratulate Edwin Leeansyah and Clare Westhorpe who both successfully completed their PhD studies at Burnet.

Laboratory Heads (Above L-R): Dr Gilda Tachedjian, Dr Melissa Churchill, Professor Suzanne Crowe (Head), Dr Catherine (Kate) Cherry, Dr Heidi Drummer, Dr Anthony Jaworowski, Associate Professor Johnson Mak, Dr Pantelis Poumbourios. Absent: Associate Professor David Anderson, Dr Elizabeth Grgacic, Associate Professor Paul Gorry, Professor Eric Gowans.

page !# Highlights

Centre for Virology investigator wins Victorian Young A low-cost, point-of-care CD# assay developed at Burnet’s Tall Poppy Science Award | GORRY LABORATORY Centre for Virology | ANDERSON/CROWE LABORATORY

Associate Professor Paul Gorry was a recipient of the Victorian Antiviral drugs are becoming increasingly available in resource Young Tall Poppy Science Award for "''%, in recognition of constrained countries for the treatment of those HIV-infected excellence in academic achievement in medical research and individuals having a low number of CD#+ T-cells in blood, promotion of science. indicating a failing immune system. However, access to drugs is limited by the need for sophisticated laboratory testing for CD#+ Paul heads the HIV Molecular Pathogenesis Laboratory and has a T-cells, typically by flow cytometry. number of research interests in the field of HIV-! pathogenesis. The Burnet Institute was awarded a grant by The CD# Initiative In one study by PhD candidate Jasminka Sterjovski, the three- (funded by the Bill and Melinda Gates Foundation) for the dimensional structures of functionally diverse HIV-! gp!"' development of a rapid point-of-care CD#+ T-cell test, specifically proteins were elucidated by homology modelling. The results designed for field use in remote settings. This continues a revealed novel structural changes that enhance the interaction longstanding collaboration with Alan Landay (Rush University between the virus and the cell (Figure !). Medical Centre, Chicago) and Tom Denny (Duke University, In a study by Postdoctoral Fellow Dr Martin Jakobsen and North Carolina). Research Assistant Anne Ellett, is characterising adaptive At Burnet, Suzanne Crowe, David Anderson and senior scientist changes in the clade C HIV-! gp!"' region that occur during Mary Garcia lead a team with expertise in diagnostic test disease progression. These studies will be critical for development. The proof-of-concept studies for a novel detection development of targeted vaccines and drug therapies for clade method for CD#+ T-cells, and the subsequent conversion of the C HIV-!, which predominates in Africa and Asia and is the most technology into a prototype field test for point-of-care use, have common HIV-! subtype worldwide. now been successfully completed. PhD candidate Michael Roche is characterising mechanisms The CD# rapid test is simple and takes (' minutes, using a involved in HIV-! resistance to Maraviroc, a new HIV-! drug, small volume of blood from a finger prick to give a visual readout which acts by preventing HIV-! binding to cells. This work will without the need for instrumentation. The test result indicates be important for development of new laboratory tests for HIV whether the patient should commence treatment. resistance to Maraviroc. Prototype test manufacture is scheduled for "''& along with Another study by PhD candidate Lachlan Gray characterises further validation and clinical studies to ensure the assay offers mechanisms involved in HIV-! neurotropism, which is reliable and reproducible results. The CD# test is an example of a collaborative effort with Dr Melissa Churchill’s HIV translational research with the potential to deliver major benefits Neuropathogenesis Laboratory. Here, we showed that brain- for the global community. derived HIV-! strains undergo adaptive changes to increase the efficiency in the way they use CCR* for entry into cells, which may increase their ability to replicate in brain microglial cells.

Figure !: Structural variations in the V( The rapid CD# test requires only 4'µL of blood obtained by a gp!"' region affecting gp!"' function. fingerprick and is designed for field use in remote settings.

page !* Snapshots

Crowe/Jaworowski Laboratory (HIV Pathogenesis) Gowans Laboratory (Hepatitis C – Molecular Biology)

Gregor Lichtfuss joined the Crowe/Jaworowski Laboratory as Eric Gowans was a Senior Principal Research Fellow at the Burnet a PhD student in "''%, coming from the Robert Koch-Institut, Institute from "''"-"''&, during which time he established a Berlin. Co-supervised by Suzanne Crowe, Anthony Jaworowski productive hepatitis C virus (HCV) research laboratory. Interests and Sharon Lewin, Gregor has started work on an exciting project of the Gowan’s Laboratory include studies of HCV replication and investigating mechanisms underlying the intense immune approaches to develop novel antiviral agents (in collaboration activation that is characteristic of HIV infection. His research with colleagues at Avexa Ltd), studies into the mechanism of HCV focuses on the impact of HIV infection on signaling processes persistence with particular emphasis on regulatory T cells (with in human blood cells. This signaling, a way of communication Dr Shuo Li) and HCV immunotherapy and vaccine development between the immune cells in blood, is crucial for coordinating the (with Associate Professor Loveland). body’s defense against pathogens. HIV infection interferes with this function. Gregor’s research links with other projects in the lab Tachedjian Laboratory (Molecular Interactions) which focus on immune cell function, immune ageing, and the risk of cardiovascular disease in HIV-infected individuals. The aim of the Tachedjian Laboratory is to understand how HIV reproduces in the cell, including the role of host cell factors in HIV-1 replication, and to study drug resistance mutations Drummer/Poumbourios Laboratory (Viral Fusion) in HIV. The lab is also involved in the preclinical development High viral mutation rates challenge the development of HCV of microbicides to prevent the sexual transmission of HIV. In and HIV vaccines and antivirals. Studies of the HCV and HIV "''%, Dr Jenny Anderson was recruited from the United States glycoproteins have revealed important sequences that are to continue her studies in understanding how APOBEC(G, a not subject to rapid change. The Drummer/Poumbourious host cell protein, blocks HIV replication. Jenny has received Laboratory has produced a new HCV vaccine candidate based NHMRC funding for this project, and will be using Deconvolution on a conserved component of glycoprotein E". Together with Microscopy to visualize whether APOBEC(G confers defects in CSL, it is demonstrated that this vaccine elicits a more effective virus trafficking to the cell nucleus. antiviral immune response in comparison to previously available vaccines. For HIV, a new target in the fusion glycoprotein gp#! has been identified, with funding obtained from ACH" and NHMRC to exploit this target in the development of antivirals.

Fluorescent microscopy examining the impact of human APOBEC(G protein on HIV (green) trafficking towards the nucleus (blue) after entry into human cells. HIV is labeled green by fusing the HIV Vpr protein to green fluorescent protein. The HIV capsid protein (red) and cell actin filaments (purple) are also stained.

Gregor Lichtfuss utilises Fluorescence Activated Cell Sorting.

page !$ Mak Laboratory (HIV Assembly) Cherry Laboratory (HIV Neuropathy and Toxicity)

Proteins are often thought to be the prime regulator of biological The Cherry Laboratory aims to find ways of predicting HIV systems, but it is now appreciated that RNA has a much greater treatment toxicities, before patients develop irreversible role in the regulation of biological processes than previously problems like neuropathy. The lab has developed a ligation- thought. It is generally accepted that stable RNA structures can mediated PCR assay, to quantify apoptosis (programmed cell be an important determinant in biological activity. Using HIV as death), and shown that patients with toxicity have higher results a probe, the Mak Laboratory has provided direct evidence that in blood than those without. With ACH" funding, David Hooker is structurally-poor RNA domains are also utilised by viruses to working to merge ligation-mediated with real-time PCR to provide regulate biological process. This study provides paradigm shift a rapid-throughput assay more suitable for clinical use. The evidence, to reveal the broad spectrum of mechanisms used by Cherry Laboratory also plans a prospective study of Australian biological systems to govern the dyanmic RNA based regulation HIV patients using modern therapies to confirm the assay’s utility network in cells. for predicting side effects and hope this work will contribute to improved future safety of HIV treatments. Churchill/Wesselingh Laboratory (HIV Neuropathogenesis)

Dr Melissa Churchill Heads the HIV Neuropathogenesis Crowe Laboratory (Clinical Research Laboratory, Laboratory. One of her major research interests is understanding World Health Organisation (WHO) Regional HIV the importance of astrocytes in the development of HIV- Drug Resistance Laboratory) associated dementia, a devastating complication of AIDS. Until The development of resistance to anti-HIV drugs poses a serious now, astrocytes were thought be rarely infected with HIV-!. In threat to effective HIV treatment. The WHO Regional HIV Drug a study recently accepted for publication in the prestigious Resistance Laboratory for the Asia and Pacific regions, supervised journal Annals of Neurology, Melissa developed highly sensitive by Dr Anna Hearps, is responsible for providing technical and new techniques to show that astrocytes in brain tissue can be logistical support for resistance testing within the region. extensively infected with HIV, and that astrocyte infection has As part of this role, the laboratory has developed a low-cost an important role in the development of brain disease (Figure). resistance test and optimised its use with dried blood spots to Melissa’s studies will alter current models and provide a enable resistance testing to be performed within remote areas of paradigm shift in understanding HIV-! neuropathogenesis. resource-constrained countries. Staff from this laboratory assist in the assessment and WHO accreditation of laboratories within the Asia and Pacific regions, and regularly attend meetings to establish international guidelines for drug resistance testing.

REGION A REGION B REGION C This diagram shows the relationships between astrocyte infection frequency, presence of HIV-associated dementia, and proximity to macrophages. Brain tissue regions analyzed for astrocyte infection. The top panels illustrate the definitions of regions A, B and C, and the bottom panels are representative double immunohistochemical stains for astrocytes (GFAP, red) and macrophage-lineage cells (CD$%, brown).

Oligodendrocyte Multinucleated giant cell Astrocyte

Microglia Macrophage Microvascular endothelial cell and perivascular macrophage

page !) Centre for Virology: our staff and students

ANDERSON/CROWE CHURCHILL/WESSELINGH CROWE/JAWOROWSKI Students LABORATORY (Diagnostics LABORATORY (HIV LABORATORY (HIV Pathogenesis) Johanna Dean, BSc(Hons) and Basic Research) Neuropathogenesis) Co-Heads Kathleen McCaffrey, BSc, BA Co-Heads, Senior Co-Heads Suzanne Crowe, MBBS, FRACP, Anna Bellamy-McIntyre, Principal Fellows Melissa Churchill, BSc(Hons), MD, NHMRC Principal Research BSc(Hons) David Anderson, BSc(Hons), PhD Fellow Yousef AlHammad, BVetsSci, PhD, NHMRC Senior Research Steve Wesslingh, BMBS, PhD, Anthony Jaworowski, PhD BSc(Hons) Fellow FRACP Hamed Gouklahni, BSc, PostDoctoral Fellow Suzanne Crowe, MBBS, PhD, MSc(Virology) Research Assistant Nicole Webster, PhD, amfAR NHMRC Principal Research Fellow Ashraf Khasawneh, BMed, BSur, Lisa Chiavaroli, BSc(Hons) Fellow MBioMedSci Senior Research Officers Students Research Assistants Mary Garcia, Dip Lab Tech Daniel Cowley, BAppSci(Hons) Jingling Zhou, MBiotech, GORRY LABORATORY Pat Mottram, PhD Lachlan Gray, BSc(Hons) Research Assistant (HIV Molecular Pathogenesis) Research Officer Jasminka Sterjovski, BSc(Hons) Wan-Jung Cheng, MSc, Research Head Nadine Barnes, BSc(Hons) MSc Jessica Wade, BSc(Hons) Assistant Paul Gorry, BAppSci(Hons), PhD Research Assistants Students PostDoctoral Fellows CROWE LABORATORY (Clinical Robyn Lloyd, BSc(Hons) Clare Westhorpe, BSc(Hons), Hilary Hoare, BSc(Hons), PhD Research Laboratory, Burnet Simone van de Waarsenburg, (NHMRC Dora Lush Scholarship) Martin Jakobsen, MSc, PhD W.H.O. Regional Reference BSc(Hons) Monash University Laboratory for HIV Resistance) Research Assistants Jocelyn Diaz, BSc Emma Tippett, (NHMRC Dora Head Anne Ellett, BSc Lush Scholarship) Monash Suzanne Crowe, MBBS, FRACP, Lachlan Gray, BSc(Hons) ANDERSON/GRGACIC University MD, NHMRC Principal Research Jasminka Sterjovski, BSc(Hons) LABORATORY (Hepatitis Edwin Leeansyah, BBMSc(Hons), Fellow Research) (Australian Postgraduate Award) Students Co-Heads Supervising Scientist Monash University Lachlan Gray, BSc(Hons) David Anderson, BSc(Hons), Lisa Morris, BSc(Hons), MBA Gregor Lichtfuss, (Monash Jasminka Sterjovski, BSc(Hons) PhD, NHMRC Senior Research International Postgraduate Jessica Wade, BSc(Hons) Quality Manager and Acting Fellow Scholarship) Monash University Michael Roche, BSc(Hons) Senior Scientist Elizabeth Grgacic, BSc, Medini Reddy Luthmoodoo, Daniel Cowley, BAppSci(Hons) Vicki Greengrass, BSc(Hons), MScPrelim, PhD, Senior Burnet Honours Student. Department Grad Dip Ed Fellow Microbiology Monash University. GOWANS LABORATORY PostDoctoral Fellow (Hepatitis C) Senior Development Scientist Anna Hearps, Supervising DRUMMER/POUMBOURIOS Head Peter Williamson, PhD Scientist WHO Regional Reference LABORATORY (Viral Fusion) Eric Gowans, MAppSci, PhD, Research Officers Lab, PhD Co-Heads NHMRC Senior Research Fellow Amanda Brass, BSc(Hons), PhD Heidi Drummer, BSc(Hons), PhD Research Assistants Post Doctoral Fellow Anna Hearps, BSc(Hons), PhD Burnet Principal Fellow, NHMRC Bruce Loveland, BSc(Hons), PhD Megan Plate, BSc(Hons), Grad RD Wright Fellow Research Assistant Dip Ed Pantelis Poumbourios, Leader, Molecular Biology Group Huy Van, BSc(Hons) Pauline Steele, BSc(Hons) BSc(Hons), PhD Gholamreza Haqshenas, DVM, Eman Aleksic, BSc(Hons) Students PhD Tom Fallshaw, BSc Post Doctoral Fellows Natalie Counihan, BSc(Hons) Annike Griffey, BSc, Grad Dip Patricia Vietheer, BSc(Hons), PhD Students Yuh Koon (Tommy) Tong, Bio Sc PhD Sook-San Wong, BBMedSc, MSc BBiomedSc(Hons) Rebecca Butcher, BSc(Hons), Xuebin Dong, MPh (Master of Student PhD Philosophy) CHERRY LABORATORY (HIV Claire Ryan, BSc(Hons) David Harrison, BSc(Hons), PhD Ali Gorzin, MSc Neuropathy and Toxicity) Personal Assistant Hamed Gouklani Head Research Assistants to Program Head Catherine (Kate) Cherry, MBBS, Irene Boo, BBiomedSci(Hons) Karen O’Keefe PhD, FRACP, Grad Dip (Clin Epi) Yanny Handoko, BSc(Hons) Kevin te Wierek, BSc(Hons) Research Officer Chan Sien Lay, BSc(Hons) David Hooker, BSc, MSc Annemarie Laumaea, Research Assistant BBiomedSci(Hons) Masqura Moborok, BSc(Hons)

page !% MAK LABORATORY BURNET AFFILIATED NHMRC Fellows (HIV Assembly) LABORATORIES NHMRC Principal Research Fellow Head Professor Suzanne Crowe Johnson Mak, BSc, PhD LEWIN LABORATORY (HIV and NHMRC Senior Research Fellow Hepatitis Immunopathogenesis) Research Officers Associate Professor Head Candida da Fonseca Pereira, David Anderson Sharon R Lewin, FRACP, PhD BSc, PhD Professor Eric Gowans Marcel Hijnen, BSc, PhD Deputy Head Paula Ellenberg, Bsc, MSc, PhD Paul U Cameron, FRACP, FRCPA, NHMRC Career Kate Jones, BSc, PhD PhD Development Award Associate Professor Students Senior Scientist Gilda Tachedjian Kate Jones, BSc(Hons) Miranda Xhilaga, PhD Associate Professor Paul Gorry David Hawkes, BSc(Hons) PostDoctoral Fellows Redmond Smyth, BSc(Hons), Dr Heidi Drummer Suha Saleh, PhD MSc Laveena Sharma, PhD NHMRC Peter Doherty Fellow Margarida Rodrigues, BSc Megan Crane, PhD Dr Hilary Hoare, BSc(Hons), PhD Vera van Hoeven, BSc, MSc Jennifer Audsley, PhD Omer Gilan, BSc(Hons) Chin Long Wong, BSc(Hons) Research Assistants OTHER FELLOWSHIPS Steve Heaton, BSc Fiona Wightman, BSc(Hons) Pfizer Foundation Fellow Sanne Pfeifer, BSc Ajantha Solomon, BSc(Hons) Associate Professor Georgina Sallmann, BSc(Hons) Johnson Mak Visiting Scientists Roland Marquet, BSc PhD Students The Netherlands Rubicon Linda Hartkamp, BSc MSc Gabriella Khoury, BSc(Hons) Fellowship Vanessa Evans, BSc(Hons) Dr Marcel Hijnen TACHEDJIAN LABORATORY David Iser, MBBS, FRACP (Molecular Interactions) Chris Desmond, MBBS, FRACP CONSULTANT Head (Principal Burnet Fellow) Reena Rajasuriar, Emeritus Professor Gilda Tachedjian, BSc(Hons), BPharm(Hons), MPharm Gregory A Tannock (Royal Melbourne Institute PhD Christina Chang, MBBS, FRACP of Technology) Gregor Lichtfuss Senior Burnet Fellow Wilson Chong Secondo Sonza, BSc(Hons), PhD Personal Assistant to Professor Senior Research Officer Lewin Jenny Anderson, BSc(Hons), PhD Sandy West Post Doctoral Fellow Seema Srivastava, BSc(Hons), PhD Research Assistants Katie Moore, BSc(Hons) David Tyssen, BAppSc Biotech Adam Johnson, BSc(Hons) Students Johanna Wapling, BSc(Hons) Soo Huey Yap, BSc(Hons) Jennifer La, BMedChem(Hons) Sushama Telewatte, BMedSc Flow Cytometry Geza Paukovics, BMedLabSc

WRIGHT GROUP (The Asia Pacific NeuroAIDS Consortium) Head Edwina Wright, MBBS, FRACP Research Officer Luxshimi Lal, BAppSci, BPharm

page !& CENTRE FOR

IMMUNThe newly formed Centre for Immunology has brought together outstanding OLOGY research groups with a wide spectrum of skills applicable to the understanding of the immune system and manipulation of this to treat disease. Key questions for our Centre are: why does the immune system attack normal cells which it should ignore, for example in diseases such as rheumatoid arthritis and lupus, but in cancer, ignores the cancerous cells it should eliminate? How is it that infectious agents avoid immune destruction? Answering these questions will lead to a greater understanding of the immune system and the development of new treatments for major diseases.

page "' CENTRE FOR IMMUN OLOGY

page "! Overview

"''% has been a year of consolidation, bringing together the The Ffrench Laboratory has participated in the most various groups into the new Centre for Immunology. We have a comprehensive study of immune responses to hepatitis C, the unique combination of researchers in Australian immunology: results of which have shown clear indications of how that disease structural biologists and protein chemists; bio-organic chemists; may be treated more effectively to prevent re-infection. cellular immunologists and molecular biologists. This allows Immunity to infection is a battle between the microbe and the us to build multi-disciplinary teams both within the Centre for immune system and our studies have provided some exciting Immunology and with other Burnet Centres and in collaborations results. The Gerondakis Laboratory has discovered the basis by around the world to focus on major health problems. which B-cells, a major immune cell, resists killing by microbes. Centre laboratories have outstanding track records in This has broad implications in the development of strategies translating basic research into new treatments which will be to improve resistance to infection. Also the Jackson Laboratory enhanced by the development of new technologies and the has identified a new role for a major adhesion molecule that recruitment of outstanding researchers. We will expand our surprisingly makes animals more susceptible to salmonella well recognised monoclonal antibody, bio-organic chemistry infection. Bruce Wines and Paul Ramsland have further defined and protein chemistry capabilities and develop gene array and how ‘golden staph’ attempts to evade the immune system. proteomics facilities. The studies of aberrant immune responses in autoimmune The cancer laboratories of Geoff Pietersz and Vasso Apostolopoulos diseases continue in the Hogarth Laboratory where 18 unique have advanced vaccine design to improve the potency of white genes involved in destructive arthritis have been identified, blood cells destined to kill tumour cells. Geoff Pietersz continues one in particular appears to regulate immune function and to develop novel immune stimulants and demonstrated superior surprisingly, resistance to infections. immunogenicity of carbohydrate modified dendrimers which The commercialisation in the Centre continues with pre-clinical eradicates tumours in mice. Pei-xiang Xing has shown that an development of a new intranasal vaccine for respiratory viruses antibody which inhibits tumour cell growth binds to a molecule and an injectable cancer vaccine. Discussions with a number of normally found inside the cell, but in prostate cancer cells, is found companies for collaborative research are in progress. outside the cell on the cell membrane. We are delighted to have recruited Dr Meredith O’Keeffe Our studies in the immunology of infection have also made from Bavarian Nordic into our Centre. She brings a wealth of substantial progress. The Pietersz Laboratory successfully experience in immune resistance to viral infection, having adapted the mannan adjuvant technology, used in our cancer completed her postdoctoral studies in Germany. The Centre will immunotherapies, for use in a unique intranasal vaccine for come together at the AMREP Campus during "''& in temporary the respiratory viruses, influenza and Respiratory Syncytial accommodation, prior to occupying our purpose-built state-of- Virus (RSV). the-art facilities in "'!'.

Laboratory Heads (Above L-R): Back: Associate Professor Bruce Loveland, Professor Geoffrey Pietersz, Dr Pat Mottram, Associate Professor Rosemary Ffrench, Associate Professor Denise Jackson, Professor Mark Hogarth (Head), Professor Vasso Apostolopoulos, Dr Bruce Wines. Front: Professor David Power, Dr Paul A Ramsland, Professor Steve Gerondakis. Absent: Professor Pei Xiang Xing.

page "" Highlights

Establishment of Burnet’s New vaccine strategies Immunological Monitoring Facility for cancer therapy

The Burnet Institute has a long track record of achievement in the Geoff Pietersz and Vasso Apostolopoulos have had a long translation of research into potential therapeutics – a number standing interest in the treatment of disease by manipulating the of vaccines, antibodies and immunotherapies for cancer or immune system. This is especially true in the development of new infectious diseases are in different phases of development. In treatments for cancer which around the globe have focused in the a major initiative, Associate Professor Rosemary Ffrench and last decade on the manipulation of the immune system to direct Associate Professor Bruce Loveland have established a central killer cells or antibodies to cancers to kill them. Immunotherapies Immunological Monitoring Facility (IMF) which will produce high to stimulate the immune system to attack cancers is showing quality data to Good Laboratory Practice (GLP) standard on the great promise in clinical testing. This year we have successfully immunogenicity (stimulating ability) of these therapies and which demonstrated the superior immunogenicity of an immune will provide the essential support for applications to regulatory stimulant based on a carbohydrate modification of a breast authorities. This is a novel approach to expedite the research and cancer target. to develop some of the more sophisticated assays. Our studies on the development of a breast cancer vaccine have The IMF Facility will support the future development of our been in progress for many years and the selective stimulation vaccines in influenza, RSV, cancer, as well as our therapeutic of immune cells using a clever trick of chemistry to modify a monoclonal antibody programs and our involvement in the sugar which is then attached to the cancer specific molecule, Cooperative Research Centre for Biomarker Translation (CRC). MUC!, has been shown to be effective in clinical testing on The facility has been carefully developed during the past year, ovarian cancer patients. In a new development this year, we with highly-skilled staff, validated immunoassay protocols have successfully modified the cancer antigen and improved and dedicated equipment to undertake tests which assess the its capacity to stimulate immune cells and show superior immune responses in small animal studies and early Phase immunogenicity in preclinical studies. Further validation of human clinical trials. The facility is available to the broader the improved vaccine in human cells will make way towards Research and Development Community in collaborative a clinical trial in the near future in concert with our new GLP partnerships and "''% saw the completion of our first Phase Immunological Monitoring Facility. This is an excellent example of I clinical trial. Conducted in association with clinical trial a combination of immunology, chemistry and structural biology, organisation, Nucleus Network Ltd, it was very successful, funded by the National Health and Medical Research Council with the immunoassay data showing a significant difference in and will also be a commercial partnership with #G Vaccines. The immune responses between test and placebo arms of the trial. improved stimulation will provide a next generation of potential We are currently undertaking a second vaccine clinical trial, immunotherapy (vaccine) based approaches to the treatment and are in the process of expanding the range of assays we can of cancer. perform to GLP standard and are being evaluated for National Association of Testing Authorities (NATA) accreditation.

L-R: Kylie Goy and Jacqueline Flynn of the Immunological A mutant peptide from myelin basic protein with a central amino acid K&! Monitoring Facility viewing cell cultures by microscope. mutated to Y&! alters immune responses drastically in animal models.

page "( Snapshots

Apostolopolous Laboratory (Immunology and Cancer Jackson Laboratory (Immunoreceptor): We have made Vaccine): Our research has shown that the function of dendritic a remarkable observation showing that PECAM (platelet/ cells (DC) is dependant on their developmental stage, and may endothelial cell adhesion molecule), which normally regulates form the basis of improved DC-based immunotherapy protocols. immunity, works against the immune system in Salmonella In a study focused on multiple sclerosis, a number of mutant infections – mice lacking PECAM are better able to resist peptide antigens were designed and shown to alter DC-driven infection. Understanding the mechanism of this resistance may immune response resulting in the suppression of MS in mice. improve our control of Salmonella infection in humans.

Ffrench Laboratory (Viral Immunology): A major Hepatitis C Pietersz Laboratory (Bio-Organic and Medicinal Chemistry): Virus (HCV) clinical trial showed clear differences in the nature of A number of novel ligands that bind to dendritic cells have been the immune response in those individuals who could clear the developed based on dendrimer modified antigens. In addition, infection compared to those that went on to chronic infection. these vaccines also incorporate synthetic danger signals to Importantly we showed that early treatment for HCV infection with efficiently activate dendritic cells to prime naïve T-cells. Similar Interferon restored effective immune responses, indicating early approaches are used to deliver genetic material to develop DNA therapy may aid in the prevention of subsequent re-infection vaccines and gene therapy strategies for the treatment of cancer. with HCV. Power Laboratory (Kidney): Renin is the most important Gerondakis Laboratory (Intracellular Signalling and controller of blood pressure. Our recent research has shown that Gene Expression): This laboratory has shown that survival its secretion is controlled, in part, by fatty acid metabolism in the of B-cells stimulated through Toll-like receptors is achieved kidney. This data suggests a new link between obesity, diabetes by the NF-KB pathway controlling several mechanisms that and blood pressure. The second area is trying to understand collectively neutralise and degrade Bim, a cellular protein which how leaks occur in the kidney. Our recent work has shown that promotes cell death when activated by stress signals such as abnormalities in lysosomal function – the body’s rubbish disposal microbial products. These findings provide new insight into the system – can lead to loss of proteins that can damage the kidney, mechanisms that limit microbial pathogenesis arising from cell leading to kidney failure and the need for dialysis. (Figure ") death during infections. Ramsland Laboratory (Structural Immunology): Recent Hogarth Laboratory (Helen Macpherson Smith Trust studies have shed new light on our understanding of Inflammatory Diseases): We have analysed (#,''' genes in carbohydrate recognition by antibodies. Dr Ramsland’s group, the mouse and identified !% that are altered during rheumatoid with collaborators, determined the structural basis of antibody arthritis development in an animal model and one candidate interactions with a carbohydrate present on pig cells, but not target identified for generation of future treatments. We are human cells GalA(!,()Gal. Automated docking studies with a elucidating how a key new subset of T-cells (Th!)) drives panel of antibodies and GalA(!,()Gal carbohydrates determined inflammatory disease. Microbes have also evolved ways of the major binding mode was end-on insertion where the terminal avoiding immunity and we have used Xray crystallography to sugar unit anchors the entire carbohydrate. discover how the Golden Staph ‘hijacks’ immunity by binding and inactivating IgA. (Figure !) Xing Laboratory (Cancer Immunotherapy): We have generated a specific antibody to a proto-oncogene PIM-!, which reacted strongly with prostate cancer. We demonstrated for the first time that the antibody induced cancer cell death. It also substantially inhibited growth of human prostate cancer cells in an animal model. This is an exciting step towards the development of new treatment for patients with prostate cancer.

Figure !: The interaction of a ‘golden staph’ protein SSL) with human IgA Fc Figure ": Normal kidney cells (left) express the SCARB( lysosomal gene (green portion. Surface representation of the two SSL) protein binding at the interface dots), but in patients lacking the gene (right) kidney function failed. of CA" and CA( which competes with the FcAR binding on inflammation cells.

page "# Centre for Immunology: our staff and students

APOSTOLOPOULOS GERONDAKIS LABORATORY PIETERSZ LABORATORY CLINICAL ASSOCIATES LABORATORY (Intracellular Signalling and (Bio-Organic and Dr Ross Baker (Immunology and Cancer Vaccine) Gene Expression) Medicinal Chemistry) Dr Russell Buchanan Head Head Head Dr Frank Ierino Vasso Apostolopoulos, Steve Gerondakis, Geoffrey A Pietersz, PhD Dr Christine McDonald BSc(Hons), PhD, Adv Cert Prot BSc(Hons), PhD Dr Paul Johnson Staff Cryst NHMRC Principal Research Fellow Professor Stamatis Vassilaros Martha Kalkanidis, PhD Post Doctoral Fellows Senior Post-Doctoral Fellows Owen Proudfoot, PhD RESEARCH ASSOCIATES Kuo-ching Sheng, BSc(Hons), Ashish Banerjee, BSc(Hons), Choon Kit-Tang, PhD Dr Mal Brandon PhD PhD Sandra Esparon, BSc Professor Dennis Burton Stephanie Day, BSc(Hons), PhD Raffi Gugasyan, BSc(Hons), PhD Student Professor John Cambier Research Assistant Senior Research Assistant/ Nicole Brooks, BSc(Hons) Dr Peter Colman Jodie Halton, BSc Laboratory Manager Dr Henry Metzger Raelene Grumont, BSc(Hons), POWER LABORATORY Clinical Associate MSc (Kidney) NHMRC FELLOWS Christine McDonald, MBBS, Head NHMRC Senior Principal PhD, FRACP HOGARTH LABORATORY David Power, MD, PhD, FRCP, Research Fellow Jennifer Perret, MBBS (Helen Macpherson Smith Trust FRACP Professor P Mark Hogarth Visiting Fellow Inflammatory Diseases) Staff NHMRC Principal Maria Katsara, BSc, MSc, PhD Head Peter Mount, MBBS, PhD, FRACP Research Fellow P Mark Hogarth, PhD, Scott Fraser, BSc(Hons), PhD Professor Steve Gerondakis Students NHMRC Senior Principal Research Marina Katerelos, BSc(Hons), Nicole Brooks, BSc(Hons) Fellow NHMRC Senior Research Fellow PhD Maria Katsara, BSc, MSc Associate Professor Post Doctoral Fellows Kurt Gleich, BSc(Hons) Denise Jackson FFRENCH LABORATORY Bruce Wines, PhD Students (Viral Immunology) Maree Powell, PhD NHMRC Career Michael Desmond, MBBS Head Pat Mottram, PhD Development Award Darren Lee, MBBS, FRACP Rosemary Ffrench, Peck Szee Tan, PhD Professor Vasso Suet-wan Choy, MBBS, FRACP BSc(Hons), PhD Angela Cendron, PhD Apostolopoulos NHMRC Industry Research Fellow Nicholas van de Velde, PhD RAMSLAND LABORATORY Dr Paul Ramsland Bock Lim, PhD Immunological Monitoring (Structural Immunology) NHMRC Industry Fellowship Facility Co-ordinator Research Assistants Head Associate Professor Kylie Goy, BSc(Hons) Soong Ling, BSc(Hons) Paul A Ramsland, PhD Rose Ffrench Halina Trist, BSc Students Staff Lee-Ann Crooks, BSc(Hons) EMERITUS PROFESSOR Rebecca Dutkowski, BSc(Hons) William Farrugia, MSc Kerry Ko, BBiomed, BSc(Hons) Professor Ian F C McKenzie, AM, Jacqueline Flynn, BSc(Hons), XING LABORATORY MD, PhD, FRACP, FRCPA MBiotech JACKSON LABORATORY (Cancer Immunotherapy) Devy Santoso, BMS (Immunoreceptor) Head Head Pei-xiang Xing, MBMM, PhD Denise Jackson, FAIMS, PhD, NHMRC Senior Research Fellow Staff Xiu Feng Hu, MBMM, PhD Post Doctoral Fellow Scott Vandervalk, BSc(Hons) Karen Harris, PhD Student Research Assistant Eunice Yang, BSc(Hons), PhD Rochna Chand, BSc(Hons) Cyndi Wong, BSc(Hons) Jana Yip, BSc(Hons) Students Eva Orlowski May Lin Yap

page "* CENTRE FOR POPUL ATION HEALTH

page "$ CENTRE FOR POPUL ATION The Centre for Population Health (CPH) strives to improve the health of the community by conducting high quality, innovative research that addresses the major public health problems associated with infectious diseases and drugs and related behaviours. CPH’s areas of specific interest are HIV, hepatitis C, sexually transmitted infections, malaria, tuberculosis and drug and alcohol misuse; all are serious health concerns in Australia and the Asia and Pacific Regions predominately affecting highly vulnerable populations. The problems and populations which the CPH addresses are decidedly challenging, but this makes our work equally rewarding and important.

page ") Overview

The Centre for Population Health (CPH) implements novel, Australian population by managing and developing innovative multidisciplinary scientific programs that use cutting-edge surveillance systems for the Victorian Government, and by epidemiology, high quality laboratory science, excellent clinical undertaking research involving the groups most at risk of and social research, and strong public health principles to HIV infection. address major health problems in our region. Working with highly is a major global public health problem, causing as many vulnerable populations, CPH undertakes a broad spectrum of Malaria work, ranging from research that helps to better understand as one billion malaria episodes each year and more than two the priority diseases and their transmission and ecology, to million deaths, predominantly in young children in the poorest discovery science with potential for longer term benefits such as communities. The Centre’s malaria program extends from basic therapeutics and vaccines, to health systems oriented research laboratory research through molecular epidemiology to large that directly influences health policy. Some areas of specific field trials of anti-malarial therapy in children in Papua New interest are described below. Guinea, all aimed at providing evidence for more effective control and treatment. Alcohol and other drug use is a major public health issue costing the Australian community an estimated $** billion per annum. Chlamydia trachomatis is a sexually transmitted infection that CPH conducts research designed to measure the nature and predominately affects young heterosexual men and women; extent of alcohol and other drug use over time, with a view to there were over $',''' new notifications in Australia in "''%. developing effective policy responses. If untreated, chlamydia infection is a major cause of pelvic inflammatory disease and tubal infertility in women. CPH aims to Hepatitis C is associated with considerable mortality and morbidity with over !%' million people infected world wide. reduce the impact of chlamydia on the community by reducing Working closely with people who inject drugs and collaborating transmission and increasing the number of young people tested with virologists, immunologists and mathematical modellers, and treated for chlamydia. CPH’s hepatitis C research focuses on improving understanding Tuberculosis (TB) remains a major public health menace with about hepatitis C virus infection and transmission, with the the number of cases worldwide increasing. The emergence of ultimate aim of developing a hepatitis C vaccine. TB that is resistant to almost all currently available drugs is a It is estimated that over (( million people throughout the significant threat to control programs internationally. The Centre world are living with HIV, and in Australia new diagnoses of HIV for Population Health is working on the epidemiology and health continue to increase. CPH aims to reduce HIV transmission in the systems implications of the emergence of drug-resistant TB.

Heads of research (Above L-R): Back: Professor Robert Power, Dr Campbell Aitken, Professor John Reeder (Co-Head), Dr Paul Gilson, Dr Alyssa Barry, Associate Professor Paul Dietze, Dr Mark Stoové. Front: Associate Professor Margaret (Co-Head), Professor Brendan Crabb.

page "% Highlights

Groundbreaking work on drug-resistant tuberculosis The networks study – an innovative multidisciplinary investigation of the hepatitis C virus In an international collaboration set in Uzbekistan, Dr Helen Cox of Burnet’s International Health Research Group and her Since early "''*, Margaret Hellard and Campbell Aitken have colleagues followed %) patients infected with multidrug-resistant collaborated with scientists from the Victorian Infectious tuberculosis, using drug sensitivity testing and molecular Diseases Reference Laboratory and the department of typing. During the course of treatment !% patients developed Immunology at the University of Melbourne on a major resistance to ofloxacin, a marker for the feared extensively drug- multidisciplinary study of the hepatitis C virus (HCV). Their resistant (XDR) strains. They demonstrated that in !( patients networks study focuses on HCV transmission within social the molecular type remained constant and the strains had networks which include several hundred injecting drug users, amplified resistance during treatment, and one patient had the population most at risk of HCV. (Approximately !%' million an initial dual infection with a sensitive and a resistant strain. people are infected with HCV worldwide, and it can lead to Alarmingly, four patients were shown to have been exogenously chronic hepatitis, cirrhosis and liver cancer. HCV infection is reinfected while actually on treatment, with strains similar to responsible for half of all cases of liver cancer and two thirds of those isolated from other patients staying in the hospital at the liver transplants in Australia.) Margaret and Campbell found that same time. These findings were published in one of the world’s people who were infected with HCV, then cleared their infection, highest impact journals, The New England Journal of Medicine were significantly more likely to be re-infected with the virus .(*&;"", "(&%/"#''0 and have major practical implications for the than those who had never contracted the disease – even after treatment of drug-resistant TB (DR-TB) in hospital settings. controlling for behaviour and other differences. (Many other infectious agents, such as the hepatitis B virus, induce total Current research centres on a collaboration with the international immunity; reinfection is impossible.) The HCV incidence rate in humanitarian organisation Médecins Sans Frontières (MSF) the group at risk of reinfection was #$.%% per annum, compared in a pilot project for treating drug-resistant TB in a large Cape with !*.*% per annum in the previously uninfected group. These Town township in South Africa. Khayelitsha has an antenatal findings suggest that clearance of an HCV infection does not HIV prevalence of around ('% and a TB case notification above confer immunity against future infection and makes subsequent !*''/!'','''/year. Not surprisingly, drug-resistant TB has infection more likely, which has obvious implications for vaccine emerged as a significant threat, with an incidence estimated to development. The importance of Margaret and Campbell’s work be higher than anywhere else in the world. Operational research was demonstrated by the publication of a paper describing the has evaluated whether providing more patient-centred care networks study in Hepatology, the most prestigious journal in the in a community setting can result in better case detection and field, in late "''%. improved treatment outcomes. Specific studies are quantifying the prevalence of DR-TB in Khayelitsha, providing data allowing the optimisation of treatment regimens and determination of whether natural ventilation can be effectively used for TB infection control in primary care clinics.

Consultation on Measuring ventilation in rooms Links between networks study participants drug-resistant TB. where XDR-TB patients will be based on injecting relationships. hospitalised.

page "& Snapshots

A novel protein export machine in malaria parasites encouraging – there was a significant improvement in sexual health knowledge and uptake of sexual health testing after Malaria is one of the most devastating infectious diseases of receiving the messages. The success of this project has led to humankind and is caused by massive infection and destruction further funding to scale up this approach. of the body’s blood cells by Plasmodium species parasites. In our work we are trying to understand how the Plasmodium parasites recognise and infect blood cells, and once there, how they are Justice health research able to grow and avoid the human immune system. In a recent The Centre for Population Health commenced a study breakthrough study we have identified novel parasite protein investigating the post-prison release experiences of offenders machines that export parasite proteins into their red blood cell with a history of injecting drug use. This study will interview hosts. The exported proteins are essential for parasite survival participants at one month, three months and six months post- and we wish to discover drugs that can block the export machine release and examine personal, behavioural and service-related thereby eradicating the parasites. outcomes during this particularly vulnerable period in their lives – a period often characterised by substantially increased risks of HIV prevalence study – ‘Suck it & See’ mortality and morbidity. This study forms part of an expanding justice health research program which has been enhanced by the Suck it and See is an innovative new study that aims to estimate arrival of Dr Stuart Kinner, an NHMRC post-doctoral scholar who is the prevalence of HIV and the extent of unrecognised infections among gay men in Melbourne. We successfully recruited )#$ examining health and integration outcomes among people with men through community-based sites including bars, clubs, sex- incarceration histories. on-premises venues and sexual health clinics. All participants self-completed a short behavioural survey and also provided Development of innovative surveillance systems an oral fluid specimen for HIV antibody testing. As the first of its CPH worked on the development of several innovative kind in Australia, it is intended that this study will be the pilot surveillance systems to improve our understanding of HIV, for a nation-wide system conducted periodically and will inform ongoing epidemiological initiatives. hepatitis C, chlamydia and syphilis transmission. These included an HIV/STI sentinel surveillance system for Victoria and the Australian Collaboration for Chlamydia Enhanced Sentinel New Burnet study addresses health Surveillance (ACCESS). Working with NCHECR, NRL and the outcomes for injecting drug users National Perinatal Statistics Unit, we are establishing six separate In "''%, we commenced a longitudinal study of the health and chlamydia sentinel surveillance networks, each providing unique social outcomes associated with injecting drug users known as information on testing uptake and prevalence of chlamydia the Melbourne Injecting Drug User Cohort Study (MIX). MIX will infection in a range of priority populations: young heterosexuals, provide new data on the typical trajectories of injecting drug use men who have sex with men, Indigenous Australians, pregnant in Australia and determine risk and protective factors for users women and sex workers. for outcomes in the health, social and psychological domains. We will measure these outcomes using linkage to health and Malaria genomics for better interventions social datasets along with direct face-to-face interviews with participants. Baseline data collection (funded by the Colonial A major obstacle to broadly effective malaria vaccines is Foundation Trust) is well underway and we will be recontacting the extraordinary genetic diversity of the malaria parasite, participants over a period of four years following the receipt of a Plasmodium falciparum. Dr Alyssa Barry and colleagues are project grant from the NHMRC. investigating the distribution and evolution of diversity of P.falciparum surface antigens, including leading vaccine candidates. These studies are essential for a better Sexual health and young people understanding of malaria epidemiology and transmission, and CPH continued its work related to sexual health and young for designing better, longer-lasting vaccines. We are also defining people. We again attended the Melbourne Big Day Out music patterns of antibody acquisition to the highly variable parasite festival in January, recruiting over "''' young people to antigen PfEMP!, to understand how natural immunity develops. complete a short behavioural survey. Participants then received This is a collaboration with the Papua New Guinea Institute of twelve sexual health promotion text messages on their mobile Medical Research, Queensland Institute of Medical Research and phones over the subsequent four months. The results were very University of California, Irvine.

page (' Centre for Population Health: our staff and students

Co-Heads Post Doctoral Fellows PhD Candidates CPH ASSOCIATES Margaret Hellard, FAFPHM, PhD, Kerstin Leykauf, Diploma, PhD Hayley Bullen, BSc(Hons) Dr Jane Hocking, BAppSc, MPH, FRACP, MBBS Mauro Azevedo, BSc, PhD Michelle Giles, MBBS, FRACP Master of Health Science, PhD John Reeder, MSc, PhD Judy Gold, BBiomedSci(Hons) Dr Anne Mijch, MBBS, FRACP Surveillance Manager Andreea Iuga, (Hons) Head, International Isabel Bergeri, MSC, PharmD Chris Lemoh, MBBS, BMedSci, Health Research Group NHMRC FELLOWS HIV Clinical Advisor FRACP, DipClinEpi John Reeder, MSc PhD NHMRC Principal Research Julian Elliot, MBBS, FRACP Megan Lim, BBiomedSci(Hons) Head, Drug and Alisa Pedrana, Fellow Alcohol Program Statistician BBiomedSci(Hons) Professor John Reeder Tim Spelman, BSc, Paul Dietze, BSc(Hons), PhD Tana Taechalertpaisarn, NHMRC Senior Research Fellow GradCertStats BSc(Hons) Associate Professor Head, HCV Program Maelenn Gouillou, MSc Campbell Aitken, BSc(Hons), Office Manager Margaret Hellard Research Officers PhD Liz Nicol (from December "''%) NHMRC Post Doctoral Fellow Carol El-Hayek, BSc, MEpi Marion Pilley (to July "''%) Peter Higgs Head, HIV/AIDS & STI Program Jane Goller, RN, Mark Stoové, PhD, GradDip GradDipNursing, MPH, Master of NHMRC Career (Ed), BAppSci(Hons) Health Science Development Award Fabian Kong, BPharm, MEpi Co-Heads, Gilson/ Associate Professor Paul Dietze Yung-Hsuan Julie Wang, MBBS, Crabb Laboratory FRACGP, MAE NHMRC Howard Florey Brendan Crabb, BSc(Hons), PhD Keflemariam Yohannes, Centenary Fellowship Paul Gilson, BSc(Hons), PhD BPsych(Hons), MPH, MAE Dr Alyssa Barry Senior Research Fellows Research Assistants NHMRC Public Health Alyssa Barry, PhD (Malaria Stuart Armstrong Fellowship Molecular Epidemiology) Sarah Charmaud, BSc(Hons) Dr Helen Cox Helen Cox, PhD (TB Duyen Duong, Diploma Epidemiology) Community Welfare Research Fellow Danielle Horyniak, Lucinda Franklin, MPH, MEpi BBiomedSci(Hons) Rebecca Jenkinson, BEng(Geol), GDipEpid and Biostat, MEpid Oanh Nguyen, BSW, MPH Brendan Quinn, BArts (Hons)/ BSc Rachel Sacks-Davis, BSc,BA(Hons) Lee Schultz, PhD Sally Von Bibra, RN, RM Rebecca Winter, BA

page (! CENTRE FOR INTERNA TIONAL HEALTH

('(" page (" CENTRE FOR

INTERNA TIONALThe Centre for International Health (CIH) is committed to improving the health of communities in low-income countries through strengthening primary health care and the control of high-burden health problems. We aim to both support evidence-informed health programs and to influence more broadly international health policies and initiatives within the developing world. CIH designs, implements and evaluates public health programs in Asia, the Pacific region and Africa, predominantly undertaking programs in partnership with local and international organisations. Areas of focus are HIV and AIDS prevention and care, including harm reduction; women’s and children’s health; and the control of other communicable diseases, including emerging infections. CIH also delivers a highly-regarded training and education program in international public health.

(( page (( Overview

During "''%, the Centres for International Health and Harm seven international NGOs, six private sector entities, and the Reduction merged to form a ‘new’ CIH, which retains a strong Global Fund to Fight AIDS, Malaria, and Tuberculosis. This resulted commitment to comprehensive harm reduction. We have in a *!% increase in revenue compared with "'') to more than expanded our traditional focus on injecting drug use to a broader $!# million, $#% of which supported our country programs. Drugs and Society approach that includes research on the impact Involvement in implementing Australian Government funded of amphetamine-type stimulants (ATS), marijuana, and alcohol ‘bilateral’ health programs has long been a core activity. During on behaviours that heighten the risk of sexually transmitted "''%, in association with GRM Pty Ltd, we commenced support infections. We also continue to work closely with law enforcement to the third phase of Australian assistance to the Indonesian officials in a number of countries, including Malaysia, Indonesia, response to HIV and AIDS through the HIV Cooperation Program and China, to enable drug users to access prevention and for Indonesia ("''% - "'!"). We continued to manage the China treatment services. Australia HIV and Health Facility and, with the Australian Red There were a number of major challenges to our work during Cross, jointly implemented the Tibet Health Sector Support "''%, including the civil disturbances in Tibet in March, which Program. The latter program has been extended for a further !* led to our program manager having to leave the region and months by the Australian Government. In Papua New Guinea limitations on our outreach work to sex workers and their clients. (PNG), AusAID extended Burnet’s contract to manage the Tingim Nevertheless, by the end of the year, we were able to sign a new Laip program, which supports community-based responses to agreement with local authorities to continue working in Lhasa for HIV in (* sites. The Pacific Regional HIV/AIDS Project came to an a further two years. end in September. An external evaluation highlighted a range of Following the devastating May cyclone in the Delta region of achievements, such as support to strategic planning, community- Myanmar, Burnet helped establish the Local Resource Centre for based and national prevention and care activities across !# mobilising community-based responses, which has provided countries in the region, and innovative communication strategies, support to local NGOs in their response to cyclone-affected such as the TV soap series, Love Patrol. communities. In addition, we received funding from AusAID to CIH reached an important milestone in "''% when our first implement an Integrated Psychosocial, Sexual and Reproductive ‘country program’ – in the Lao PDR – celebrated its !'th Health Program in partnership with Marie Stopes International anniversary. It was in Lao PDR where Burnet established its first and the Antares Foundation Australia. These new programs led country office and in March "''%, we opened a regional office in to a rapid increase in the number of Burnet national staff from Bangkok. The Aceh Partnerships in Health program, established around !" to nearly $'. after the Indonesian tsunami, came to an end and we closed our Despite the beginnings of the financial crisis, CIH experienced Banda Aceh office. However, we will continue to provide support significant growth. Overall, we managed &% contracted pieces of to HIV prevention activities through a local NGO, Medan Aceh work in "''% with funding from #' different sources, including Partnerships. We maintained our other programs in Mozambique, eight governments, seven UN agencies, two development banks, Indonesia, PNG, Sri Lanka, and Vietnam.

Management Group (Above L-R): Back: Mark Tennent, Dr Chris Morgan, Robyn Whitney, Professor Mike Toole (Head). Front: Bruce Parnell, Marion Brown, Dr Wendy Holmes. Absent: Robert Power.

page (# Country programs

Indonesia In October, our Youth Ambassador, Collingwood footballer Heritier O’Brien visited Manica and has become a strong A review of Burnet’s Indonesia Country Program resulted in a advocate for Burnet’s HIV work in Mozambique. more focused strategic plan. Burnet staff have been active in several national networks, including HIV counselling and gay, transgender and other men who have sex with men. Burnet’s Myanmar counseling training was acknowledged at the national level as a model of good practice. The Levi Strauss Foundation continues The devastating natural disaster of Cyclone Nargis left over to support capacity building for local responses to HIV among !(',''' people either dead or missing and directly affected drug users in Bekasi, West Java. Our program of capacity building another " million people. In response to Nargis, our team in HIV prevention and care continues in NTB province. AusAID in Myanmar grew to *% full-time staff in order to deliver commissioned Burnet to assess methods to ‘mainstream’ HIV in services through the Local Resource Centre and the Integrated all development programs. Psychosocial Sexual Reproductive Health project (with Marie Stopes International). In the midst of these diverse public health and emergency activities the Burnet Institute program Lao People’s Democratic Republic in Myanmar continued its focus on strengthening the capacity of local partners to build community responses to HIV. With In "''%, the Lao program developed a wide-ranging portfolio funding from the ( Diseases Fund and AusAID, our team delivered of new activities. The mining company LXML funded a maternal training, mentoring and leadership support to !' organisations, and child health and nutrition project in the surrounding district. ranging from local women’s groups to national partners: the Burnet is a sub-recipient in a new Global Fund grant; our role is Myanmar Red Cross and Anti Narcotics Association. During "''% to promote safer sex among men who have sex with men in three our team prepared for the return of the Global Fund by developing provinces. We successfully tendered for a two-year HIV prevention proposals for HIV prevention activities for men who have sex with project, funded by the Asian Development Bank (ADB), in men and injecting drug users. communities along a newly constructed highway in the North. Local staff engaged in a range of consultancies for development partners, including ADB, World Vision and Lux-Development. Papua New Guinea

We appointed a new country representative, Jim Benn, during "''%. Our core activity continued to be the Tingim Laip Mozambique HIV prevention project. The East New Britain Sexual Health The fifth year of our program witnessed significant achievements, Improvement Project became fully operational with STI training including increasing proficiency of the Manica core team as for health workers and the development of community-based trainers and mentors, strengthened capacity of our partner ‘stret tokers’ who promote prevention, including condoms. There MONASO Manica, and increasing institutional and technical was a successful second measles supplementary immunisation capacity of NGOs in Manica and Sofala provinces. Burnet and the activity – with social mobilisation from Burnet. We engaged with MOH are working closely on the Advanced Counselling Initiative. the Ministerial Taskforce on Maternal Mortality from September Local partner OMES continues to play a leading role in HIV "''%. Burnet’s new Director, during a visit, signalled that all of prevention in Manica and the Chimoio STI Night Clinic provides Burnet’s four Centres have the potential to engage in research effective, non-judgemental care. and public health activities in Papua New Guinea.

Young Indonesians Burnet’s Tibet Program Manager Heritier ‘Harry’ O’Brien plays footy benefit from Burnet’s Chris Hagerty signs a two year with local children in Mozambique. health messages. cooperation agreement.

page (* Country programs (cont.)

China (Tibet), Sri Lanka, and Vietnam Research included studies related to Drugs and Society in ì ,Q7LEHWDWZR\HDU&RRSHUDWLRQ$JUHHPHQWZDVHQGRUVHGDQG Asia and the Pacific, such as the AusAID-funded Illicit Drugs new support received from the Canada Fund to implement the Initiative – research and capacity building on amphetamine-type Duilong Dechen Community HIV Prevention Project. stimulants (ATS) in Lao PDR, Cambodia and Thailand. The Pacific Drug and Alcohol Research Network (ten countries) is in its fourth ì ,QWKLVıIWK\HDURIWKH6UL/DQNDSURMHFWWRLPSURYHWKHKHDOWK year, supported by AusAID, UNODC and WHO. Burnet and The Fiji and well-being of elders in tea estates, there was a focus School of Medicine, with AusAID funding, is conducting situation on advocacy, disseminating lessons learned and building assessments of STI/HIV risks associated with drugs and alcohol sustainability of activities. in !$ Pacific countries. ì :LWKD3ODQHW:KHHOHU*UDQW&,+VXSSRUWHGWKH9LHWQDP Community Mobilisation Centre for HIV/AIDS Control to The Centre for International Health contributed to a range of implement harm reduction activities in Hanoi, including peer activities commissioned by a number of international partners. education, outreach, and a drop-in centre. For example, a study of HIV epidemiology and surveillance in Pacific countries was commissioned by UNAIDS for the Commission on AIDS in the Pacific. Other activities included the Other highlights development of the Pacific Regional HIV Strategic Implementation Plan (SPC), evaluation of the national needle and syringe program In "''%, AusAID established four new ‘knowledge hubs’. The in Malaysia (WHO), technical direction of the Central Asia Women’s and Children’s Health (WCH) Knowledge Hub (Compass) Regional HIV/AIDS Program (DFID), development of a national is a partnership between Burnet’s Centre for International strategy on HIV prevention in mothers and children for Sri Lanka Health, the Menzies School of Health Research and the Centre (World Bank), development of an advocacy tool around HIV and for International Child Health at the University of Melbourne. men who have sex with men in South East Asia (RTI/USAID), The purpose of Compass is to establish a central knowledge capacity building in essential drugs management in the Pacific point for those who work to improve WCH, advocating for greater (WHO), review of Uzbekistan’s harm reduction program (World investment, facilitating partnerships, and influencing policy Vision), and HIV prevention in prisons in China (UNODC). and practice, with a focus on contributing to equitable progress towards the United Nations’ Millennium Development Goals Finally, there was a continued increase in student enrolments in (MDG) # and *. our !" post-graduate courses, with a steadily higher proportion of international students, reaching ((% in "''%.

Consultation with the elders on the tea plantations in Sri Lanka. Meetings are vital to Tingim Laip’s community-based approach in Papua New Guinea.

page ($ Centre for International Health Melbourne office: our staff and students

Head HIV and Development Personal Assistant Senior Contracts and Mike Toole, MBBS, BMedSc Specialists to Deputy Head Program Manager (Monash), DTM&H (London) Lisa Renkin, BA (UQ), MPH Trish Clark, DipBus (Swinburne) Mark Tennent, BSc(Hons), Grad (UNSW) Dip Acc, CPA (until July "''%) Deputy Head, Principal Fellow Technical Programs International Health and Harm Reduction Senior Fellow, HIV and Wendy Holmes, MBBS (London), Development Specialists Jimmy Dorabjee, BA (Sociology) Development Specialist MSc Community Health in Chris Hagarty, MPH India Bruce Parnell, BA, MPH Developing Countries (LSHTM) International Health, Bachelor (Monash), GradDipComDev Project Manager and of Podiatry La Trobe (from (Phillip Institute of Technology) Principal for Disease Prevention Research Assistant August "''%) Robert Power, BSc Economics, Lucina Schmich, ANU Senior Fellow, Medical Karl Dorning, DipT, BEd (La PhD (LSE), PGCE (London) Bachelor Arts Asian Studies Epidemiologist Trobe) – (Vietnamese), Monash LLM Tony Stewart, MBBS (Monash) Deputy Head, Management Damien Morgan, BEd, PhD (La (Juris Doctor) ongoing MAppEpid (ANU) FAFPHM Geoff Drenkhahn, MBA Tech Mgr Trobe), NursCert (currently on (Deakin), FAIM (until July "''%) leave without pay) Project Manager – Senior Project Manager Suzanne O’Neill, M Conflict China Program Shaun Liddell, BE (Civil) (Hons) Deputy Head, Management Resolution (La Trobe), DipHealth Satoko Kiyota, Bachelor of (Canterbury), MPH Mark Tennent, BSc(Hons), Grad Sciences (La Trobe), BA Economics (YCU, Japan), Master Dip Acc, CPA (from July "''%) Training and Education (Melbourne) of Health Administration Administration Officer Adolescent Health and (UNSW) International HIV and Andrea Eakins Development Specialist Development Specialists Project Manager – Mick Creati, MBBS, MPH Epi Women’s and Children’s Chad Hughes, BSc(Biomed), Mekong Delta Region and Biostats (Melbourne), Health Advisor MPH (Monash) Meg Quartermaine, MPH FRACP (on sabbatical from July Clare Murphy, RN, BEdSt, Lisa Natoli, DipAppSc Nursing to December "''%) MPH&TM, MHSc Project Manager – (La Trobe), MPH Intl Health Myanmar (Burma) Program (Monash) Community Health Coordinator International Programs Dino Asproloupos, BA (Leisure Chris Morgan, MBBS (Sydney), Women’s and Children’s Accountant Services) (UVIC), IMBA DTCH (Liverpool) FRAC Health Specialist Sarah Thomson, BA, BEc (International Strategy) (York) Natalie Gray, FAFPHM, Masters Education Services Coordinator Asian Studies (ANU), Project Manager – PNG Program of International Public Health Marion Brown, BA, Bed TESL GradDipCommerce (UNSW), CA Tansie Jarrett, BA (Hons) (Syd), MBBS (Hons) (La Trobe), DipEd (Monash), International Programs (Anthropology), BA Asian (Syd), BSc, LLB (Hons) (Class !) MAss&Eval (Melbourne) Finance Officers Studies (Indonesian and (from November "''%) Essential Drugs and Community James Lawson Contemporary Asian Society) Women’s and Children’s Health Specialist Dean Garreffa, BComm La Trobe (ANU) Health Research Officer Beverley Snell, PhC (Victorian Kelly Xiao, BCom (Accounting), Public Health Anna Bauze, BSc(Hons !), MPH, College of Pharmacy), MAppSc BEng (Environmental) (Hons), Management Specialist GradDipTechMgmt (Research) (La Trobe), PHCb Melbourne (from November Clement Malau, MBBS, MMed (London IOE) "''%) Youth Health Advisor, HIV and Community Health (PNG), MPH Development Coordinator Harm Reduction and Medical Epidemiologist (Harvard), DTM&H (Mahidol) Cathy Vaughan (currently on Development Advisor Ben Coghlan, MBBS (currently on leave without pay) leave without pay) Andrea Fischer, BA/BSc, (Melbourne), MPH&TM Public Health Specialist GradDip (EpiPopHealth) (ANU), (James Cook) Resident Associate Brad Otto, BA (Denver) (until MPH (Monash) Tony Mellen – Business Mozambique Program Director February "''%) Development Health Economist and Program Quality and Rohan Sweeney, B Ec, PGrad Learning Advisor Dip Health Eco & Eval, Robyn Whitney, BA/ MPH Intl Health SocSc(Hons) (La Trobe), Postgrad Cert in Assess & Eval

page () Centre for International Health overseas offices: our staff

CHINA #TIBET$ Program Support Manager LAO PDR MOZAMBIQUE Country Program Manager Evy Suryanti, Master of HR Country Program Manager Maputo Office Chris Hagarty, MPH Management (until August Niramonh Chanlivong, Country Representative International Health, Bachelor "''%) MD (Prague), MPH (NSW), Dr Paulo Proto de Souza, MD, of Podiatry La Trobe (until GradDipHE (Gandhigram MPH Technical Assistant August "''%) Institute) Erijadi Sulaeman Accounts Assistant Office Manager and Assistant Project Officer Volunteer Mariamo Jamaldine Outreach Project Officer Souvanhthong Lorkham, BA Rob Booker, Diploma in Social Wangmo English, Laos Finance Manager Administration Benjamim Antonio, Bachelor Outreach Project Officers Finance and Office Manager of Business Adm Moz Sonam Palmo (Finances) Vanmixay Boudtavong, English Wangdue (IEC Development) Lombok Office Dip (Laos) Project Assistant Project Assistant Zomkyi Edna Sandra Reis Imam Sofian, Bachelor in Law Finance Assistant Thavisouk Homsombath, Dip Volunteer Project Officer Fiona Sillars FIJI BA, Economics & Business Ika Christi, Diploma in HIV/AIDS Program Management Management(Laos) International Relations Specialist, Team Leader Pacific Onsite Project Officer Chimoio Office Regional HIV/AIDS Project Lathatana Chanthala, English Regional Coordinator Dr Tamara Kwarteng, MSc Banda Aceh Office Dip (Laos) Alfeu Manuel Muchine, BA (University of Ghana & LSHTM), Program Manager PhD (LSHTM), Grad DipEpid Hamsya, Bachelor in Project Coordinator Cleaner/Office Assistant (Melbourne) Applied Physics Viroth Beuypanpittouleth, Victorino Durbek Higher Dip(Laos) Cleaner Driver INDONESIA Ely Darweti Project Management Advisor Vicente Fernando Silva Bali Office Philippa Sackett, BSc Driver Country Representative (Psychology), MA (Human Mr Fauzi Amanda Morgan, BTEC HND Rights) in Business and Finance Finance & Office Manager Project Officers Management Hadya Noer, Diploma in Bangone Santavasy, M.A Management Finance Officer (Thailand) Edwin Timotius, Bachelor Health Technical Specialist Anongly Phimmasone, Dip in Accounting Nur Rokhmah Hidayati, MPH BA, Economics & Business Management (Laos) Office and M&E Training Coordinator Phansamai Vilasack, (rd year of Administration Manager Erwien Temasmico, Bachelor English Dip (Laos) Ferny Hapsari, Bachelor in in Economics Amphone Keooudom, MD (Laos) Agricultural Technology Office Assistant Senior Project Officer Office Assistant Fitria Khankham Southavilay, MA Yufri Isomoyo DipHistory (Comsomol) Office Keeper I Gst Ayu Kadek Program Manager Marcia Soumokil, MPH Program Officers Tono Permana Muhamad Mashadi Mulyo, Bachelor in Law Ima Susilowati, Bachelor in Psychology (until October "''%) Asti Widihastuti, Masters of Health Counseling

page (% MYANMAR M&E Officers PAPUA NEW GUINEA #PNG$ Receptionist Country Representative Mon Mon Senior Program Manager Nora Luanda (until May "''%) Kim Benton, BBSc, GradDipBHC Banyar Tun Jim Benn, BSocSc(Waikato), Lillian Tau (La Trobe), GradDip Drama PG DipAcc (Wellington), PG Program Secretariat Manager Regional Coordinator (Auckland), LTh (NZJBTS), LTCL Dip Community Development Phone Myint Win Tingim Laip (Deakin) (from April "''%) Administration Assistants Joan Usan Project Officers Naw Cecilia Aye Admin Assistant Port Moresby Joanne Ganoka Aung Min Thein Zin Mar Nay Win Freda Joup Judy Tokeimota Nwe Mar Tanya Mossman Administration Coordinator Zin Mar Thu Admin Assistant ENBSHIP Nyi Nyi Win, Assoc in AppSc Myo Than Elizabeth Norman Senior Technical Advisor (New York City Technical Ye’ Min Htoon Annette Coppola, RN, CMW, Community Worker ENBSHIP College) Khin Hnin Oo Post Grad Dip SH&V, MIM, MPH Aung Myint Than Ellen Kavang Social Mobilisation Health Administration Officers Wai Lin Kyaw Sakaia Luana Nee Sin Thweit Aye Promotion Ne Chye Thwin Drivers Port Moresby May Thu Shein Lester Bisibierra Nay Myo Aung Harry Fong Myo Khin Doi Ra Irunah Sagah Abari (until Team Leader ENBSHIP Centre Coordinator Sai Aung Kyaw Myint October "''%) Joan Macfarlane Myint Su, BSc Zoology (Yangon) Nay Lin Aung Terence Kassman (until Training Coordinator September "''%) Cleaners Project Training Coordinator Erica Ogoba Ni Ni Mar Khine Nandar Sein Tun Finance Assistant New’ New’ Ohn Naomi Vele Regional Officer THAILAND Consultant (part time) Swe San Oo Finance Manager (office established Kerren Hedlund Team Leaders Kathleen Waninara-Kema March %&&') Driver Cho Cho Mar, BCom (Institute Health Extension Officer Asia Regional Representative Naing Htoo Zaw (a) Zaw Zaw of Economics, Yangon), CPA Geralding Wambo Brad Otto, BA (Denver) (Myanmar Accountancy Council) Finance Officers Tin Aung Win, BVetSc (Inst of Janitor Port Moresby Aung Iwin Animal Husbandry & Science, Inara Udia Wintwar Tun Yangon), DipFood Tech (Yangon Logistics Officer Finance Managers Inst of Tech) Caroline Talei Bunemiga Naing Naing Win Nang Pann El Kham M&E Coordinator Min Min Htike Htar Htar, BSc (Mawlamyaing), DipAcc (London) Fidelis Jogamup Housekeeping Supervisor National Manager – San San Aye Technical Advisor Kelly Macdonald, MSc Tingim Laip program Housekeeper Reproductive & Sexual Health Ako Maniana Nwe Nwe Ohn (from August (London), MSc Rural Planning Office Manager "''%) & Dev (Ontario), BA Int Dev Beranice Reuben Studies (Calgary) HR Assistant Project Manager Aye Myat Soe Technical Support Officers Lesley Bola (until January "''%) Aung Moe Than Information Management Pyae Phyo Aung Project Officers Coordinator Thet Thet Mar Benson McRubins Aye Myat Thu Wah Wah Lynn Bridget Taimbari Information Management Denys Waibauru Thematic Coordinators Officer James Sakul Hla Htay Nang Nechi Minn Jimmy Frumpui (until September Tin Tin Mar, BSc Zoology "''%) IT Officers (Yangon) Joseph Mocke Myo Min Min Htike Khin Pa Pa Naing Lazarus Pomo (until May "''%) Lwin Min Ko Translator Meredith Tutumang Logistics Officer Patrick Macormick Paul Weriyai Thida Win Simon Kange Ronald Kwenama Rose Mauyet

page (& CORPOR ATE AND SUPPORT SERVICES

page #' ORPOR ATE AND SUPPORT SERVICES

page #! Overview

The role of Chief Operating Officer for the Burnet Institute was Governance, Strategic, Commercial, Financial, Research and established in mid "''% and I thank the Director and the Board Development, Facilities and Operations, and Personnel. High for the opportunity to move into the role from my previous levels of risk are prioritised and mitigating strategies enacted. position within the Centre for International Health. The need for Plans for "''& include development of the Human Resource such a role reflects the growth of the Institute, both in size and area to address issues associated with overseas-based staff, the diversity of activities and the subsequent need to support implementing opportunities for sharing services with AMREP those activities in an integrated and co-ordinated manner partners, and further refinement of the risk management and across our financial services, human resources, corporate internal audit framework. affairs, fundraising, IT, building services and laboratory support. The areas of Commerialisation, IP and Legal also form part Burnet’s Public Affairs and Development (PAD) team continued of Corporate and Support Services but will be reported upon to expand its broad range of activities increasing the brand separately in this annual report. In addition to these ongoing awareness of the Burnet Institute and raising funds in support of services it has been an exciting challenge to oversee the the Institute’s laboratory research and public health programs. development of the Institute’s new building via the Alfred Centre The past year while demanding, has been one of our most Stage " (ACS") project, also to be reported on separately. successful in fundraising, however, with the current global financial crisis we anticipate "''& to be more challenging. Business Services at the Burnet Institute constitutes finance, The main challenge continues to be attracting new funding purchasing and supply, human resources, corporate governance for infrastructure, in particular from donations, bequests and and general administration. We are fortunate to have a very commercial collaborations, so that the Burnet Institute can talented and stable team in this area able to continue the continue to provide the best available resources for its scientists. excellent provision of services despite the growth in staff and During "''%, $"."( million was raised via PAD initiatives. activities requiring support, as evidenced by the doubling of the Institute’s financial turnover in the last three years. Major brand awareness activities undertaken in "''% included Initiatives in this area during "''% include implementation of the Melbourne City Romp initially launched in "'') and the an internal auditing program, installation of a web-based expansion of this to Brisbane attracting a combined total of purchase ordering system, and continued investment in new "',''' participants. Other events included the Burnet Oration and replacement equipment. with the Hon Justice Michael Kirby, the Thomas Heywood Organ Recital which was arranged by the Friends of Burnet, and the Financial management of the ACS" development was a key focus Melbourne World AIDS Day event focused on Burnets HIV for "''% which saw significant work in financial modelling, programs in Mozambique. managing cash flows and maximising returns on investments. We also undertook further refinement of a well established The Bosom Buddies Breast Cancer Foundation continued its risk management process which is reviewed regularly by the annual charity ball and corporate golf days with the support of Board. Key risk issues are grouped by risk category and include: a dedicated committee led by Patron Mr Bill Jane OAM and the

Executive team (Above L-R): Back: Professor Brendan Crabb, Geoff Drenkhahn, Paul Rathbone, Associate Professor Bruce Loveland, Peter Spiller, Professor Mark Hogarth. Front: Paul Stephens. Absent: Paul Duffy, Dana Herrmann.

page #" Rotary Club of Berwick. I would also like to extend our thanks to organisations these included the China-Australia Health HIV/AIDS all our dedicated volunteers and committees for their support Facility and the Australian Collaboration for Chlamydia Enhanced at our events and to our Youth Ambassador Heritier O’Brien and Sentinel Surveillance (ACCESS). Ambassador Deanna Blegg for their commitment to the Institute. Maintaining laboratory and facilities services across two sites The Institute was the recipient of a number of major grants from is always a challenge. Striving for consistency in standards and Trusts and Foundations as well as private donations for which operational approach has to be tempered by the undeniably we are most grateful. Of particular significance was funding from different physical conditions and historical influences on each the Janina and Bill Amiet Foundation supporting the Institute’s site. Despite these challenges our Laboratory Services team cancer research programs. In addition, major grants were have continued to provide high level support to our operations received from the Miller Foundation, the Ian Potter Foundation at both campuses. The ever-growing regulatory compliance and the Percy Baxter Charitable Trust. The Institute would like to demands have professionally and effectively been addressed acknowledge and thank all those Trusts and Foundations which and the safety of our staff and our operations remains a priority supported Burnet in "''%, this support has enabled the Institute as demonstrated by the recruitment of a dedicated laboratory to undertake a number of important research and public health safety consultant. programs both within Australia and internationally, which would While officially this report is to cover "''% it would be remiss otherwise have not been possible. of me not to mention two points of significance that occurred in In "''%, several major IT infrastructure projects were February "''&. Firstly the Institute’s Laboratory and Operations implemented, the most popular of these was the Institute-wide Manager, Dana Herrmann retired from the Institute after !' years wireless network which has saved the Institute from installing of dedicated and valuable service. In addition to overseeing additional wiring to support new staff and visiting researchers. the move to the current AMREP campus she has provided the foundations for what is a highly regarded and professionally- Due to the growth in IT services, server room space and power run set of laboratories and associated services including a are at a premium. With this in mind, a process of consolidating very effective OHS record. Secondly, an external review of the backup tape systems and server disk systems was completed Corporate and Support Services was undertaken in February utilising a one-tape library system for all server and desktop to seek opportunities to better align the services to meet the backups, and a new consolidated NAS/SAN disk unit providing all evolving needs of the Institute. The recommendations and server disk storage. In addition, a project to migrate IT services of findings of that review are currently being considered with a our larger aging Sun Solaris servers onto faster and more efficient revised structure expected to be in place by mid "''&. Intel servers running the Open Source Linux operating system was implemented. I would like to thank all staff across the corporate services units for their support and assistance over the past six months and I Two new administrative facilities were installed including the look forward to an exciting and challenging year in "''&. online IPOS ordering system replacing the in-house facility that was developed in !&&%. This is integrated with the finance system; and the new Connx online HR facility that will be expanded in "''& allowing staff to receive their pay slips electronically and apply for leave online. A number of websites were developed for various collaborative projects with other Geoff Drenkhahn, Chief Operating Officer

Melbourne City Romp teams IMPACT, Burnet’s regular newsletter. Burnet’s Brendan Crabb and Alastair Lucas, with celebrating at Federation Square. Professor Tim Flannery (centre), guest speaker at the Annual Burnet Business Breakfast.

page #( Corporate and Support Services: our staff

EXECUTIVE BUSINESS UNIT MELBOURNE AND FACILITIES AND RESEARCH BRISBANE CITY ROMPS SUPPORT SERVICES Director Chief Financial Officer Brendan Crabb, PhD Peter Spiller, BBus, CPA Event Director Operations Manager Brendon Grail, BBus Dana Herrman, BAppSc, MBA Deputy Directors Accounting Manager P Mark Hogarth, PhD, NHMRC Pixie Tan, BCom, CPA Deputy Event Director Research Services Manager Senior Principal Research Fellow Fiona Rhody-Nicoll, LLB(Hons) Soto Kolivas, PhD Finance Manager David Anderson, BSc(Hons), Rob Tanner, BBA, CA Event Manager, Technical Assistant PhD, NHMRC Senior Research Brisbane City Romp Leanne Reardon Assistant Accountant Fellow Emma Leishman (February to Barb Ledwidge Peter Dib November "''%) Chief Operating Officer Laboratory Safety Advisor Receptionist Geoff Drenkhahn, MBA Tech Mgr Customer Services Co-ordinator, Sol Hall (from October "''%) Sieyin Phung, BBus (Deakin), FAIM (from July "''%) Brisbane City Romp Storeman Finance Officer Bianca Sardoni (June to Executive Officer Blaine Oataway (from November Liz Kitchen October "''%) Janet Cameron, BA(Hons), LLB "''%) (to June "''%) Payroll Officer Volunteer Co-ordinator, Maintenance Technician Jack Bambino Brisbane City Romp Company Secretary Chris Pope Talei Wright (June to Peter Spiller, BBus, CPA Purchasing Officers October "''%) Biological Research Mark Hamilton, BA Personal Assistant Facility Manager Kevin Hesse Customer Services Co-ordinator, to the Director Charlotte Priest, AssDipAppSc, Melbourne City Romp Valerie Skahill, BA(Hons) Melissa Mulcahy, Adv Dip Animal Technology Personal Assistants Health Sciences (from July to Assistant Manager PUBLIC AFFAIRS AND to Deputy Directors November "''%) Julie Toussaint DEVELOPMENT Susan Collins (Professor Volunteer Co-ordinator, Staff Hogarth) Director Melbourne City Romp Josh Lorimer Nadine Barnes (Associate Paul Rathbone, BAppSc, FAIMS, Grace Daley, BA Dev Studies, Carlie Tobias, DipAppSc, Animal Professor Anderson) Grad Dip (Public Relations), (from July to November "''%) Technology MBus (Marketing) Alfred Centre Stage % Tricia Murphy, DipAppSc, Project Manager Marketing and Animal Technology Bruce Loveland, PhD Communications Manager INFORMATION TECHNOLOGY Gillian Chamberlain, Human Resources Manager AdvCertBus (RMIT), CertEdit/ Head Paul Duffy, BA, Grad Dip(HR/IR) Pub (RMIT), CertDirMar (ADMA) Paul Stephens, BComp Senior Public Affairs Officer Staff Tracy Routledge, Britta Taylor, MA BA (Communications) Damon Warren, BSurv(Hons) (from July "''%) Gary Jamieson, PhD Matt Gray, Dip InfoSys Community Relations Officer Dyson Simmons, Ian Haigh, BA B InfoSys(Hons) Client Development Coordinator Pin Affleck, BFA(Hons)(from August "''%) Public Affairs and Development Officer Hazel Squair, BMA (Public Relations) (from July "''%) Public Affairs Officers Claire Gorst (to April "''%) Rachel Lenders, BA

page ## KAZAKHSTAN MONGOLIA

UZBEKISTAN KYRGYZSTAN TURKMENISTAN TAJIKISTAN AREAS OF BURNET’S WORK BURNET’S OPERATIONAL CENTRES AFGHANISTAN CHINA

NEPAL

BANGLADESH

INDIA MYANMAR LAOS

THAILAND THE PHILIPPINES VIETNAM CAMBODIA

SRI LANKA

KIRIBATI DEM. REP. CONGO TUVALU INDONESIA PAPUA SOLOMON NEW GUINEA ISLANDS TIMOR LESTE SAMOA MOZAMBIQUE VANUATU FIJI ZIMBABWE TONGA

AUSTRALIA

SOUTH AFRICA

Beijing Mataram Colombo Bali Lhasa Jakarta Kokopo Maputo Yangon Vientiane Port Moresby Chimoio Banda Aceh Bangkok Melbourne Suva

Where we work

page #* Commercialisation

The Institute continued to focus on translating its research into The test aims to provide a quick and accurate method of health outcomes during "''%. measuring CD# levels in HIV-infected individuals, suitable for use in resource-poor settings where there is no access to ì 7KH%XUQHW,QVWLWXWHFRQWLQXHVWREHDPDMRUSDUWLFLSDQWLQ laboratory infrastructure. This new test is expected to help the Cooperative Research Centre for Biomarker Translation manage HIV infection particularly in the developing world. The (CRC) that officially commenced operation in "''). Other grant is worth approximately US$( million over four years. participants include La Trobe University, The Mater Medical Research Institute, Mater Misericordiae Health Services, ì 3URIHVVRUV'DYLG$QGHUVRQDQG*HRİUH\3LHWHUV]ZHUH The Women’s and Children’s Health Research Institute, and successful in receiving NHMRC development grants worth The Institute of Medical and Veterinary Science. The over AUD$((',''' in total for the further development of commercial partners are Amgen (USA) and Becton Dickinson Professor Anderson’s CD# ELISA-based test and Professor Biosciences (USA). The CRC’s principal objective is the Pietersz’s novel vaccine formulation for the immunotherapy of development of antibodies directed against therapeutic and adenocarcinomas. diagnostic targets (biomarkers) present on cells that play a key role in major diseases including autoimmune disease (especially rheumatoid arthritis) and cancers (haematological, OUR STAFF colorectal, breast and prostate). The CRC has been awarded Director, Commercialisation and Strategic Development AUD$('.$ million over seven years. P Mark Hogarth, PhD, NHMRC Senior Principal Research Fellow ì %XUQHWåVSDUWQHUFRPSDQLHV,J$YD[3W\/WGDQG#G Vaccines Chair, IP and Commercialisation Working Group Pty Ltd continued research into developing an effective Geoffrey Pietersz, PhD intranasal vaccine for respiratory diseases and a vaccine for the Commercialisation Manager treatment of and protection against breast cancer. Research is Serina Cucuzza, BCom, BSc(Hons) progressing according to milestones and both companies are IP Manager likely to reach clinical stage by "'!'. Maria Harrison-Smith ì 3URIHVVRUV'DYLG$QGHUVRQDQG6X]DQQH&URZHKDYHFRQWLQXHG Legal Advisor to progress their project for the development of a point-of-care Alison Greenway, BSc(Hons), LLB, PhD CD# test, funded by the CD# Initiative, Imperial College London Project Manager through a grant from the Bill and Melinda Gates Foundation. Pat Mottram, PhD

Our team (L-R): Back: Associate Professor Bruce Loveland, Burnet places great emphasis on translational research. Associate Professor David Anderson. Centre: Dr Alison Greenway, Serina Cucuzza, Dr Pat Mottram, Professor Mark Hogarth. Front: Maria Harrison-Smith, Professor Geoffrey Pietersz.

page #$ Commercialisation

New Patents and Applications #$$%

Title Country Filing Date Number

PATENTS GRANTED – #**( Transgenic Animal Model for Autoimmune Diseases Australia $)*Jun*$+ #$$+#++#!)

Transgenic Animal Model for Autoimmune Diseases New Zealand $)*Jun*$+ (+)')+

Transgenic Animal Model for Autoimmune Diseases US $)*Jun*$+ "+(&%"(

Fc Receptor Modulating Compounds and Compositions US #!*Dec*$+ "++#)+&

Antigenic Carbohydrate Compounds and their Use in Immunotherapy Canada &(*Nov*'! #&+(%++

Composition Comprising Immunogenic Virus Sized Particles Australia &!*Sep*$& #$$)#$$$!(

Composition Comprising Immunogenic Virus Sized Particles Australia &!*Sep*$& #$$)#$!)#$

Antibodies Against Cancer US #)*Mar*$# "+&%'#!

Immunoreactive Antigens of Hepatitis E Virus Europe #+*Sep*'! "##!'' A Nucleic Acid Construct Encoding a Processing Component Derived from US #"*Sep*$# "+!&"#+ the N-term reg of the Hep Virus ORF#, and an Antigenic Peptide NEW PCTs – #**( Chemically Modified Macromolecules (mannan and aldehyde dendrimers) PCT &+*Jun*$% PCT/AU#$$%/$$$%)!

Dendritic Cell Markers and Uses Thereof PCT +$*Aug*$% PCT/AU#$$%/$$&#'! Peptide Analogues and Conjugates Thereof PCT #$*Nov*$%PCT/IB #$$%/$$+!'+ (mbp epitope analogues for MS vacc.) NEW PROVISIONALS – #**( Methods of Detecting Dead and Dying Cells US Prov $&*Jun*$% )$/')'&&% Peptide Analogues and Conjugates Thereof Au prov &#*Sep*$% #$$%'$!"(" (mbp epitope analogues for MS vacc.)

A number of Burnet researchers were successful in securing funding from the ACH# scheme including Heidi Drummer, Andy Poumbourios, Margaret Hellard, David Anderson. The scheme funds translational projects specifically in the area of HIV and Hepatitis.

Summary of Income and Expenditure #$$%

TOTAL INCOME !$"#.$% MILLION& TOTAL EXPENDITURE !$'#.() MILLION&

R & D Laboratory (non-salaries) &&% Other &#% Infrastructure &#% International Sources '% R & D Public Health (non-salaries) #(% Commercial Contracts !%

Donations (%

Research Foundation &% Building Development #% Depreciation #% State Government #'% Commonwealth Government !$% Employee Costs !%%

The full finance report reflected in the Summary of Income and Expenditure above is available on request.

page !" Education and capacity building program

The Burnet Institute continued to play an important role in The Institute also offered an advanced coursework module education and capacity building during "''%, both within for Monash/AMREP Honours students. This module involved Australia and overseas. Burnet provided training in laboratory advanced training in deconvolution microscopy, flow cytometry and social research, with students from Australian and and sorting, laser capture microscopy and multi-plex cytokine international universities undertaking postgraduate independent analysis using bead array. These training sessions were provided research projects across all of the program areas. Burnet was by senior scientists at Burnet with expert knowledge of these also actively involved in the delivery of public health courses at techniques. The students then completed an assessment task, undergraduate and postgraduate levels, through associations describing how they would use the equipment in a grant proposal with the University of Melbourne, Monash University, Deakin to study a particular aspect of viral infection or viral immunity. University, La Trobe University, and Udayana University (Bali) and The Honours year also involved completion of other core Atma Jaya Catholic University in Indonesia. coursework subjects, such as: advanced statistics, production of a review of the literature related to their thesis topic, several oral Honours program at the Burnet Institute presentations, and the final submission of their Honours thesis describing their year’s research in October/November. This was Ten students undertook a BSc(Hons) or BMed Sci(Hons) program followed by an oral defence of the thesis by their examiners. at Burnet in "''% – six from Monash University, and four from University of Melbourne. Overall, the students at Burnet did very well achieving six First Class Honours and four H"I or H"A marks. Three of the students Six of these students studied within the Centre for Virology and have gone on to beginning a PhD at Burnet or elsewhere, four within the Centre for Immunology, across a wide range of while most other students have now started work as research projects. These included the role of heterosubtypic immunity assistants. One student with a combined Law/BMS(Hons) degree in influenza (Rebecca Dutkowski), tetraspanins in thrombus is now working in patent law in Japan. stability (Eva Orlowski), PECAM-! in salmonella infections (May Lin Yap), Hepatitis C virus glycoprotein structure and function The "''% Honours coordinators at Burnet were Associate (Mark Edmunds), truncated HCV E" in different viral genotypes Professor Paul Gorry and Associate Professor Rosemary Ffrench. (Yousef Alhammad), the role of SR proteins in HIV replication Further enquiries regarding the Honours program at Burnet in macrophages (Sushama Telwatte), HIV-associated host cell should be sent to [email protected]. factors (Chin Long Wong), HIV gag protein structure (Omer Gilan), determinants of HIV viral assembly (Vera van Hoeven), and memory B-cells responses in Hepatitis C virus infection (Devy Santoso).

Our Education team (L-R): Marion Brown, Associate Professor Rosemary Ffrench, Students who attended Burnet’s HIV course in Phnom Penh, "''%. Dr Anthony Jaworowski. Absent: Professor Steve Gerondakis.

page #% Education and capacity building program

Postgraduate Study in Refugee Settings and the Managing Community-based HIV Programs in Developing Countries attracted interest well beyond During "''%, (% students undertook postgraduate research at the #' places available in each course. The two international Burnet in basic laboratory-based and public health research. health core subjects, Primary Health Care in Developing Countries These students were recruited from a variety of Australian and and Field Methods for International Health Planning and international universities, including universities from Jordan, Iraq, Evaluation, were delivered in both semesters in "''% – to meet Germany and Portugal; enrolled through both Monash University high demand and to ensure that all students completed these and the University of Melbourne. During this year, eight Doctoral compulsory units. Degrees and one Masters Degree were awarded to Burnet Institute students. In addition to this core teaching, CIH was involved in some exciting education and training activities. The three-year contract The Burnet Institute places great emphasis on postgraduate with AusAID to provide HIV training for AusAID staff ended in study, with the aim of providing high quality research training July "''%, following CIH facilitated workshops in Canberra, in areas related to public health and basic science in infectious Suva (!$ AusAID staff from seven Pacific countries), Vientiane, diseases and immunology. To assist in fostering this aim, Phnom Penh and Hanoi. The Asia Regional HIV course was Burnet has an active postgraduate committee, chaired by Dr again conducted in Phnom Penh, attracting "! participants from Anthony Jaworowski, which liaises with each student’s academic eight countries. In the latter half of "''%, with funding from the department. The functions of this committee include mentoring, AusAID Australian Leadership Awards Fellowship scheme, CIH monitoring student progress and conflict mediation. In addition, provided public health training to !) staff members from Udayana the committee organises seminars and postgraduate symposia to University in Bali to support them in introducing a Masters of nurture the academic life of our postgraduate students. Public Health course in "''&.

Advanced Medical Science (AMS) students Centre for Population Health (CPH) The AMS program is a one-year research program for third The Centre for Population Health (CPH) provided a number of year medical students from the University of Melbourne. In short courses in conjunction with the Centre for International "''%, Burnet had three AMS students – one in the Centre for Health (CIH) during "''%. CPH staff also presented teaching Immunology; one in the Centre for Virology; and one in the Centre sessions, as needed, for other organisations. These teaching for Population Health. sessions included General Practice Victoria and the HIV, Hepatitis and STI Education and Resource Centre. In addition, Centre for International Health (CIH) CPH provided the field placement component for one Master of A record number of students enrolled in the !# postgraduate Applied Epidemiology student, studying the course through the subjects that were offered by Centre for International Health (CIH) Australian National University’s National Centre for Epidemiology in "''%. This high number is in line with international trends and Public Health. which show that courses in epidemiology, public health and For the past three years, CPH has been successfully running a global health are ‘hot’ classes on campuses these days!. These training program which offers young people from marginalised CIH subjects, accredited by Monash University and/or University communities the chance to undertake a traineeship in which of Melbourne, can be credited towards a Master of Public Health they gain practical research skills, and also allows them to study or Master of International Health degree, a Graduate Diploma in and obtain a qualification in a relevant field. The program is International Health, or may even be attended by students not supported by grants from the Myer, Bokhara, IOOF, Invergowrie seeking any academic accreditation. A total of "## students were and Matana Foundations, and the Gandel Charitable Trust. Each enrolled in these courses, with many completing two or more traineeship is for a two-year period, with a new trainee selected subjects. Total subject enrolments within Burnet’s CIH for "''% to start each year. In "''%, one of the two trainees focused on were ()%. Similar to previous years, the enrolment data shows hepatitis C outreach and field work, and the other was involved that the student cohort comprises more women (!%&) than men with research on sexually transmitted infections in collaboration (**). While all subjects proved to be popular, the Public Health with the Victorian Aboriginal Service.

! Brown, D. For a Global Generation, Public Health is a Hot Field. The Washington Post "''% September !&; page A'!

page #& Committee members

BOARD SUB)COMMITTEES: INTERNAL COMMITTEES: PhD Committee: Anthony Jaworowski (Chair until Audit Finance & Risk Committee: Scientific Advisory Committee: * May "''&) Ross Cooke – Chair Brendan Crabb – Chair Rosemary Ffrench (Chair from Neil Edwards David Anderson * May "''&) Marion Brown Investment Committee: Campbell Aitken Suzanne Crowe Denise Allen – Chair Alyssa Barry (from * May "''&) Steve Gerondakis Sid Khotkar* Melissa Churchill Margaret Hellard David Lee* Heidi Drummer (from * May "''&) Mark Hogarth Alastair Lucas Paul Gorry Robert Power Elizabeth Grgacic IP & Commercialisation Committee: John Reeder Paul Ramsland Rob Milne – Chair Mike Toole Gilda Tachedjian David Anderson OH&S Committee: Serina Cucuzza Laboratory Equipment and Con Sonza – Chair Tracey Batten (until December "''%) Facilities Committee: Sarah Charnaud P Mark Hogarth Melissa Churchill – Chair Trish Clark Ian Wightwick (until December "''%) Ashish Banjeere Brendan Crabb (from "''&) Alyssa Barry Research Advisory Committee: Johanna Dean Brendan Crabb James McCluskey – Chair Geoff Drenkhahn (from "''&) Kylie Goy Michael Alpers* Paula Ellenberg Vicki Greengrass Lorena Brown* Anne Ellet David Harrison Nick Crofts* Rosemary Ffrench Marcel Hinjen Brendan Crabb Paul Gilson Gary Jamieson Peter Doherty Matt Gray Soto Kolivas John Dowling Raelene Grumont Maree Powell P Mark Hogarth Sol Hall Paul Rathbone Anne Kelso* (from "''&) Soto Kolivas Hazel Squair Bruce Loveland Fundraising Committee: Gilda Tachedjian Johnson Mak (from "''&) Garry Hounsell – Chair Blaine Oataway IP Working Group: Pin Affleck Andy Poumbourios (from "''&) Geoff Piertersz – Chair Julius Colman* Laveena Sharma David Anderson Brendan Crabb Serina Cucuzza P Mark Hogarth Laboratory Users Group: Alison Greenway Henry Lanzer Heidi Drummer – Chair Maria Harrison-Smith Alastair Lucas David Anderson Pat Mottram Maria Myers Jenny Anderson Paul Rathbone Alyssa Barry AMREP Precinct Animal Centre: Melissa Churchill Graeme Ryan – Chair* ACS% Project Committee: Brendan Crabb David Anderson Rob Milne – Chair Geoff Drenkhahn Jay Chin-Dusting* Ross Cooke Rosemary Ffrench Steve Gerondakis (since August "''%) Brendan Crabb Steve Gerondakis Jenny Grace* Neil Edwards Paul Gilson Mark Hogarth (until August "''%) P Mark Hogarth Paul Gorry David Lloyd* Alastair Lucas Eric Gowans (until November "''%0 Hatem Salem* Elizabeth Grgacic Steve Wesselingh* Mark Hamilton AMREP Animal Ethics Committee: Dana Hermann (until February "''%) Raffi Gugasyan – Chair Anthony Jaworowski Ashish Banerjee Bruce Loveland Kay Juliff* Johnson Mak Charles Hardy* Andy Poumbourios Robyn Sullivan* Li Shuo Patricia Baitz* Ajantha Solomon Debbie Ramsey* Con Sonza Gilda Tachedijan

*Member external to the Burnet Institute

page *' Governance statement

The Board of Directors has adopted a Governance framework Composition of the Board which incorporates the ‘Corporate Governance Principles and In accordance with the Institute’s Constitution, the number of Recommendations’ of the Australian Stock Exchange and which directors constituting the Board must not be less than eight is appropriate for the size, complexity and operations of the and not more than "' and will include the Executive Director Burnet Institute. While some of these provisions are particular in its number. A majority of the Board should be independent to listed for-profit corporations, many are just as relevant to directors, in particular the role of the Chair and Executive Director a complex not-for-profit entity such as the Burnet Institute as should not be exercised by the same person. Directors shall they are to the commercial sector. The ongoing relevance and be appointed by resolution of the Board and each Affiliated effectiveness of this framework will be periodically reviewed University may propose one director. to reflect changing circumstances and ways of improving the practices we have adopted. The appointment of Board Members is run by the Chair of the Board who will review nominations in consultation with the Executive Director and other Members. Appointments will be Role of the Board and Management approved by the Board and confirmed at the AGM. The Board’s primary role is the protection and enhancement All Board Members appointed to the Burnet Institute Board will of the long-term interests of the Burnet Institute and its receive a letter of appointment from the Chair, which sets out stakeholders. To fulfil this role, the Board gives consideration to the basis of the appointment. That letter will outline background the range of research and other activities which are appropriate information, documentation and policies including: to the Institute ensuring that the key stakeholders’ interests are addressed. The Board is responsible for the overall governance ì 7HUPRIDSSRLQWPHQW of the Institute including formulating (on the advice of the ì 0HHWLQJDWWHQGDQFHH[SHFWDWLRQV Executive Director) its strategic direction, ensuring that risk ì *RYHUQDQFHFKDUWHU management policies are in place and are being monitored, ì &RQVWLWXWLRQ establishing and monitoring the Executive Director’s and management’s goals and performance and ensuring the integrity ì &RPPLWWHHV of internal control and management information systems. It is ì %RDUGSDSHUV also responsible for approving and monitoring financial and ì &RQıGHQWLDOLW\ other reporting. ì $FFHVVWRSURIHVVLRQDODGYLFH To assist the execution of its responsibilities, the Board has ì &RQIJLFWVRILQWHUHVW established the following Board committees: ì ,QGXFWLRQ ì $XGLW)LQDQFHDQG5LVN As a general rule, Board Members are not expected to serve for ì ,QYHVWPHQW more than ten years. This rule will be subject to review on a case- ì ,QWHOOHFWXDO3URSHUW\DQG&RPPHUFLDOLVDWLRQ by-case basis. ì )XQGUDLVLQJ ì 3URMHFW Ethical and Responsible Decision Making ì 5HVHDUFK$GYLVRU\ All Directors and employees are expected to discharge their Matters attended to by Board Committees are reported to the duties in good faith and act honestly in the best interests of Board following each committee meeting. Board Committees are the Institute, striving at all times to enhance the reputation authorised to seek any information they require from any officer and performance of the Institute. Directors must ensure that of the Institute and may take such independent professional they use the powers of office for the proper purpose and in the advice as they consider necessary. They have no executive best interests of the Institute as a whole. They must not make powers regarding their findings and recommendations. The Board improper use of information gained through their position as a may at any time determine to address matters identified within a director, or take improper advantage of their position as committee’s terms of reference at the full Board level. a director.

Responsibility for the operation and administration of the Directors are required to undertake diligent analysis of all Institute has been delegated to the Executive Director and the proposals placed before the Board and make reasonable executive management team. These responsibilities have been enquiries to ensure that the Institute is operating efficiently, delineated by formal authority delegations. effectively and legally towards achieving its goals.

page *! Governance statement (cont.)

Directors must keep the Board advised, on an ongoing basis, of ì 0RQLWRULQJLQWHUQDOFRQWUROVLQUHODWLRQWRıQDQFLDODQG any interest that could potentially conflict with those of the commercial activities, legislative and regulatory conformance Institute and any development which may impact the directors’ and asset protection perceived or actual independence. The Board has procedures in ì (QVXULQJWKDWWKHSUHSDUDWLRQDQGSUHVHQWDWLRQRIWKHDQQXDO place to allow directors to disclose potential conflicts of interests. financial statements show a true and fair view and comply with Directors do not participate in the day-to-day management of all relevant accounting standards and statutory requirements the Institute. Consequently, representations or agreements with ì )DFLOLWDWLQJRSHQFRPPXQLFDWLRQEHWZHHQWKH%RDUG$XGLW suppliers, clients , employees, consultants, professional firms or Finance and Risk Committee, Senior Management and Auditors other parties or organisations are made by management unless ì 'HWHUPLQLQJWKHDGHTXDF\RIWKH,QVWLWXWHåVDGPLQLVWUDWLYH such an authority is explicitly delegated by the Board to directors, quality, project and accounting systems either individually or as a Member of a Committee. ì 'HYHORSLQJDQGHQIRUFLQJDIUDPHZRUNIRUDFFRXQWDELOLW\DWDOO The Institute has adopted guidelines for dealing in securities. levels of the organisation. Directors and employees have been advised of the seriousness and consequences of trading in public companies with which Remuneration and Succession Planning the Institute has entered into commercial arrangements, when in possession of confidential information which would have The Remuneration Committee reviews and makes a material effect on the share price of those companies. The recommendations to the Executive Director on remuneration Company Secretary’s written approval must be sought before packages and policies applicable to senior staff. Board Members and employees can trade shares in these The review of the Executive Director’s performance is conducted companies. Approval will be granted when the Company by the Chair with one other Board Member. However, all Board Secretary is satisfied that the Board Member or employee does Members have the opportunity to provide input into the process. not have confidential information in these companies. The Executive Director’s remuneration is approved by the Board.

Succession planning is undertaken as follows: Risk Management ì ,QUHODWLRQWRWKH([HFXWLYH'LUHFWRUâFRQGXFWHGE\WKH%RDUG The Board, through its Audit, Finance and Risk Committee, has ì ,QUHODWLRQWRRWKHUVHQLRUVWDİâE\WKH([HFXWLYH'LUHFWRUZLWK responsibility for ensuring that risk management policies are input from the Board in place and are being monitored. The Audit, Finance and Risk Committee reports to the Board regularly on the status of risks. ì ,QUHODWLRQWRVWDİEHORZVHQLRUOHYHOâE\WKH([HFXWLYH Director with input from the senior management team. The Institute’s risk management process is supported by: ì $XVWUDOLDQ1HZ=HDODQG6WDQGDUG$61=6#($':!&&& - Integrity in Financial Reporting Risk Management, which provides a generic guide for the establishment and implementation of the risk management The Audit, Finance and Risk Committee manages the relationship process involving the identification, analysis, evaluation, between the Institute and the external auditor on behalf of treatment and ongoing monitoring of risks the Board. It recommends to the Board potential auditors ì %XUQHW,QVWLWXWHåV5LVN0DQDJHPHQWJXLGHOLQHV for appointment and the terms of engagement, including ì 7UDLQLQJDVUHTXLUHGWRHQVXUHWKDWPDQDJHPHQWDQGVWDİRI remuneration. The Audit, Finance and Risk Committee evaluates the Burnet Institute understand and implement this Policy. the performance of the external auditor during its term of appointment against specified criteria which include delivering value to stakeholders and the Institute, cost-effectiveness and Audit, Finance and Risk Committee maintaining the highest levels of professional integrity, objectivity The main role of the Audit, Finance and Risk Committee is to and independence. audit the business operations and to oversee the finance and The Executive Director and the Chief Financial Officer provide risk management functions. The Committee shall have unlimited formal statements to the Board that in all material respects: access to the Internal and External Auditors and to senior ì 7KH,QVWLWXWHåVıQDQFLDOVWDWHPHQWVSUHVHQWDWUXHDQGIDLUYLHZ management and may require reports and presentations on of the Institute’s financial condition and operational results specific items. and comply with relevant accounting standards Specific responsibilities of the Committee include: ì 7KHULVNPDQDJHPHQWDQGLQWHUQDOFRPSOLDQFHDQGFRQWURO ì 5HYLHZLQJWKHULVNPDQDJHPHQWIUDPHZRUNDQGLQWHUQDOFRQWURO systems are sound, appropriate and operating efficiently processes relating to all risks of the Institute and effectively.

page *" ASX Corporate Governance Principles and Recommendations

ASX Recommendation Compliance

* Lay solid foundations for management and oversight !.! Establish the functions reserved to the Board and those delegated to senior executives Comply

% Structure the Board to add value ".! A majority of the Board should be independent Directors Comply "." The Chair should be an independent Director Comply ".( The roles of Chair and Chief Executive Officer (CEO) should not be exercised by same person Comply ".# The Board should establish a nomination committee Comply ".* Disclose the process for evaluating the performance of the board, its committees and individual directors Comply

+ Promote ethical and responsible decision-making (.! Establish a code of conduct Comply (." Establish a policy concerning trading in company securities by Directors, senior executives and employees Comply

, Safeguard integrity in financial reporting #.! Establish an Audit Committee. Comply #." Audit Committee structure to include: ì 2QO\QRQH[HFXWLYH'LUHFWRUV Comply ì $PDMRULW\RILQGHSHQGHQW'LUHFWRUV Comply ì $QLQGHSHQGHQWFKDLUSHUVRQZKRLVQRWFKDLUSHUVRQRIWKH%RDUG Comply ì &RQVLVWVRIDWOHDVWWKUHHPHPEHUV Comply

- Make timely and balanced disclosures *.! Continuous policies and procedures Not applicable

. Respect the rights of stakeholders $.! Design a communications policy for promoting effective communication with stakeholders and encourage Comply their participation at general meetings

/ Recognise and manage risk ).! Establish policies for the oversight and management of material business risks Comply )." Management to design and implement the risk management and internal control system to manage the Comply material business risks ).( Written statement to Board by CEO and CFO in accordance with section "&*A of the Corporations Act Comply

' Remunerate fairly and responsibly %.! The Board should establish a Remuneration Committee Comply %." Distinguish non-executive directors’ remuneration from that of executive directors and senior executives Comply

page *( Achievements

Croft N, Hellard M. $"#','#'. NCHECR. A prospective, longitudinal, Current Grants Australian cohort study of newly acquired hepatitis C (HCV) infection, and the impact and efficacy of therapy with PEG-interferon alpha-"a, "''(-"''&. Adams JM, Bouillet P, Colman P, Cory S, Gerondakis S, Huang D, Lindeman G, Strasser A, Vaux D, Visvader J. $!,$'','''. Chief Crowe SM, Ryan CE, Darcy A, Rogers G, Kama M. $$','$). Secretariat Investigator NHMRC Program Grant Roles of impaired apoptosis and of the Pacific Community and WHO. HIV molecular surveillance study differentiation in tumorigenesis and therapy, "'')-"'!!. in Pacific Island countries and territories, "'')-"''%. Adams JM, Cory S, Colman P, Strasser A, Vaux DL, Bouillet P, Crowe SM, Anderson D, Landay A, Denny T. $!,%!',)"". Bill & Melinda Gerondakis S, Huang DSC. $%'','''. Principal Investigator, Leukemia Gates Foundation administered through CD# Initiative/Imperial and Lymphoma Society of America. Renewal of Specialized Centre of College. A point-of-care test for examining CD# in remote areas, Research Grant Apoptosis in Hematopoiesis, Leukemogenesis and "'')-"''%. Therary, "''$-"'!'. Crowe SM, Lavu E, Hearps A, Markby J. $!*,*''. National AIDS Council Apostolopoulos V. US$"#&,)*'. The Susan G Komen for the Cure (NACS). Monitoring of the anti retrovirus treatment (ART) of HIV/AIDS Project Grant, USA. Role: Principle Investigator, Development of a in patients in Port Moresby General Hospital (PMGH) by CD# count and DNA breast cancer vaccine, "''$–"''&. HIV viral load, "''%-"'!'. Barry A. $()','''. Population genomics of malaria surface antigen Crowe SM, Malau C, O’Connor J, Tiban K, Spelman D, Aleksic E, genes. Ryan CE. $!'',!#$. AusAID (via Secretariat of the Pacific Community). Centre for International Health. $!!),$#). Levi Strauss Foundation. Molecular epidemiology of mycobacterium tuberculosis in Kiribati, Capacity Building for Local Responses to HIV amongst Injecting Drug "'')-"''%. Users in Bekasi, West Java. Indonesia, "'')-"''%. Crowe SM. $!,*'','''. National Health and Medical Research Council Centre for International Health. $",')(,'(#. UNOPS. (D Fund – (NHMRC). Program Grant. Pathogenesis of persistent human virus Reducing burden of CD morbidity/mortality in Myanmar, "'')-"''&. infections of global significance, "''*-"''&. Centre for International Health. $",%'',!#&. AusAID. Tingim Laip Crowe SM. $#','''. Australian Centre for HIV and Hepatitis Virology project, Papua New Guinea, "'')-"''%. Research (ACH"). HIV monitoring in resource constrained countries, "'')-"''%. Centre for International Health. $"%,'''. Australian Red Cross. Xinjiang HIV/AIDS Prevention and Care Project. China – Tibet, Crowe SM. $#$,"%'. Australia/India Council (DFAT). Training program "'')-"''%. on antiretroviral drugs for Indian doctors, "''%-"''&. Centre for International Health. $('','''. AusAID. Provision of Short Crowe SM. $%','''. Australian Centre for HIV and Hepatitis Virology Course training for AusAID personnel on HIV and AIDS, "''*-"''%. Research (ACH"). Development of dried blood spot and dried plasma spot technology for HIV monitoring assays, "'')-"''%. Centre for International Health. $(!,%'','''. AusAID. AusAID development initiative. China-Australia Health and HIV/AIDS Facility, Crowe SM. National Health and Medical Research Council (NHMRC). "'')-"'!". Principal Research Fellowship, "''%-"'!". Centre for International Health. $(%,$!'. South Barkly Grow Well Cunningham A, Brew B, Crowe SM, Lewin SR, Slobedman B, Project Consultancy. Anyinginyi Health Aboriginal Corporation Wesselingh SL. $!',''','''. National Health and Medical Research "''$-"''%. Council (NHMRC). Program Grant. Pathogenesis of persistent human viral infections of global significance, "''#-"''&. Centre for International Health. $*)#,&)&. NZAID. Building Capacity for HIV prevention & support programs among local NGOs. Indonesia, Dietze P, Munir V, Johnston J, Fry C, Smit D & Degenhardt L. $(!',!"*. "''$-"''&. NHMRC. The risk factors for ecstasy and related drug overdose: A case- Cherry CL, Hooker DJ, Wesselingh SL, McLean CA. $!)",*'' (for !% crossover study, "'')-"'!'. months). Australian Centre for HIV and Hepatitis Research (ACH"). Drummer H, Poumbourios P. $!*','''. Australian Centre for HIV and Project Grant. Establishing the use and interpretation of an LM-PCR- Hepatitis Virology Research (ACH"). Monoclonal antibodies specific to based phenotypic assay for antiretroviral toxicity, "'')-"''%. novel epitopes in glycoprotein E" diagnostic and therapeutic research, Cherry CL. $($",'''. National Health and Medical Research Council Jul "''%-Dec "''&. (NHMRC). Career Development Award. Understanding the side effects Drummer HE, Poumbourios P, Dore G, Hellard M, Torrezi J. $#$),)#%. of HAART in HIV patients, "''&-"'!". National Health and Medical Research Council (NHMRC). Project Grant. Cherry CL. Paid consultancy to CNS Bio Australia on studies Characterization of neutralizing antibody responses in HCV infected investigating the efficacy of flupirtine for the treatment of painful individuals, "''$-"''%. HIV-associated neuropathies. $#',''' per year since "''). Drummer HE, Poumbourios P, Elhassen D. $*!(,'''. Project Grant. Churchill M, Gorry P. $!)","*'. Australian Centre for HIV and Hepatitis National Health and Medical Research Council (NHMRC). Structure and Virology Research (ACH"). Quantitative, real time assay for HIV-! function of the hepatitis C virus glycoproteins E! and E", "'')-"''&. Neutralising antibody & entry inhibitor potency, "'')-"''&. Drummer HE, Poumbourios P. $!((,'''. Australian Centre for HIV Crabb B and Ralph S. $"&%,'''. NHMRC. Epigenetic control of and Hepatitis Virology Research (ACH"). Evaluation of a minimal antigenic variation in Plasmodium falciparum, "'')-"''&. core domain of the HCV glycoprotein E" as a vaccine candidate with potential to elicit broadly neutralizing antibodies, Jan "'')-Jun "''%. Crabb B, Cowman A and others. US$".&!$ million. Bill and Melinda Gates Foundation. Preclinical prioritization of blood-stage malaria Drummer HE. $#*",*''. National Health and Medical Research Council vaccine candidates, "'')-"'!'. (NHMRC). RD Wright Career Development Award, "'')-"'!!. page *# Emery S, Hoy J, Pett S, Roth N, Wright E. $#'*,#'!. National Health and Kaldor J, Crofts N, Dore J, Hellard M, Lloyd A, Rawlinson W, Medical Research Council (NHMRC). Randomised trial to determine MacCaughan G, Haber P, van Beek I, Dolan K. US$!.% million. NIH. the safety and efficacy of early versus deferred treatment of adult HIV Longitudinal Cohort Study of Newly Acquired Hepatitis C Virus Infection infection, "''%-"''&. among Injecting Drug Users, "''(-"''%. Farrell L, Fry T, Aitken C. $!$*,'''. ARC. An investigation of illicit Kong F, Dietze P, Hellard M. $#%,'''. Commonwealth Department of tobacco use – its prevalence, economic impact and the motivations Health and Ageing. Ecstasy and related drugs reporting system (EDRS), and perceptions of consumers, "''$-"''%. "''*-"'!'. Ffrench R. $#)*,'''. NHMRC Industry Fellowship, Development and Lehmann D, Reeder J. £&#','''. Wellcome Trust International immunogenicity testing of ‘Virus-like particle’ vaccines, "''$-"'!'. Collaborative Research Grant. Neonatal immunization with Gilson P, de Koning-Ward T, Boddey J. NHMRC. $($","*'. pneumococcal conjugate vaccine in PNG, "''*-"'!'. Identification of the Plasmodium falciparum translocon that exports Lewin SR, Cameron PU, Jaworowski A. $($#,%)*. National Health and parasite proteins into their erythocytic hosts, "''%-"'!'. Medical Research Council (NHMRC). Project Grant. Modulation of HIV-! Gorry PR, Churchill M, Lewin SR, Tachedjian G. $!*',%)*. Australian latency by chemokines and dendritic cells, "''%-"'!'. Centre for HIV and Hepatitis Virology Research (ACH"). In vitro assay for Lewin SR, Crowe SM. $"*,'''. Find Award Application. Development HIV resistance to the CCR* inhibitor maraviroc, "''%-"''&. of a rapid test to quantify HIV-! fitness of drug resistant viruses, Gorry PR, Mijch M, Churchill M. $!(%,'''. Australian Centre for HIV "'')-"''%. and Hepatitis Virology Research (ACH"). Rapid assay for plasma HIV-! coreceptor specificity, "'')-"''%. Lloyd A, Harvey C, Ffrench R, Zaunders J, Kumar R, Grimm M. $(!*,'''. NHMRC Project grant. Positioning and function of T cells in HCV Gorry PR, Poumbourios P, Center R, Churchill M. $($!,%)*. National infected liver, "''$-"''%. Health and Medical Research Council (NHMRC). Project Grant. Pathogenesis of CCR*-restricted HIV-!, "'')-"''&. Mak J, Jaworowski A, da Fonseca Pereira C. $*%",)*'. National Health and Medical Research Council (NHMRC). Project Grant. Does HIV Gorry PR, Tachedjian G, Lewin S, Churchill M. $!*',%)*. Australian function as a lipid raft during infection, "''%-"'!'. Centre for HIV and Hepatitis Virology Research (ACH"). In vitro assay for HIV resistance to the CCR* inhibitor Maraviroc, "''%-"''&. Mak J, Tachedjian G. $(&$,()*. National Health and Medical Research Council (NHMRC). Project Grant. Retroviral Recombination, . $#"$,"*'. National Health and Medical Research Council Gorry PR "''$-"''%. (NHMRC). R.D. Wright Career Development Award. Pathogenesis of macrophage-tropic HIV-!, "''*-"''&. Mak J. $!,''','''. Pfizer Foundation Fellowship. HIV Assembly, "''#-"''&. Gowans EJ, Li S, Loveland BE. $#!",%)*. National Health and Medical Research Council (NHMRC). Project Grant. Understanding hepatitis C Netter HJ, Gowans EJ. $!$*,'''. ARC. Linkage Grant. Antiviral virus-specific T cell tolerance, "'')-"''&. compounds to inhibit the replicase of hepatitis C virus, "''%-"'!'. Gowans EJ, Martyn J. $!"&,'''. Australian Centre for HIV and Pietersz GA, Apostolopoulos V. $*!%,"*'. NHMRC Project Grant. Hepatitis Virology Research (ACH"). Grant in aid. A novel recombinant Polynucleotide Vaccine based on targeted delivery to antigen baculovirus as a vaccine delivery vehicle for HCV, "'')-"''%. presenting cells, "''%-"'!'. Grgacic EVL. $")$,)*'. National Health and Medical Research Council Poumbourios P, Drummer HE, Gorry PR. $%'!,'''. National Health (NHMRC). Project Grant. A new insight into hepatitis B infection: the and Medical Research Council (NHMRC). Project Grant. Delineation HBV fusion peptide, "'')-"''&. of receptor-activated conformational signalling pathways on HIV-! Haqshenas G, Gowans EJ. $!($,*''. Australian Centre for HIV and envelope glycoproteins, "''%-"'!'. Hepatitis Virology Research (ACH"). Grant in aid. Construction of Poumbourios P, Drummer HE. $!(",'''. Australian Centre for HIV and HCV chimeric viruses which encode the p) protein from multiple Hepatitis Research (ACH"). Project Grant. Terminal interactions in gp#!: genotypes, "'')-"''%. a novel target for fusion inhibitors, Jan "'')-June "''%. Hellard M, Aitken C, Lim M, Hocking J. $*,'''. Pierce Armstrong Trust. Poumbourios P, Drummer HE. $!*','''. Australian Centre for HIV and SMS to improve young people’s sexual health, "'')-"''%. Hepatitis Research (ACH"). Project Grant. The terminal fusion clasp of Hellard M, Aitken C. $!'','''. Gandel Charitable Trust. A research gp#!: a new target for antiviral discovery, July "''%–Dec "''&. traineeship for an outreach worker from a marginalised community, "'')-"''&. Power DA. $(&",$"*. NHMRC Project Grant. The energy sensor AMPK in acute renal failure, "''$-"''%. Hellard M, Donovan B, Guy R, Kaldor J, Sullivan E, Dimech W. $!,'%(,%#(. Federal Government Chlamydia Targeted Grants Power DA. $*!!,*''. NHMRC Project Grant. Protein kinases regulate Program. Australian Collaboration for Chlamydia Enhanced Sentinel salt reabsorption in the kidney, "'')-"''&. Surveillance, "'')-"''&. Price P, Cherry CL, Wesselingh SL. $!"',''' (for !% months). Hellard M, Fairley C, Aitken C, Hocking J. $!&",)(*. Australian Heath Australian Centre for HIV and Hepatitis Research (ACH"). Project Ministers Advisory Council Priority Driven Research Grants. The impact Grant. Developing a pharmacogenetic test to estimate an individual’s of text & email messaging on the sexual risk behaviour of young men & neuropathy risk prior to commencing antiretroviral therapy, women: a randomised controlled trial, "''$-"''%. "'')-"''%. Hellard M, Guy R, Minge A, White B, $&#,"(".''. DHS Victoria. Ramsland PA. NHMRC R Douglas Wright Biomedical Career Evaluation of the Victorian public health prisoner initiative, Development Award, Structural investigations of carbohydrate "''$-"''%. recognition by antibodies with emerging importance in medicine, Hellard M, Guy R, Winter R. $*%,*!'. DHS Victoria. Evaluation of "''$-"'!'. Hepatitis C treatment, information and support for Victorian prisoners. Reeder J. PNG Kina %&',''' (^US$('','''). UNICEF. Enhancing Hijnen M. $!'','''. The Netherlands Rubicon Fellowship. Structural Pregnancy Outcomes in PNG: a "-centre intervention trial, "''$-"''%. biology of HIV, "''$-"''%. Reeder J. US$".$million. Bill and Melinda Gates Foundation, Infectious Hogarth PM, Mottram P, Powell MS. $*!$,()*. NHMRC Project Grant. Disease Program award. Intermittent preventative treatment during EPI Mechanisms of tissue destruction in autoimmunity, "''%-"'!'. for the prevention of malaria and anaemia in PNG infants, "''*-"''&. Hogarth PM, Wines BD, Powell MS. $)#!,'''. NHMRC Project Grant. Reeder J. US$"*','''. MalGen consortium (Gates Global Grand Structure and function of antibody Fc receptors, "''%-"'!'. Challenge). Genetics of malaria in PNG, "''*-"''%. Hogarth PM. $!#*,'''. NHMRC Senior Principal Research Fellowship, Reeder J. US$)*','''. Fogarty International. International Global "'')-"'!!. Infectious Disease Research Training Program award.

page ** Rogerson S, Jaworowski A. $($*,)*'. National Health and Medical Centre for International Health. $!,'#','''. AusAID. AusAID Cyclone Research Council (NHMRC). Project Grant. HIV and Immunity to Nargis Relief – Local Resource Centre for Community based responses. Malaria, "''$-"''%. Myanmar. Stojanovska L, Apostolopoulos V, Tay M. $&,)''. CRGC industry Centre for International Health. $!','''. South Barkly Grow Well grant, Victoria University, Role: Co-Chief Investigator, Effects of Tsugae Project Consultancy. Anyinginyi Health Aboriginal Corporation. var jannieae on hormone profiles, inflammatory biomarkers and Australia. symptoms in post-menopausal women, "''%. Centre for International Health. $!!",)*'. AusAID. Investigating the Tachedjian G. Co-Leader of Project ". PI Paull J. US$%%*,*(#. U!& role of drug & alcohol use in the spread of HIV & other STIs in Pacific, AI'$'*&%/NIH/NIAID Integrated Preclinical/Clinical Program for "''%-"''&. Topical Microbicides. Development of Dendrimer and Combination Centre for International Health. $!!%,$(*. JTAI. Fiji Health Sector Microbicides, "''#-"''&. Improvement Program – Immunisation coverage survey. Pacific. Tachedjian G, Harrigan R, Sluis-Cremer N. $($!,%)*. National Centre for International Health. $!#,*%(. SPC. Facilitate two Health and Medical Research Council (NHMRC). Project Grant. Drug sub-regional meetings for national & regional stakeholders. Pacific. resistance mutations in the connection subdomain of the HIV reverse transcriptase, "'')-"''&. Centre for International Health. $!*,(''. AIHI, University of Melbourne. HIV AIDS Regional Project (HAARP). Review & updating of Tachedjian G, Mak J. $")),*''. National Health and Medical Research the law enforcement & advocacy manuals. Council (NHMRC). Project Grant. The Role of the HIV-! Reverse Transcriptase Domain in Correct Processing of Viral Proteins to form Centre for International Health. $!*,&'#. WHO. Development of Infectious Virus, "''$-"''%. training module on medicines supply & management for Pacific health workers. Tachedjian G. Chalmers D, Rhodes D. $!*','''. Australian Centre for HIV and Hepatitis Virology Research (ACH"). Inhibitors of HIV-! reverse Centre for International Health. $!*',%)'. Oxiana Lane Xang Minerals transcriptase dimerization, "'')-"''%. Ltd (LXML). Mother and Child Health Project. Laos, "''%-"'!!. Wesselingh S, Churchill M, Gorry PR. $*!(,'''. National Health and Centre for International Health. $!$,%(*. MAC. Technical assistance for Medical Research Council (NHMRC). Project Grant. Molecular studies NSEP Capacity Building & Peer Education Workshop. Malaysia. of the astrocyte reservoir of HIV-! in the central nervous system, Centre for International Health. $!&,*%&. University Malaya. Design "'')-"''&. mission & delivery of professional development training for Prisons & Wesselingh S, Tachedjian G, McCarthy T, Grippner G. $&),*''. AADK. Malaysia. Australian Centre for HIV and Hepatitis Virology Research (ACH"). Centre for International Health. $",)!',)&". AusAID. Tingim Laip Structure function analysis of multi-surface dendrimer based project, Papua New Guinea. microbicide, "'')-"''%. Centre for International Health. $"'','''. AusAID. Myanmar Local Resource Centre. Centre for International Health. $"'&,*)'. AusAID. Australian New Grants Leadership Awards (ALA) Fellowships funding support. Centre for International Health. $"),'''. World Vision Australia. Needs Assessment for HIV Mainstreaming in AusAID’s Indonesia Aitken C, Dietze P, Winter R, Power R. $&#,)*!. DHS Victoria. Program. Evaluation of the Council of Australian Governments (COAG) ‘Supporting Measures Relating to Needle and Syringe Programs Centre for International Health. $"&,(#%. WHO PNG. Improving (NSPs)’ in Victoria. Immunisation Service Delivery at the Aid Post level in PNG. Aitken C, Dixon H, Lim M, Wakefield M, Ferrari G, Hope J, Hellard M. Centre for International Health. $"&,$"&. UNFPA. Female peer $$%,*&(. Vic Health Discovery Grant. Using text messaging (SMS) to education on sexual & reproductive health. Laos. promote health issues to young people: a randomised controlled trial. Centre for International Health. $(','''. Mott MacDonald (HLSP). Aitken C, Hellard M, Stoové M, Higgs P, Winter R. $&(,#'". DHS HIV AIDS Asian Regional Project (HAARP) inputs EAP Site Assessment Victoria. An investigation of the environmental, behavioural and Mission. immunological factors that allow some injecting drug users to avoid Centre for International Health. $(!,"*'. UNAIDS Pacific. Review & hepatitis C virus exposure. Synthesis of data to describe current epidemic. Pacific. Aitken C, Winter R. NZ$%','''. New Zealand Ministry of Health. Centre for International Health. $(",%!'. JTAI. HIV Training to the Review of needle exchange services in New Zealand. PNG-Australia HIV/AIDS Program. Papua New Guinea. Anderson D, Garcia M, Crowe S. $!*&,)*'. National Health and Centre for International Health. $($,'''. PNG IMR. Final report for the Medical Research Council (NHMRC). Development Grant. Development research findings on the enhancing pregnancy outcomes. and prototype manufacture of a high-throughput CD# T-cell test for management of HIV/AIDS infections, "''%-"''&. Centre for International Health. $($,'''. UNODC. Desk review & field visits for HIV/AIDS control in closed settings & drug users. China, Anderson D, Garcia M, Ffrench R. $!*%,$)*. Australian Centre for "''%-"''&. HIV and Hepatitis Virology Research (ACH"). EOI Grant. Serological diagnosis of neonatal HIV infection in resource-poor settings: selective Centre for International Health. $($,(#'. PACT. Young Male Peer Education under the PACT Community REACH Program, Laos. detection of endogenous HIV-specific IgA, "''%-"''&. Centre for International Health. $(),$*$. Australian Federation of AIDS Anderson J, Hope T, Tachedjian G. $*!%,"*'. National Health and Organisations. Support for Gay, Transgender & other men who have Medical Research Council (NHMRC). Project Grant. Mechanisms sex with men Working Group & Network. Indonesia. underlying APOBEC(G restriction of HIV-!, "''%–"'!'. Centre for International Health. $(&!,*$&. AusAID. APAC Reducing Centre for International Health with Centre for Population Health. Community Vulnerability to HIV and AIDS. Africa, "''%-"''&. AUD$()&,)('. AusAID. Mapping sexual and social networks of men who have sex with both men and women in Laos and Vietnam, Centre for International Health. $#!,%%*. Dutch Embassy, Bangkok. countries with concentrated HIV epidemics. Female peer education on sexual & reproductive health. Laos. Centre for International Health. $!,''','''. AusAID funded HIV Centre for International Health. $*((,(((. RTI – USAID Health Policy Cooperation Program for Indonesia with GRM, "''%-"'!(. Initiative, "''%–"'!'. page *$ Centre for International Health. $*$,"*'. ADB. Provide advice & Gorry PR. $#'','''. National Health and Medical Research Council guidance on MPWT in developing an HIV/AIDS Strategic Plan plus an (NHMRC). Biomedical Career Development Award (Level "). Envelope Action Plan for awareness. Laos. glycoprotein determinants underlying cytopathicity of CCR*-restricted human immunodeficiency virus type !, "''&-"'!". Centre for International Health. $$','''. Wheeler Foundation. Support of the Dove Club to undertake Peer Outreach Activities with Gowans EJ, Loveland BE, Torresi J, Li S. $!$*,'''. Australian Centre for IDU. Mekong Delta, "''%-"''&. HIV and Hepatitis Virology Research (ACH"). Grant in aid. A replication defective vaccine strategy for HCV, "''%-"''&. Centre for International Health. $$#,'''. Robert Christie Foundation. Grant for establishing Intl School for Development & Project Planning. Gowans EJ, Roberts SK, Loveland BE. $#&#,"#). National Health and India. Medical Research Council (NHMRC). Project Grant. A new HCV cell therapy, "''&-"'!!. Centre for International Health. $&%,$)'. ANCD. Situational Assessment in !$ Pacific Island Countries and Territories, "''%-"''&. Hellard M, Ffrench R, Drummer H. $!!%,'''. Identifying key immunological markers that predict injecting drug users risk Centre for International Health. AUD$$'',''' per year from of hepatitis C virus reinfection ACH!, "''%-"''&. Centre for "''%-"'!!. AusAID. Women’s and Children’s Health Knowledge Hub. Immunology, Centre for Population Health, Centre for Virology. Centre for International Health. US$!'',''' Ford Foundation. Towards greater involvement of men in pregnancy, childbirth, postpartum care Hellard M, Ffrench R, Drummer H. $!!%,%%$. ACH". Identifying key and infant care: knowledge, attitudes, beliefs and practices in Bali. immunological markers that predict injecting drug users risk of Indonesia. hepatitis C virus re-infection. Centre for International Health. US$!'','''. Ford Foundation. Hellard M, Goller J, Winter R, Downing S, Aitken C. $%&,)**.$'. Promoting men’s involvement in ante natal care services. Indonesia. Western Australian Department of Health. Evaluation of the Western Australian HIV/AIDS, STI and Hepatitis C Action Plans, "''$-"''% and Centre for International Health. US$)','''. Levi Strauss Foundation. the Western Australian Aboriginal Sexual Health Strategy, "''*-"''%. Capacity Building for Local Responses to HIV amongst Injecting Drug Users in Bekasi, West Java. Indonesia. Hellard M. $*$','''. NHMRC. Senior Research Fellowship. Innovative research approaches to understanding the transmission and reduce Coulibaly F, Ffrench R, Mak J. US$!'','''. Gates Foundation the impact of blood borne viruses and sexually transmitted infections Exploration Grand Challenge: MicroCubes as Vaccines for the on the community. Developing World, "''&. Higgs P. $&,)'%. UNSW Faculty of Medicine Post-doctoral Small Grant Crowe SM, Anderson D, Landay A, Denny T. $!,')$,""$. Bill & Melinda Scheme award. How do long term injecting drug users avoid exposure Gates Foundation administered through CD# Initiative/Imperial to hepatitis C infection? College. A point-of-care test for examining CD# in remote areas, "''%-"''&. Hooker DJ, Cherry CL, Wesselingh SL. $!$#,*'' (for !% months). Australian Centre for HIV and Hepatitis Research (ACH"). Project Grant. Crowe SM. $!",*''. Abbott. HIV training program for doctors in the Measuring and monitoring apoptosis and antiretroviral therapy by Pacific Islands, "''&-"''&. merging real-time and ligation-mediated PCR, "''%-"''&. Crowe SM. $"&,"'&.#'. Tibotec, a Division of Janssen-Cilag Pty Jackson DE. $!(','''. National Heart Foundation Grant-in-Aid. Ltd. Educational Grant. HIV training programme for doctors in Laos, Signaling mechanisms that regulate platelet thrombus formation and "''%-"''&. growth, "''&-"'!'. Crowe SM. $#$,"%'. Australia/India Council (DFAT). Training program Jackson DE. $$!%,)*'. NHMRC Senior Research Fellowship (SRFB). on antiretroviral drugs for Indian doctors, "''%-"''&. Jaworowski A, Crowe SM. $#(%,'''. National Health and Medical Danta M, Hellard M, Sasadeusz J, Prestage G, Matthews G. $(%','*'. Research Council (NHMRC). Project Grant. ITAM signalling proteins in NHMRC. Defining sexual transmisison of hepatitis C among gay men. chronic viral disease, "''&-"'!!. Davenport MP, Kent SJ, Mak J. $*!','''. ARC Discovery Project: The Jolley D, Degenhardt L, Fry C, Johnston J, De Villiers, Munir V, Dietze P. Dynamics of Viral Latency in Chronic Infection, "''& $(!',!"*. NHMRC. A study of ecstasy and related drug (ERD) overdose Dietze P, Aitken C, Jolley D, Kerr D, Hickman M and Stoové M. risk factors. $)'%,(**. NHMRC. The natural history of injecting drug use among IDU Mak J, Hijnen M. $("*,'''. National Health and Medical Research in Melbourne. Council (NHMRC). Project Grant. Virus-Host Cell Interplay, "''&-"'!!. Drummer HE, Poumbourios P. $*"!,"*'. National Health and Medical Munn A, Mak J, Lewin SR. $!#','''. Australian Centre for HIV and Research Council (NHMRC). How variable regions in HCV E" modulate Hepatitis Virology Research (ACH"). Project Grant. Effect of a novel anti- glycoprotein function, "''&-"'!!. HIV compound on early events in infection, "''%-"''&. Fairlie D, Young P, Tachedjian G. $$!!,"*'. National Health and Medical Neaton J, Larson G, Wright EJ, Brew B, Price RW, Robertson K. Research Council (NHMRC). Project Grant. Investigating a novel generic $(,('#,##(. NIH (NIMH & NINDS) START Neurology Substudy, approach to anti-infective agents, "''%–"'!'. "''%-"'!". Ffrench R, Lloyd A, Dore G. $!*%,'''. The influence of HCV treatment Pattison P, Robbins G, McBride E, Hellard M. $**','''. ARC Discovery strategies on the development and maintenance of potentially Grant. The structure and dynamics of social contact for human disease protective cellular immune responses. ACH", "''%-"''&. transmission model. , Shannon F. $#)$,'''. NHMRC Project grant. The Gerondakis S Pietersz GA. $!)#,*''. NHMRC Development Grant. Novel vaccine transcription factors c-Rel and RelA serve distinct roles in the formulation for the immunotherapy of adenocarcinomas, "''&. development and function of CD# regulatory T cells, "''&-"'!". Pietersz GA. $")),'(%. Cancer Council of Victoria project grant. Hocking J, $!*,'''. DHS Victoria. Gold J, Aitken C, Lim M, Hellard M. Vaccine for breast cancer, "''&-"'!!. SMS to promote sexual health to young people. Poumbourios P, Drummer HE, Wilce M. $*'%,*''. National Health Gorry PR, Churchill M. $#!',(*'. National Health and Medical and Medical Research Council (NHMRC). Project Grant. Structural and Research Council (NHMRC). Project Grant. Adaptive changes in HIV-! functional role of HIV-! gp#! terminal interactions in the membrane subtype C envelope glycoproteins contributing to pathogenicity, fusion mechanism, "''&-"'!!. "''&-"'!!. Power DA. $#(%,'''. NHMRC Project Grant. The role of the lysosomal Gorry PR, Tachedjian G, Churchill M, Lewin SR. $!#','''. Australian protein SCARB" in kidney disease, "''&-"'!!. Centre for HIV and Hepatitis Virology Research ACH". Project Grant. In vitro assay for assessment of resistance to the CCR* antagonist Ramsland PA, Wines BD. $#$",)*'. NHMRC Project Grant. Bacterial maraviroc, "''%–"''&. evasion of IgA immunity, "''&-"'!!.

page *) Reeder J, Barry A. $()',*''. NHMRC. Population genomics of *. Aitken C, Tracy S, Revill P, Bharadwaj M, Bowden S, Winter R, Plasmodium falciparum surface antigen genes. Hellard M. Consecutive infections with different hepatitis C virus genotypes in an injecting drug user. Journal of Clinical Virology Reeder J. $$)),*''. NHMRC. Principal Research Fellowship. "''%; #!(#); "&(–"&$. Sandrin MS, Vaughan HA, Christiansen D, Ramsland PA. $*#!,*''. $. Aitken C, Wain D, Lubman D, Hides L & Hellard M. Mental health NHMRC Project Grant. The role of carbohydrates in transplantation, screening among IDUs outside treatment settings – implications "''&-"'!!. for research and health services. Mental Health and Substance Scott AM, Ramsland PA, Ravetch JV. $*#(,*''. NHMRC Project Grant. Use: Dual Diagnosis "''%; !("):&&-!'(. Using the immune system to treat cancers, "''&-"'!!. ). Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden D S, Bharadwaj Sonza S, Tachedjian G, Cone R. $!$*,'''. Australian Centre for HIV M, Drummer H, Hellard M. High incidence of hepatitis C virus and Hepatitis Virology Research. Lactic acid as a natural microbicide reinfection in a cohort of injecting drug users. Hepatology, for HIV. "''%–"''&. "''%;#%:!)#$–*".

Stoové M, Crofts N, Lintzeris N, Walsh N. $!%$,**&. DHS Victoria. %. Allen K, Guy R, Leslie D, Goller J, Medland N, Roth N, Lewis J, Exploring the health and support service experiences of prisoners Hellard M. The rise of infectious syphilis in Victoria and the impact of enhanced clinical testing. Australian & New Zealand post-release: prisoners, family and service providers’ perspectives. Journal of Public Health. "''%;("(!):(%–#". Stoové M, Guy R, Hellard M, Pedrana A, Prestage, Kennedy, Best. &. Apostolopoulos V, Yuriev E, Lazoura E, Yu M, Ramsland PA. $*',%$*. DHS Victoria. Determining HIV sero-prevalence and MHC and MHC-like molecules: Structural perspectives on unrecognised HIV infection among gay and homosexually active men the design of molecular vaccines. Human Vaccines, "''%, in Melbourne. #:#''–#'& [Featured on the journal’s cover]. Stoové M, Guy R, Pedrana A, Hellard M. $!!%,!'&. DHS Victoria. !'. Baldwin S, Boisen N, Power R. Managing information: using Evaluation Mechanism for HIV Prevention Initiatives. systematic data collection to estimate process and impact Stoové M, Guy R, Yohannes K, Jenkinson R, Hellard M. $!"#,()#. indicators related to harm reduction services in Myanmar. DHS Victoria. Development of a Local HIV information and Testing International Journal of Drug Policy; "''%; !&: )#–)&. System (HITS). !!. Banerjee A, Grumont R, Gugasyan R, White C, Strasser A, Stoové M, Higgs P, Fischer, Power, Brogan, Kelsall. $#),#"). Gerondakis S. NF-kappaB# and c-Rel cooperate to promote the Queensland Injectors Health Network(QuIHN)/Queensland Health. survival of TLR$%activated B cells by neutralizing Bim via distinct QuIHN Mix Up project evaluation. mechanisms. Blood "''%; !!": *'$(–*')(.

Tachedjian G. $(#!,)%!. Subcontract. NIH/NIAID – HIV Microbicide !". Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M,

Design and Development Teams Contract (Starpharma) Vears DF, Lüllmann-Rauch R, Blanz J, ZhangKW, StankovichJ, Kalnins RM, Dowling JP, Andermann E, Andermann F, Faldini E, HHSN"$$"''*'''#"C. SPL)'!(-''(: Study of duration of retention D’Hooge R, Vadlamudi L, Macdonell RA, Hodgson BL, Bayly MA, of antiviral activity of SPL)'!( following vaginal administration of Savige J, Mulley JC, Smyth GK, Power DA, Saftig P, Bahlo M. SPL)'!( Gel (VivaGel®), "''%-"''&. Myoclonus epilepsy and glomerulosclerosis due to deficiency Vickerman P, Hickman M, Watts C, Hope V, Craine N, Prins M, of the lysosomal membrane protein SCARB!/Limp!. Am J Hum Hutchinson S, Goldberg D, Hellard M, Aitken C, De Angelis D, Parry J, Genet "''%, Mar;%"(():$)(–%# Irving W. £($','''. MRC (UK). Using modelling to analyse the !(. Bobrova N, Rughnikov U, Neifeld E, Rhodes T, Alcorn R, disparate longitudinal trends in the dynamics of HCV and HIV amongst Kirichenko S, Power R. Challenges in providing drug user injecting drug users in different settings: implications for harm treatment services in Russia: providers’ views. Substance use & reduction interventions. misuse; "''%; #(: !))'-!)%#. Westhorpe C, Crowe SM, Jaworowski A. $!#(,(*'. Australian Centre !#. Borggren M, Repits J, Kuylenstierna C, Sterjovski J, Churchill MJ, " for HIV and Hepatitis Virology Research (ACH ). Project Grant. Markers Purcell DFJ, Karlsson A, Albert J, Gorry PR, Jansson M. Evolution of monocyte activation as correlates of CardioVascular Disease in HIV of DC-SIGN use revealed by fitness studies of R& HIV-# variants patients, "''%-"''&. emerging during AIDS progression. Retrovirology. "''%;*:"%. !*. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, The JS, Lo JCY, Jensen K, Rizzitelli A, Wu L, Vremec D, Maraskovsky E, Braley H, Davey D, Mottram P, van de Velde N, Shizuo A, Lew AM, Wright Publications MD, Heath WR, Shortman K, and Lahoud MH. The dendritic cell subtype restricted C-type lectin Clec'A is a target for vaccine enhancement. Blood, "''% Vol.!!", no.%: ("$#–(")(. PEER REVIEWED !$. Campbell EM, Perez O, Anderson JL, Hope TJ. Visualization of a proteosome-independent intermediate during restriction !. Affandi JS, Price P, Imran D, Yunihastuti E, Djauzi S, Cherry CL. of HIV-# by rhesus TRIM&alpha. The Journal of Cell Biology. Can we predict neuropathy risk before stavudine prescription "''%;!%':*)&–*$!. in a resource limited setting? AIDS Res and Hum Retroviruses !). Carlton J, Adams J, Silva J, Bidwell S, Lorenzi H, Caler E, Crabtree J, "''%;"#:!"%!–!"%#. Angiuoli S, Merino E, Amedeo P, Cheng Q, Coulson R, Crabb B, ". Aitken C, Higgs P, and Hellard M. Buprenorphine injection in Del Portillo H, Essien K, Feldblyum T, Fernandez-Becerra C, Melbourne, Australia – an update. Drug and Alcohol Review Gilson P, Gueye A, Guo X, Kang’a S, Kooij T, Korsinczky M, "''%; "):!&)-!&&. Meyer E, Nene V, Paulsen I, White O, Ralph S, Ren Q, Sargeant T, Salzberg S, Stoeckert C, Sullivan S, Yamamoto M, Hoffman S, (. Aitken C, Higgs P, Bowden S. Differences in the social networks Wortman J, Gardner M, Galinski M, Barnwell J, Fraser-Liggett C. of ethnic Vietnamese and non-Vietnamese injecting drug users Comparative genomics of the neglected human malaria parasite and their implications for blood-borne virus transmission. Plasmodium vivax. Nature "''%; #**:)*)–$(. Epidemiology & Infection "''%; !($:#!'–$. !%. Cendron AC, Wines BD, Brownlee RT, Ramsland PA, Pietersz GA, #. Aitken C, Power R, Dwyer R. A very low response rate in an on- Hogarth PM. An FcGRIIa-binding peptide that mimics the line survey of medical practitioners. Australian and New Zealand interaction between FcGRIIa and IgG. Mol Immunol., "''%; #*("): Journal of Public Health "''%; ("(():"%%–"%&. (')-!&. page *% !&. Chan K, Stoové M, Reidpath D. Stigma, social reciprocity and (*. Dietze P. What more can we learn from the heroin drought? exclusion of HIV/AIDS patients with illicit drug histories: A study International Journal of Drug Policy "''%; !&(#):")'–")". of Thai nurses’ attitudes. Harm Reduction Journal, "''%; *:"%. ($. Dyer WB, Zaunders JJ, Yuan FF, Wang B, Learmont JC, Geczy AF, "'. Chan K, Stoové M, Sringernyuang L, Reidpath D. Stigmatization Saksena NK, McPhee DA, Gorry PR, Sullivan JS. Mechanisms of AIDS patients: Disentangling Thai nursing students’ attitudes of HIV non-progression; robust and sustained CD$+ T-cell towards HIV/AIDS, drug use, and commercial sex. AIDS & proliferative responses to p!$ antigen correlate with control Behavior "''%; !", !#$-!*). of viraemia and lack of disease progression after long-term "!. Cherry CL, Duncan AJ, Mackie KF, Wesselingh SL, Brew BJ. transfusion–acquired HIV-# infection. Retrovirology "''%;*:!!". A report on the effect of commencing enfuvirtide on (). Elam G, Macdonald N, Hickson F, Imrie J, Power R, McGarrigle C, peripheral neuropathy. AIDS Res and Hum Retroviruses Fenton K, Gilbart V, Ward H, Evans B on behalf of the INSIGHT "''%;"#:!'")-!'('. Collaborative Research Team. Risky sexual behaviour in context: "". Cherry CL, Hoy JF, Altman P, Rowe JS, Krum H, Mills J, Lewin SR. qualitative results from an investigation into risk factors for Phase # single dose studies to optimize the pharmacokinetics seroconversion among gay men who test for HIV. Sex Transm Inf; of DG#(, a novel HIV-protease inhibitor prodrug, using "''%; %#: #)(–#)). sodium bicarbonate and ritonavir. Current HIV Research "''%;$:")"–")*. (%. Elliott J, Lynen L, Calmy A, De Luca A, Shafer R, Zolfo M, Clotet B, Huffam S, Boucher C, Cooper D, Schapiro JM. Rational long term "(. Cherry CL, Rosenow A, Affandi JS, McArthur JC, Wesselingh SL, use of antiretroviral therapy in low and middle income countries: Price P. Cytokine genotype establishes a role for inflammation in optimising regimen sequencing and switching. AIDS "''%; "", NRTI-associated sensory neuropathy (NRTI-SN) and predicts an "'*(–"'$). individual’s NRTI-SN risk. AIDS Research and Human Retroviruses "''%;"#:!!)-!"(. (&. Figueiredo A, Zelina S, Sluis-Cremer N, Tachedjian G. Relationship between increased heterodimer stability and "#. Chojnacki J, Grgacic EVL. Enveloped viral fusion: insights into the fusion of hepatitis B virus. Future Virology "''%; (($):*#(–**". enzyme function in HIV-# reverse transcriptase. Current HIV Research. "''%;$:!('–!(). "*. Chua B, Eriksson EM, Brown LE, Zeng W, Gowans EJ, Torresi J, Jackson DC. A self-adjuvanting lipopeptide-based vaccine #'. Fillipas S, Bowtell-Harris CA, Ciccutini F, Holland AE, candidate for the treatment of hepatitis C virus infection. Cherry CL. Physical activity uptake in patients with Human Vaccine "''%;"$:#%$$–)*. Immunodeficiency Virus. Who does how much? International Journal of STD and AIDS "''%;!&:*!#–*!%. "$. Cowan F, Pascoe S, Langhaug L, Dirawo J, Chidiya S, Jaffar S, Mbizvo M, Stephenson J, Johnson A, Power R, Woelk G, Hayes H. #!. Fry C, Khosnood K, Power R, Sharma M. Harm reduction ethics: The Regai Dzive Shiri Project: a cluster randomised controlled acknowledging the values and beliefs behind our actions. The trial to determine the effectiveness of a multi-component International Journal of Drug Policy; "''%; !&: !–(. community-based HIV prevention intervention for rural youth in Zimbabwe – study design and baseline results. Tropical Medicine #". Gardiner EE, Karunakaran D, Arthur JF, Mu FT, Powell MS, & International Health; !))*; !(:!', !"(*-!"##. Baker RI, Hogarth PM, Kahn ML, Andrews RK, Berndt MC. Dual ITAM-mediated proteolytic pathways for irreversible "). Cox H, McDermid C. Commentary: XDR Tuberculosis can be cured inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa. with aggressive treatment. Lancet "''%; ()", !($(–*. Blood, "''% (!):!$*–)#. "%. Cox H, Morrow M, Deutschmann P. The long term efficacy of DOTS #(. Genton B, D’Acremont V, Rare L, Bae K, Reeder J, Alpers M, short-course regimens for tuberculosis: a systematic review of Müller I. lasmodium vivax and mixed infections are associated disease recurrence after successful treatment. British Medical with severe malaria: A prospective cohort study from Papua New Journal "''%; (($: #%#–#%). Guinea. PLoS Medicine "''%; *, e!"). "&. Cox H, Sibilia K, Kalon S, Karimovich H, Mills C, Niemann S. Development of oflococin resistance and extensively drug ##. Giles M, McDonald A, Elliott EJ, Ziegler JB, Hellard M, Lewin SR, resistant tuberculosis during MDR-TB treatment results from both Kaldor J. Variable uptake of recommended interventions to reduce resistance amplification and exogenous reinfection. NEJM "''%; perinatal HIV transmission in Australia #'*!–!))&. Medical (*&, "(&%–"#''. Journal of Australia. "''%;!%&:!*!–#. ('. Crosby IT, Pietersz GA, Ripper JA. Synthesis of #*. Goller J, Stoové M, Hellard M. Chlamydia testing and notification succinimidoalkylbenzaldehyde analogues: Potential bifunctional in Australia: more money, more tests. Sex Transm Infect "''%; linkers for bioconjugation. Aust J Chem, "''%, $!:!(%-!#(. %#()):*$&. (!. Cvetkovski S, Dietze P. The incidence and characteristics of #$. Goy K, Von Bibra S, Lewis J, Laurie K, Barr I, Anderson D, volatile substance misuse related ambulance attendances in Hellard M, Ffrench R. Heterosubtypic T-cell responses against metropolitan Melbourne, Australia. Social Science and Medicine avian influenza H& haemagglutinin are frequently detected in "''%; $$(():))$–)%(. individuals vaccinated against or previously infected with human (". Deraos G, Chatzantoni K, Matsoukas M-T, Katsara M, Tselios T, subtypes of influenza. Influenza and Other Respiratory Viruses, Deraos S, Papathanasopoulos P, Vynios D, Mouzaki A*, "''%, " (#), !!*-!"*. Centre for Immunology and Centre for Matsoukas J*, Apostolopoulos V*. Citrullination of linear Population Health. and cyclic altered peptide ligands from myelin basic protein #). Greenwood DL, Dynon K, Kalkanidis M, Xiang S, Plebanski M, (MBP*(–'') epitope elicits a Th# polarized responses by T Scheerlinck JP, Vaccination Against Foot-and-Mouth Disease cells isolated from multiple sclerosis patients: implications Virus Using Peptides Conjugated to Nano-Beads, Vaccine, "''%, in triggering disease.Journal of Medicinal Chemistry, "''%, "$, ")'$ *!("#):)%(#–)%#". (*equal contribution). #%. Grove J, Nielsen S, Zhong J, Bassendine MF, , ((. Dietze P. Cvetkovski S, Barrat M, Clemens S. Patterns and Drummer HE incidence of gamma-hydroxybutyrate (GHB) related ambulance Balfe P, McKeating JA. Identification of a residue in hepatitis attendances in Melbourne, Australia. Medical Journal of Australia C virus E! glycoprotein that determines scavenger receptor BI "''%; !%%(!"):)'&–)!". and CD*# receptor dependency and sensitivity to neutralizing antibodies. J Virol "''%;%":!"'"'–&. (#. Dietze P. Fitzgerald J, Jenkinson R. Drinking by professional Australian Football League (AFL) players: prevalence #&. Gruen RL, Elliott J, Nolan, M, Lawton P, Parkhill A, McLaren C, and correlates of risk. Medical Journal of Australia "''%; Lavis JN. Sustainability science: an integrated approach for !%&(&):#)&–#%(. health-programme planning. Lancet "''%; ()", !*)&-!*%&.

page *& *'. Guy R, Devadason D, Lim M, Higgins N, Pedrana A, Gibson K, $$. Kerr D, Dietze P. Jolley D, Kelly A-M. Attitudes of Australian heroin Lewis J, White B, Kaldor J, Hellard M. Enhanced case detection users to peer distribution of naloxone for heroin overdose: for newly acquired hepatitis C infection: epidemiological Perspectives on intranasal administration. Journal of Urban findings and health service implications. Communicable Disease Health "''%; %*(():(*"–($'. Intelligence June "''%; Vol ("("): "*'–"*$). $). Kerr D, Dietze P. Kelly A-M. Intranasal naloxone for the treatment *!. Guy R, McDonald A, Bartlett M, Murray J, Giele C, Davey T, of suspected heroin overdose. Addiction "''%; !'(:()&–(%$. Appuhamy R, Knibbs P, Coleman D, Hellard M, Grulich A, Kaldor J. $%. Laslett A, Dwyer R, Dietze P. The oral health of street-recruited Characteristics of HIV diagnoses in Australia, #'',–!))-. Sexual injecting drug users: prevalence and correlates of problems. Health. "''%; *:&!–$. Addiction "''%; !'((!!):!%"!-!%"(. *". Harris K, Jackson DE. Unravelling the complicated networks of $&. Lim M, Hocking J, Hellard M, Aitken C. A cross-sectional survey of integrin A B signalling in platelets. Current Signal Transduction IIb , young people attending a music festival: associations between Therapy "''%;((();!*%-!$). drug use and musical preference. Drug and Alcohol Review "''%; *(. Higgs P, Owada K, Hellard M, Power R, & Maher L. "''%. Gender, "); #(&–#!. culture and harm: an exploratory study of female heroin users )'. Lim M, Hocking JS, Hellard M, Aitken C. SMS STI: A review of of Vietnamese ethnicity. Culture, Health & Sexuality; "''%; the uses of mobile phone text-messaging in sexual health. !'()):$%!–$&*. International Journal of STD and AIDS, "''%;!&:"%)–"&'. *#. Holmes W, Maher L, Rosenthal S. Attitudes of men in an )!. Livingston M, Laslett A, Dietze P. Individual and community Australian male tolerance study towards microbicide use. correlates of young people’s high-risk drinking in Victoria, Sexual Health "''%; *((), ")(–")%. Australia. Drug Alcohol Depend "''%; &%("#!–"#%). **. Horyniak D, Armstrong S, Higgs P, Wain D, Aitken C. ‘Poor )". Lundie R, de Koning-Ward, Davey G, Nie C, Hansen D, Lau L, Man’s Smack’: A qualitative study of buprenorphine injecting Mintern J, Belz G, Schofield L, Carbone F, Villadangos J, Crabb B, in Melbourne, Australia. Contemporary Drug Problems "''%; Heath W. Blood-stage Plasmodium infection induces CD*+ (#(():*"*–*#%. cytotoxic T lymphocyte effectors specific for parasite-expressed *$. Hu WP, Lu Y, Precioso NA, Chen HY, Howard T, Anderson D, antigens, largely regulated by CD*a+ dendritic cells. PNAS "''%; Guan M. Double-antigen enzyme-linked immunosorbent assay !'*:!#*'&-!#. for detection of hepatitis E virus-specific antibodies in human or )(. Macdonald N, Elam G, Hickson F, Imrie J, McGarrigle C, Fenton K, swine sera. Clinical Vaccine Immunology "''%;!*:!!*!-!!*). Baster K, Ward H, Gilbart V, Power R, Evans B. Factors associated with HIV seroconversion in gay men in England at the start of the *). Jerums G, Panagiotopoulos S, Premaratne E, Power DA, !#st century. Sex Transm Inf; "''%; %#: %–!(. MacIsaac RJ. Lowering of Proteinuria in Response to Antihypertensive Therapy Predicts Improved Renal Function in )#. Marfurt J, de Monbrison F, Brega S, Barbollat L, Müller I, Sie A, Late but Not in Early Diabetic Nephropathy: A Pooled Analysis. Goroti M, Reeder J, Beck H-P, Picot S, Genton B. Molecular Am J Nephrol. "''% Feb !&;"%(#):$!# markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulphadoxine-pyrimethamine: mutations in pvdhfr and *%. Jones KL, Brown LE, Eriksson EMY, Ffrench RA, Latour PA, pvmdr#. Journal of Infectious Diseases "''%; !&%, #'&–#!). Loveland BE, Dominic M. Wall DM, Roberts SK, Jackson DC, Gowans EJ. Human dendritic cells pulsed with specific )*. Marfurt J, Müller I, Sie A, Oa O, Reeder J, Smith TA, Beck H-P, lipopeptides stimulate autologous antigen-specific CD*+ T-cells Genton B. The usefulness of twenty-four molecular markers without the addition of exogenous maturation factors. J Viral in predicting treatment outcome with combination therapy of Hepatitis "''%, !*:)$!–))". amodiaquine or chloroquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malaria Journal *&. . Primary T-lymphocytes rescue the Jones KL, Sonza S, Mak J "''%; ): $!. replication of HIV DIS RNA mutants in part by facilitating reverse transcription. Nucleic Acids Research "''%;($:!*)%-!*%%. )$. Mavhu W, Langhaug L, Manyonga B, Power R and Cowan F. What is ‘sex’ exactly? Using cognitive interviewing to improve $'. Kadekoppala M, O’Donnell R, Grainger M, Crabb B, Holder A. the validity of sexual behaviour reporting among young people Deletion of the Plasmodium falciparum Merozoite Surface Protein in rural Zimbabwe. Culture, Health & Sexuality; "''%; !':$, ( gene impairs parasite invasion of erythrocytes. Eukaryot Cell *$(–*)". "''%; ):"!"(–"!(". )). Mefford ME, Gorry PR, Kunstman K, Wolinsky SM, Gabuzda D. $!. Katsara M, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Bioinformatic prediction programs underestimate the frequency Design of novel altered peptide ligands of myelin basic protein of CXCR$ usage by R&X$ HIV-# in brain and other tissues. AIDS MBP*,–'' modulate immune responses in SJL/J mice. Journal of Res. Human Retroviruses. "''%;"#:!"!*-!""'. Med. Chem, "''%, *!:(&)!–(&)%. )%. Meintjes G, Lawn S, Scano F, Maartens G, French M, Worodria W, $". Katsara M, Matsoukas J, Deraos G, Apostolopoulos V. Towards Elliott J, et al. Tuberculosis-associated immune reconstitution immunotherapeutic drugs and vaccines against multiple inflammatory syndrome: case definitions for use in resource- sclerosis. Acta Biochimica et Biophysica Sinica, "''%, limited settings. Lancet Infectious Diseases "''%; %, *!$–*"(. #':$($–$#". )&. Milland J, Yuriev E, Xing PX, McKenzie IF, Ramsland PA, $(. Katsara M, Minigo G, Plebanski M, Apostolopoulos V. The Christiansen D, Sandrin MS. Reply to Response to Milland et al.: good, the bad and the ugly: How altered peptide ligands Carbohydrate residues downstream of the terminal galA(#,,) modulate immunity. Expert Opinion on Biological Therapy, "''%, gal epitope modulate the specificity of xenoreactive antibodies. %(!"):!%)(-!%%#. Immunol Cell Biol, "''%, %$:$((–(#. $#. Katsara M, Yuriev E, Ramsland PA, Deraos G, Tselios T, %'. Morrissey CO, Bardy PG, Slavin MA, et al. Diagnostic and Matsoukas J, Apostolopoulos V. Mannosylation of mutated therapeutic approach to persistent or recurrent fevers of unknown

MBP*,–'' peptides diverts immune responses from Th# to Th!. Mol origin in adult stem cell transplantation and haematological Immunol, "''%, #*:($$!–($)'. malignancy. Internal Medicine Journal, "''%, (%.$B0: #))-#&* $*. Katsara M, Yuriev E, Ramsland PA, Deraos G, Tselios T, %!. Nielsen S, Dietze P. Cantwell K, Lee N, Taylor D. Methadone and Matsoukas J, Apostolopoulos V. A double mutation of MBP*,–'' Buprenorphine related ambulance attendances in Metropolitan peptide induces IL–$ responses and antagonizes IFN-G responses. Melbourne, Australia: Incidence and case characteristics. Journal J Neuroimmunol, "''%, "'':))–%&. of Substance Abuse Treatment "''%; (*(#):#*)–#$!. page $' %". Norman J, Walsh N., Mugavin J, Stoové M, Kelsall J, Austin K and !''. Stevens W, Gelman R, Glencross DK, Scott LE, Crowe SM, Lintzeris N. A peer and community-based model of HCV treatment Spira, T. Evaluating new CD$ enumeration technologies for delivery to injecting drug users: an evaluation of patient resource-constrained countries. Nature Reviews Microbiology. perspectives. Harm Reduction Journal, "''%; *:%. "''%;S"&-S(%. %(. Owe-Young R, Webster NL, Mukhtar M, Pomerantz RJ, Smythe G, !'!. Stoové M, Dietze P, Aitken C, and Jolley D. Mortality among Walker D, Armati PJ, Crowe SM, Brew BJ. Kynurenine Pathway injecting drug users in Melbourne: a #-%year follow-up of the Metabolism in Human Blood-Brain Barrier Cells: Implications for VICS cohort. Drug & Alcohol Dependence "''%; &$((), "%!–"%*. Immune Tolerance & Neurotoxicity, Journal of Neurochemistry . !'". Stoové M, Fry, C & Lintzeris, N. Approximating predictive risk for "''%;!'*:!(#$–*). community-based HCV surveillance, education and prevention: %#. Pankonin C, Higgs P, Reid G, Aitken C. Selling Syringes to IDUs: A Application of a new weighted scoring system to the Blood-Borne study of five pharmacies in Hanoi, Vietnam. Journal of Infection in Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). Developing Countries "''%; "(!):*!–*%. Harm Reduction Journal."''%; *:!". %*. Pedrana A, Aitken C, Higgs P, Hellard M. Blood borne viruses and !'(. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, risk behaviours among transient farm workers in rural Victoria. Friedland RP, Ramsland PA, Edmundson AB, Paul S. Autoantibody Australian Journal of Rural Health June "''%; Vol !$((): !#(–!#&). catalyzed hydrolysis of amyloid B peptide. J Biol Chem, "''%, "%(:#)!#–#)"". %$. Pedrana A, Hellard M, Giles M. Registered post achieved a higher response rate than normal mail – a randomised controlled trial. !'#. Tang CK, Apostolopoulos V. Strategies used for MUC# Journal of Clinical Epidemiology September "''%; Vol $!(&): immunotherapy: preclinical studies. Expert Rev Vaccines "''%, %&$–%&&). )()):&*!–&$". %). Percy CJ, Power DA, Gobe GC. Renal ageing: changes in the !'*. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC# cellular mechanism of energy metabolism and oxidant handling. immunotherapy: human clinical studies. Expert Rev Vaccines Nephrology (Carlton). "''% Apr;!(("):!#)–*". "''%, )()):&$(–&)*. %%. Powell MS, Hogarth PM. Fc Receptors. Adv Exp Med Biol. !'$. Tang CK, Sheng KC, Apostolopoulos V, Pietersz GA. Protein/ "''%:""–(#. peptide and DNA vaccine delivery by targeting C-type lectin receptors. Expert Rev Vaccines "''%, ()):!''*-!'!%. %&. Power DA, Ford D. Biological drugs and the coming of !'). Pouniotis D, , Son HY, Kim CW, biosimilars. Journal of Pharmacy Practice and Research "''%; (%: Tang CK, Sheng KC, Esparon S Pietersz GA, Apostolopoulos V. Oxidized and reduced mannan !()–(&. mediated MUC# DNA immunization induce effective anti-tumor &'. Reeder J. The Malaria Genomic Epidemiology Network (!))*) responses. Vaccine "''%, "$((!):(%")–(#. A global network for investigating the genomic epidemiology of !'%. Thammanichanond D, Yotnda P, Aitken C, Earnest-Silveira L, malaria. Nature, #*$, )("–)(%. Jackson D, Hellard M, McCluskey J, Torresi J, Bharadwaj M. Fiber- &!. Repits J, Sterjovski J, Badia-Martinez D, Mild M, Gray L, modified recombinant adenoviral constructs encoding hepatitis C Churchill MJ, Purcell DFJ, Karlsson A, Albert J, Fenyo EM, Achour virus proteins induce potent HCV-specific T cell response. Clinical A, Gorry PR, Jansson M. Primary HIV-# R& isolates from end-stage Immunology "''%; !"%(():("&–(&. disease display enhanced viral fitness in parallel with increased !'&. Walsh N, Lim M, Hellard M. Using a surveillance system to gp#!) net charge. Virology "''%;()&:!"*-!(#. identify and treat newly acquired hepatitis C infection. Journal of &". Rodriguez Lay Lde L, Quintana A, Villalba MC, Lemos G, Gastroenterology and Hepatology "''%; "( (!"); !%&!–#. Corredor MB, Moreno AG, Prieto PA, Guzman MG, Anderson D. !!'. Winter R, Nguyen O, Higgs P, Armstrong S, Duong D, Thach M, Dual infection with hepatitis A and E viruses in outbreaks and Aitken C, Hellard M. Integrating enhanced Hepatitis C testing in sporadic clinical cases: Cuba #''*–!)),. Journal of Medical and counseling in research. International Journal of Drug Policy. Virology "''%;%':)&%–%'". "''%; !&:$$–)'. &(. Sacks-Davis R, Gold J, Hellard M. Hepatitis C treatment outcomes !!!. Wong MX, Hayball JD and Jackson DE. PECAM-1-regulated for injecting drug users: review of the evidence. Journal of signaling thresholds control tolerance in anergic transgenic B Gastroenterology & Hepatology "''%; "( (Supp $):()'. cells. Mol. Immunol. "''%, #*:!)$)-!)%!. &#. Sacks-Davis R, Gold J, Hellard M. Treating injecting drug users !!". Woollard DJ, Haqshenas G, Dong X, Pratt BF, Kent S, Gowans EJ. for hepatitis C: myths and reality. Journal of Gastroenterology & Virus-Specific T Cell Immunity Correlates with Control of GBV-B Hepatology "''%; "( (Supp $):()'. Infection in Marmosets. J Virol "''%;%":('*#–$'. &*. Shearer J, Johnston J, Kaye S, Dillon P, Dietze P, Collins L. !!(. Wright E, Brew B, Arayawichanont A, Robertson K, An Australian profile on cocaine supply: Implications for drug Samintharapanya K, Kongsaengdao S, Lim M, Vontanak S, law enforcement. Howard Journal of Criminal Justice "''%; Lal L, Sarim C, Huffam S, Li P, Imran D, Lewis J, Hui Lun W, #)(!):$)–%'. Kamarulzaman A, Tau G, Ty Ali A, Kishore K, Bain M, Dwyer R, &$. Sheng KC, Kalkanidis K, Pouniotis DS, Wright MD, Pietersz GA, McCormack G, Hellard M, Cherry C, McArthur J, Wesselingh S. Apostolopoulos V. The adjuvanticity of a mannosylated antigen Neurological disorders are prevalent in HIV positive outpatients reveals toll-like receptor $ functionality essential for subset in the Asia- Pacific Region. Neurology. "''%; )!(!):*'–$. specialization and functional maturation of mouse dendritic cells. !!#. Wright EJ, Brew BJ, Arayawichanont A, Robertson KR, J Immunol. "''%, !%!:"#**–$#. Samintharapanya K, Kongsaengdao S, Lim M, Lal L, Vonthanak S, Sarim C, Huffam S, Li P, Imran D, Lewis J, Lun WH, &). Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Kamarulzaman A, Tau G, Ali ST, Kishore K, Bain M, Dwyer R, Apostolopoulos V, Pietersz GA. Delivery of antigen using a novel McCormack G, , , McArthur JC, Wesselingh SL. mannosylated dendrimer potentiates immunogenicity in vitro Hellard M Cherry CL HIV-associated Neurocognitive Impairment, Symptomatic and in vivo. Eur J Immunol. "''%, (%:#"#–#($. Peripheral Neuropathy and Depression are Prevalent in the Asia &%. Sluis-Cremer N, Tachedjian G. Mechanisms by which NNRTI Pacific Region. Neurology "''%;)!:*(–*&. inhibit HIV replication. Virus Research "''%;!(#:!#)–!*$. !!*. Wright EJ, Brew BJ, Lal L, Ty Ali S, Arayawichanont A, Imran D, &&. Snooks MJ, Bhat P, Mackenzie J, Counihan NA, Vaughan N, Kamarulzaman A, Kongsaengdao S, Kruy L, Parwati Merati Anderson DA. Vectorial entry and release of hepatitis A T, Samintharapanya K, Sarim C, Tau G, Thangsing C, Vin- virus in polarized human hepatocytes. Journal of Virology Samnang C, Wesselingh SL. Response to Birbeck et al. Epilepsia "''%;%":%)((–%)#". "''%;#&:*#!–(.

page $! !!$. Wright EJ, Nunn M, Joseph J, Robertson K, Lal L, Brew BJ. Dorabjee J. Review of World Vision Uzbekistan’s HIV/AIDS Prevention NeuroAIDS in the Asia Pacific Region. J Neurovirol "''%;!#:!–&. among IDUs program in Tashkent, Uzbekistan. !!). Yuriev E, Sandrin MS, Ramsland PA. Antibody-ligand docking: Dwyer R, Horyniak D, Dietze P, Aitken C, Higgs P. People who drink in Insights into peptide-carbohydrate mimicry. Mol Simulation, Public Spaces in the Footscray CBD. Report to Maribyrnong Council. "''%, (#:#$!–#$%. Melbourne. !!%. Zhan Y, Gerondakis S, Coghill E, Bourges D, Xu Y, Brady JL, El-Hayek C, Horyniak D. HIV Surveillance In Victoria, #'*,–!))(:A Lew AM. Glucocorticoid-induced TNF receptor expression by Special Report. DHS Victoria. Melbourne. T cells is reciprocally regulated by NF-KB and NFAT. J. Immunol. HIV Testing Surveillance, "''). Annual Report. "''%, !%!:*#'*–*#!(. El-Hayek C, Horyniak D. DHS Victoria. Melbourne. El-Hayek C, Horyniak D. HIV/AIDS Surveillance Quarterly reports. BOOKS AND CHAPTERS Victorian Infectious Diseases Bulletin. DHS Victoria. Melbourne. El-Hayek C, Horyniak D. HIV/AIDS Update. Victorian Infectious !. Anderson DA, Shrestha IL. Hepatitis E virus. Chapter in: Clinical Diseases Bulletin September "''%; !!((). Virology. Richman DD, Whitley RJ, Hayden FG, ed. ASM Press. El-Hayek C, Horyniak D. Targeted Report # – New HIV Diagnoses and Washington, D.C, #th edition, "''%:!!")–#(. People Living With HIV in Victoria: Country/Region of Birth. DHS ". Apostolopoulos V, Lazoura E, Yu M. MHC and MHC-like Victoria. Melbourne. molecules: structural perspectives for the design of molecular El-Hayek C, Horyniak D. Targeted Report ! – New HIV Diagnoses and vaccines. In: Multichain immune recognition receptor signaling: People Living With HIV in Victoria: Females and males without a history from spatiotemporal organisation to human disease. Ed: A. of male-to-male-sex. DHS Victoria. Melbourne. Sigalov, Landes Bioscience, $#':"*"–"$), "''%. Gold J, Lim M. Using SMS for Health Promotion. Yikes (Newsletter of (. Donaghy H, Wright EJ, Cunningham AL. The role of dendritic cells the Youth Affairs Council of Victoria) May "''%; $("): "%–"&. in neuro-inflammation. In Kilpatrick, Wesselingh & Ransohoff: Neuroinflammation of the Brain. Cambridge University Press, Goller J, Lim M, Horyniak D, Aitken C, Stoové M, Samuel King J, "''%. Brown J, Fairley C, Higgins N, Hellard M. Understanding the epidemiology of hepatitis C in Victoria: review of current surveillance #. , Tselios T, Matsoukas J, Katsara M, Ramsland PA mechanisms. Poster. "''%. Apostolopoulos V. Chapter V: A structural perspective of peptides from myelin basic protein. In: Myelin Basic Protein. Ed. Boggs JM. Goller, J, Winter R, Downing S, Aitken C, Hellard M. Evaluation of the Nova Science Publishers, Inc, New York, USA, "''%, pp%)–!'". Western Australian Aboriginal Sexual Health Strategy (!))&–!))*) and the WA HIV/AIDS, Sexually Transmitted Infection and Hepatitis C *. Torok EM, Kambugu A, Wright EJ. Immune reconstitution Action Plans !))-–!))*. Melbourne. Communicable Disease Control disease of the central nervous system. Current Opinion in HIV Directorate of the Western Australian Department of Health. and AIDS, "''%. Hagarty C, Otto B, Young F. Mapping donor support for HIV $. Wright EJ, Brew BJ, Wesselingh SL. Pathogenesis and diagnosis programming for men who have sex with men in the Greater Mekong of viral infections of the nervous system. Neurol Clinic, "''%. Subregion. USAID Health Policy Initiative. Higgs P, Aitken C, Hellard M, Maher L. How do some people manage COMMISSIONED REPORTS AND to avoid hepatitis C infection despite injecting for many years? Good OTHER PUBLISHED MATERIAL Liver, "''%; Summer: %–&. Higgs P. From complexity to stability. Synergy No. ". (Co-morbidity !) "''%; !). Aitken C, Fry T, Grahlmann L, Masters T. Health perceptions of home- grown tobacco (chop-chop) smokers. Nicotine and Tobacco Research Higgs P. Rethinking vulnerability and gender relations: Women in "''%; !'(():#!(–#!$. relationships with HIV-positive men (review). ASHM Journal Club "''%; Aitken C, Winter R. Review of New Zealand’s Needle Exchange !) (():*–). Programme. Wellington. Final Report. New Zealand Ministry of Health. Higgs P. Thinking globally: !&th conference on reduction of drug Melbourne. related harm. Good Liver "''%; Spring: !(. Apostolopoulos V, Weiner D, Gong J. Editorial. Cancer vaccines % Horyniak D, Lim M, Yohannes K. HIV Surveillance in Victoria, methods for inducing immunity. Expert Review of Vaccines, "''%, !&%(–"''): A Special Report. Report to the Department of Human ):%$!–%$". Services, Victoria. Melbourne. Apostolopoulos V. Guest Editor: Expert Reviews of Vaccines. Special Horyniak D, Pedrana A, Hellard M, Aitken C. Feeling fruity: Risk Focus issue on Cancer Vaccines. Vol. ) No. ), September, "''%. behaviours and blood borne virus exposure among transient workers Apostolopoulos V. Journal Cover image. Human Vaccines, Vol. #, No. in rural Victoria. ANEX Bulletin "''%; $("):(. $ (November/December) "''%. Structure of a non-canonical peptide Katsara M, Deraos G, Matsoukas J, Apostolopoulos V. T cell receptor [a glycopeptide derived from the tumour associated peptide MUC#-*], altered peptide ligands of Myelin Basic Protein (MBP) and Proteolipid which utilises the GalNAc residue for high affinity binding from Protein (PLP) peptides (Linear and Cyclic) can modulate immune publication Apostolopoulos et al "''%, #($):#''–#'&. responses in SJL/J mice: Bioactive peptides for Multiple Sclerosis. Coghlan B, Gouillou M, van Gemert C, Hocking J, Spelman T, Watson- Proceedings of the #th International peptide symposium. Australian Jones R, Xue B. HIV in the Pacific: summary of surveillance data, Peptide Association, "''%, ""&:!–(. !&%#-"''). Commissioned by UNAIDS for the Commission on AIDS in Katsara M, Yuriev E, Ramsland P, Deraos G, Matsoukas J, the Pacific. Apostolopoulos V. Development of a vaccine against Multiple Dorabjee J. Evaluation of the Harm Reduction Program, Xinjiang HIV/ Sclerosis. Journal of Peptide Science, "''%, !#, "'–"' (P""!''–#%). AIDS Prevention and Care Project, Xinjiang Uygur Autonomous Region, Lenton E, White B, Higgs P, Aitken C, Hellard M. Supporting young PR China. people at risk of hepatitis C infection: A pilot of an individualised, Dorabjee J. Review of the AusAID funded Xinjiang HIV/AIDS Prevention structured intervention to reduce the negative health consequences for and Care Project, Needle Syringe Program (NSP) in Urumqi and Yining, young people who have had contact with the criminal justice system. Xinjiang Uygur Autonomous Region, PR China. Report to the Department of Human Services, Victoria. Melbourne. page $" Loveland BE, Cebon J. Cancer exploiting the complement system: a clue Dietze P. Liquor licensing in Melbourne/Victoria: Creating a or an exception? Nat Immunol "''%;&:!"'*–'$. sophisticated café culture or boozy cesspit? The London School of Hygiene and Tropical Medicine, London, UK. Nielsen, S, Bruno, R, Caruthers, S, Fischer, J, Fry, C, Lintzeris, N, Stoové, M. Investigation of pharmaceutical misuse among drug Dietze P. Randomised Controlled Trial Comparing The Effectiveness treatment clients. Report to the Commonwealth Government Ministerial and Safety of Intranasal and Intramuscular Naloxone For The Treatment Council on Drug Strategy and the Victorian Department of Human Of Heroin Overdose, National Addiction Centre, Maudsley Hospital, Services. Melbourne. Kings College. London, UK. Parnell BW. Infrastructure, mobility and HIV: selected multisectoral Dietze P. Randomised Controlled Trial Comparing The Effectiveness action. UNDP. and Safety of Intranasal and Intramuscular Naloxone For The Treatment Of Heroin Overdose, Harm Reduction Coalition, New York City, USA. Perret J, Pouniotis DS, McDonald C, Apostolopoulos V. T helper-#( cell responses in chronic obstructive pulmonary disease: A pilot study. Gerondakis S. RIKEN Centre, Tskuba City, Japan. October "''%. Respirology, "''%, !(: Supp": A*!. Gerondakis S. Vaccine Centre, Emory University, Georgia. February Pouniotis DS, Apostolopoulos V, Pietersz GA. Delivery of tumor "''%. antigens using a membrane translocating peptide to dendritic Hellard M. The role of network studies in understanding hepatitis C cells induces cellular and protective immune responses. Cancer transmission and immunovirology. The Networks " Study – what we Immunology Immunotherapy, "''%, *):S!–S*( (P'("). have learnt thus far (invited speaker), GGD "''%. Amsterdam. Power R, Winter R, Liddell S, Wain D. Local Solutions to Public Katsara M. Linear/cyclic mutant analogues of self antigens (MBP Injecting, DHS Victoria. and PLP) manipulate immune responses in mice. &th International Power R, Wodak A. Review and evaluation of harm reduction program Conference in Medicinal Chemistry: Drug Discovery and Design. in Malaysia, WHO Commissioned Report. University of Patras, Greece. March "''%. Sheng KC, Kalkanidis M, Pietersz GA, Pouniotis DS, Esparon S, Leeansyah E. The effect of HIV-# infection on Fcgamma receptor Tang CK, Apostolopoulos V. A novel mannose-based antigen delivery signalling and function. Partners AIDS Center, Massachusetts General system potentiates immunogenicity via specific DC subtypes and TLR$ Hospital, Harvard Medical School. functionality. Cancer Immunology Immunotherapy, "''%, *):S!–S*( Parnell BW. HIV national strategic planning in South East Asia and the (P!(&). Pacific. World Bank AIDS Strategy and Action Plan lead consultants’ Wright EJ, Brew BJ. Progressive Multifocal Meukoencephalopathy. In: meeting. July "''%. Washington, USA. HIV Management in Australasia: a guide for clinical care. Edited by Hoy Parnell BW. Mobility and HIV in South East Asia. UNDP consultation: and Lewin. Second edition Published by the Australasian Society of a new agenda for mainstreaming HIV/AIDS in low prevalence HIV Medicine, "''%. environments. November "''%. New Delhi, India. Wright EJ, Cherry CL, Brew BJ. Neurological disorders in HIV/AIDS. In: Tachedjian G. Activity of priostar based microbicides. NIH Face to Face HIV Management in Australasia: a guide for clinical care. Edited by Hoy Meeting, New Delhi, India. and Lewin. Second edition Published by the Australasian Society of HIV Medicine, "''%. Tachedjian G. The tale of two suppressors that restore HIV-# reverse transcriptase dimerization. University of Pittsburgh School of Yohannes K, Horyniak D. HIV/AIDS Update. Victorian Infectious Medicine, Department of Medicine, Division of Infectious Diseases, Diseases Bulletin March "''%; !!(!). Pittsburgh, PA. USA. Yohannes K, Horyniak D. HIV/AIDS Update. Victorian Infectious Toole M. ,& years in international health: war, sex, and weaning foods. Diseases Bulletin June "''%; !!("). Boston Medical Centre. March "''%. Boston, USA. Toole M. Global progress in child health. Medical University of South Carolina. March "''%. Charleston, USA. Presentations Toole M. Health emergencies in developing countries. Kyushu International Nursing University. March "''%. Fukuoka, Japan.

INVITED LECTURES AND SEMINARS Xing P-X. Antibody-based immunotherapy, Jiang Hang University, China, March "''%.

International National Anderson D. Development of a Rapid, point-of care Aitken C. A social network approach to hepatitis C virus epidemiology immunochromatographic test for measurement of CD$ T-cells. CD# in Melbourne. Turning Point Alcohol & Drug Centre. Melbourne, Initiative meeting, New Orleans, Louisiana, USA. Australia. Anderson D. Development of a Rapid, point-of care Aitken C. Social network methods in hepatitis C virus epidemiology. immunochromatographic test for measurement of CD$ T-cells. CD# Nossal Institute for Global Health. ") October "''%. Melbourne. Initiative meeting and MSF Open Day, Geneva, Switzerland. Anderson JL. Defining TRIM&A and APOBEC,G host cell protein Crabb B. Early events mediating invasion into erythrocytes by the restrictions of HIV-#. Seminar Series, Macfarlane Burnet Institute for malaria parasite. Berard Nocht Institute for Tropical Medicine, Medical Research and Public Health, Melbourne. Hamburg University. Anderson JL. Viruses & Host Cell Interactions. Restriction of retroviruses Crabb B. Johns Hopkins Research Institute International Malaria by cellular TRIM& proteins. The Australian Society for Microbiology Conference, Baltimore, USA. Conference, Melbourne. Crabb B. Keystone Symposium on Pathogenesis and Control of Apostolopoulos V. Guest Lecture. Victoria University, Human Emerging Infections and Drug Resistant Organisms, Thailand. Biomedical Sciences, "nd Year Pathology Nursing Students, St Albans Crabb B. New Insights into Merozoite Invasion and Post-Invasion Campus, VIC Australia. Neoplasia (# Lectures), August/September Events. Keystone Symposium on Malaria: Immunology, Pathogenesis "''%. & Vaccine Perspectives, Alpbach, Austria. Apostolopoulos V. Guest Speaker. Brimbank Central Rotary Club, How Crabb B. New Insights into RBC invasion by P. falciparum merozoites. far are we off a cancer vaccine? Australia, May "''%. Nanyang Technical University, Singapore. Apostolopoulos V. Guest Speaker. Careers Week. Achievement and Crabb B. RBC invasion & malaria vaccine development. Papua New Setting Goals [Speech to Yr !'–!" students], St Johns College, Preston, Guinea Institute of Medical Research – #'th Anniversary Colloquium. Australia, August "''%.

page $( Apostolopoulos V. Invited Guest Speaker, Address to Year !" Students: Hellard M. Lessons from the field; working with IDUs to understand life after high school and achievement. St Johns College, Preston, HCV transmission. University of Melbourne, Public Health Symposium. Australia, November "''%. "''%, Melbourne. Apostolopoulos V. Special Guest Lecture (invited). The Ladies Probus Hellard M. The Networks ! Study – using a social network approach to Club of Jells Park, Development of a vaccine against breast cancer, understand hepatitis C transmission and immunity in injecting drug Australia, June "''%. users. National Centre for HIV Epidemiology and Clinical Research. "''%, Sydney. Apostolopoulos V. Special Guest Lecture. The Williamstown-Point Gellibrand Ladies Probus Club, Cancer research and development of Hellard M. The Swiss Statement – The evidence for, against and the cancer vaccines, Williamstown, Australia, February "''%. public health implications. ASHM. "''%, Sydney. Barry, A. Geographic variation of malaria surface antigens. Monash Hellard M. Turning Point Fitzroy. A social network approach to hepatitis C virus epidemiology in Melbourne. Turning Point Alcohol and Drug University, Department of Microbiology Sept "''%, Melbourne. Centre Talking Point. (! June, "''%. Melbourne. Cherry CL. HIV-associated neuropathy. Medical Research Foundation Jenkinson R, Quinn B. Amphetamine Type Stimulant Use and Seminar Series, University of Western Australia, Perth. Associated Outcomes. Amphetamine Type Stimulant (ATS) Treatment Cherry CL. Neuropathy in HIV: an old problem revisited. University of Approaches Study Tour. July "''%, Melbourne. Melbourne Centre for Neurosciences Post-graduate Seminar Series, Kalkanidis M. Delivered Medicinal Chemistry lectures to !nd year Melbourne. undergraduate students, Chemistry Department, La Trobe University, Crabb B. Molecular Approaches to Malaria !))*. Lorne, Victoria. Melbourne, July – November "''%. Crabb B. Pathogenesis and Control of Emerging Infections and Drug Kalkanidis M. Novel Cancer Vaccines Based on Tumour Antigens, Resistant Organisms. Department of Immunology, Monash University. (rd year undergraduate students, Chemistry Department, La Trobe "''%. Melbourne. University, Melbourne, October "''%. Crabb B. Walter & Eliza Hall Institute. "''%, Melbourne. Kong F. Ecstasy and Related Drugs Reporting System (EDRS) Preliminary Results And Changes. Australian National Council on Drugs Dietze P. Recent developments in the use of naloxone for the reversal of (ANCD). ")th-"%th November "''%, Melbourne. opioid overdose: Results of a randomised controlled trial of intranasal Lim M. Sexual Health Risks. Harm Reduction: controlling HIV in drug naloxone and implications for the development of peer-distribution users. Burnet Institute, in conjunction with the Nossal Institute programs. National Centre in HIV Epidemiology and Clinical Research. for Global Health, University of Melbourne. November !), "''%, August, "''%, Sydney. Melbourne. Dietze P. The effects of cannabis, alone and in combination with Lim M. Surveillance of Drug Use at a Music Festival. Victorian alcohol, on the simulated driving of experienced and inexperienced Substance Use Research Forum. September "$, "''%, Melbourne. drivers. Victorian Substance Use Research Forum series. August "''%, Melbourne. Natoli L Early childhood feeding and nutrition. University of Melbourne, International Child Health course, "''%, Melbourne, Drummer HE. HCV Vaccine Initiative Workshop, Sydney. Australia. Ffrench RA. Immune defenses against bacterial infections. Monash Natoli L. Breast feeding. University of Melbourne, International Child University, (rd year Immunology lecture, May "''%. Health course, "''%, Melbourne, Australia. Ffrench RA. Induced innate immune responses. Monash University, (rd Perret J. Systemic cytokines in chronic obstructive pulmonary disease year Immunology lecture, March "''%. (COPD): A pilot study. Victorian Branch: Thoracic Society of Australia and New Zealand, Melbourne October, "''%. Gorry PR. Adaptive changes in CCR&-restricted HIV-# affecting entry inhibitor potency. Invited symposium presentation, Australian Society Power DA. The lysosomal pathway to proteinuria. Florence May for HIV Medicine Conference, Perth. McCredie Symposium, Royal Children’s Hospital, Melbourne, September "''%. Gorry PR. Heterogeneity in CCR&-restricted HIV phenotypes affecting pathogenicity and sensitivity to HIV entry inhibitors. Plenary Lecture., Stoové, M. HIV and Hepatitis C Epidemiology. Alfred Hospital "*th Australian National Serology Reference Laboratory Workshop on Education and Resource Centre as part of Pre and Post HIV/Hep C Test Serology, Melbourne. Counselling Course, "''%, Melbourne. Gorry PR. Heterogeneity in primary R& HIV-# gp#!) structures affecting Tachedjian G. Antivirals and Drug Resistance. Drug resistance CD$ and CCR& interactions and exposure of neutralising antibody mutations in the C-terminal domains of the HIV reverse transcriptase. epitopes. Plenary Lecture, Australian Society for HIV Medicine The Australian Society for Microbiology Conference, Melbourne. Conference, Perth. Tachedjian G. Drug resistance mutations in the HIV reverse transcriptase. Centre for Immunology Research Seminar Series, Gorry PR. Tissue-specific adaptive changes in V, of gp#!) enables National Centre for Epidemiology and Clinical Research, Darlinghurst, persistence of Maraviroc-sensitive R&X$ HIV-# in brain. Invited NSW. symposium presentation, Australian Society for HIV Medicine Conference, Perth. Tachedjian G. Drug resistance mutations in the HIV reverse transcriptase connection domain. Department of Microbiology and Gowans EJ. Flavivirus Vaccines-Progress and developments. Asia Immunology Seminar Series, University of Melbourne, Melbourne. Pacific International Conference on Travel Medicine Conference, Melbourne. Tachedjian G. Drug resistance mutations in the HIV reverse transcriptase. Monash Infectious Diseases Society, Alfred ID Unit, Gowans EJ. Immunotherapy to treat persistent infection with hepatitis C Melbourne. virus. Sir Mark Oliphant Conferences-International Frontiers of Science and Technology. Vaccine and Immunotherapy Technologies, Canberra. Tachedjian G. HIV-# reverse transcriptase: critical roles in early and late stages of virus replication. Seminar Series, Macfarlane Burnet Institute Gowans EJ. Vaccine and antiviral approaches to prevent HCV infection. for Medical Research and Public Health, Melbourne. Women’s and Children’s Health Research Institute, Adelaide. Tachedjian G. Preclinial Development of Microbicides. Microbicides Grgacic EVL. The Duck Hepatitis B Virus Model: Studies in Assembly, and HIV Biomedical Prevention Symposium: Gender and Vulnerability, Entry and Vaccine Technology Department, Microbiology Monash University of Sydney. University, Melbourne. Tachedjian G. Role of HIV-# reverse transcriptase dimerization in Hellard M. Doin’ “it” Swiss. The implications of the Swiss Statement. viral replication. Institute for Molecular Bioscience, The University of ASHM. "''%, Melbourne. Queensland, St Lucia, Queensland. page $# Toole M. HIV Prevention: thinking outside the boxes. Fenner Lecture. Dorabjee J. Lessons learnt from the Asia Regional HIV/AIDS Program. May "''%. Melbourne, Australia. HAARP Consultation and Coordination Forum (HCCF) Meeting. Response Beyond Borders – the !st Asian Consultation on the Wines BD. The myeloid IgA-receptor (FcaRI) and the staphylococcal prevention of HIV related to Drug Use. January "''%, Goa, India. decoy protein SSL(. Department of Microbiology and Immunology, Melbourne University, April "''%. Dorabjee J. Outcomes of the #st Asian Consultation on the Prevention of HIV related to Drug Use. United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific. March "''%, CONFERENCE PRESENTATIONS Thailand. Dorabjee J. The importance of Cross Border Interventions. HAARP Consultation and Coordination Forum (HCCF) Meeting. October "''%, International Phnom Penh, Cambodia. Allison WE, Wright E, Schaefer M, Lal L, Smith J, Kaldor J. A survey of Ffrench RA. Heterosubtypic T cell responses against avian influenza paediatric diagnostic, treatment and support services for HIV infection H& HA are frequently detected in individuals previously infected with in the Asia Pacific region. World AIDS Conference, IAS, Mexico City. human influenza strains. International Congress of Virology, Istanbul, Anderson D. CD# Initiative Investigators Meeting, New Orleans. Turkey, August "''% Anderson D. CD# Initiative Investigators Meeting, Open Day and Gerondakis S. Congress of the Federation of Immunological Societies Steering Committee meeting, Geneva. of Asia-Oceania (FIMSA), Taiwan, October "''%. Invited speaker. Anderson D. Clinical Investigators Meeting, Doris Duke Charitable Gerondakis S. Keystone Symposia, NF-KB. Banff. Alberta, Canada. Foundation, Rhode Island. February "''%. Invited Plenary Speaker. Anderson D. Development of a Rapid, point-of care Greengrass V, Plate M, Steele P, Denholm J, Cherry CL, Morris L, immunochromatographic test for measurement of CD$ T-cells. Doris Crowe SM. Evaluation of the new version , Cavidi ExaVir™ Load Duke Innovations in Clinical Research Investigators meeting, Newport, quantitative HIV RT load kit as an alternative HIV viral load monitoring Rhode Island, USA. assay for use in Melbourne, Australia. !)th International AIDS Conference, Mexico City. Apostolopoulos V. Mannosylated antigens induces potent immune responses in vivo. 'th International Conference in Medicinal Chemistry. Hellard M. Acute and Early Chronic HCV Treatment Responses within Drug Discovery and Design, Conference. Department of Chemistry a Predominantly Injecting Drug User Population. The Australian Trial and Pharmacology, University of Patras, Greece, March "''%. Invited in Acute Hepatitis C International Harm Reduction Conference, "''% Plenary Lecture. Barcelona. Apostolopoulos V. Peptide based vaccines: A structural and Hogarth PM. Differences in the organisation of Fc receptors immunological perspective. !st International Conference on Drug regulate the interaction with Ig and are critical in determining ITAM Design & Discovery, Dubai, UAE. February "''%. Invited Keynote based signaling outcomes. FASEB Summer Research Conference Speaker. ‘Immunoreceptors’, New Haven, USA, August "''%. Invited speaker. Barry A. Extensive population subdivision of the genes encoding Power DA. The lysosomal pathway to proteinuria. Podocyte "''% twelve leading malaria vaccine candidates. Molecular Epidemiology Meeting, Toronto, Canada, June "''%. Invited Speaker. and Evolution of Infectious Diseases IX. October, "''%. Irvine, Power R. A new paradigm for harm reduction. Response Beyond California. Borders. January "''%, Goa, India. Cendron A. Crystallization studies of a human IgG receptor and Fab Power R. The Pacific Drug and Alcohol Research Network. International th fragments from anti-receptor antibodies. !" International School Harm Reduction Conference, (on behalf of PDARN). May "''%, & Conference on the Crystallisation of Biological Macromolecules. Barcelona, Spain. Cancun, Mexico, May "''%. Reeder J. Opening Address, PNG Institute of Medical Research #'th Cherry CL. Managing antiretroviral drug toxicities. (Invited plenary Anniversary Colloquium "''%. Goroka, PNG. lecture.) Annual meeting of the Indonesian Society for Physicians Working with HIV/AIDS, Jakarta. Reeder, J. Invited Moderator, Understanding the genetic basis to infectious diseases. ASTMH "''%. New Orleans, USA Crowe SM. Invited Plenary Speaker: HIV Congress "''%. Low cost viral load testing in resource constrained countries. Bombay, India. Snell B. Pharmaceuticals Activities in Pacific Island Countries. Regional Consultation Health Action International, August "&, "''%, Crowe SM. Invited Speaker: ""nd Conference of the European Bangkok, Thailand. Macrophage and Dendritic Cell Society, Role of monocytes in HIV pathogenesis. Brescia, Italy. Snell B. Strengthening human resources in medicines supply and management: Role of pharmacy workforce in medicines supply Crowe SM. Invited Speaker: Optimizing HIV monitoring technologies in management; training module on medicines supply management. South East Europe. Skopje, Macedonia. Workshop on Pharmaceutical Policies and Access to Essential Medicines for Pacific Island Countries. "*-") August "''%,Nadi, Fiji. Crowe SM. Invited Symposium Speaker: PITTCON ’"''% (Pittsburgh Conference). HIV/AIDS-related Diagnostics for Resource-limited Tannock G. Symposium on Molecular Biology, Institute for Countries. Towards a point-of-care viral load assay in resource-poor Biotechnology, Hanoi Vietnam. countries. New Orleans. Vietheer PTK, McCaffrey K, Quinn C, Owczarek C, Hardy M, Walker L, De Souza P, Whitney R, Lai P, Uaquiço A. Sustainable civil society Fabri L, Scotney P, Poumbourios P, Drummer HE. Evaluation of a capacity: strengthening technical and institutional capacity of local modified E!--# glycoprotein core domain as a HCV vaccine candidate. NGOs in Manica/Mozambique. XVII International AIDS Conference (-% !*th International Symposium on Hepatitis C Virus & Related Viruses, August "''%, Mexico City, Mexico. San Antonio. Dorabjee J. Debate: This house believes that methadone maintenance Wong C, Liu Y, Yip J, Wee JL, Oates L, Beauchemin N, Jackson DE. therapy only prolongs addiction and abstinence is the only cure. CEACAM# is a negative regulator of platelet-collagen interactions and HAARP Consultation and Coordination Forum (HCCF) Meeting, Phnom thrombus growth in vivo. (Poster and short oral presentation). Gordon Penh, Cambodia. October "''%. Research Conference, Waterville Valley, USA. July "''%. Dorabjee J. Drug Policies – more harm than good. Parliamentarians, Xing P-X. Immunotherapy of cancer based on monoclonal antibody to Policy Makers & Drug User Forum: The !st Asian Consultation on the Cripto. Annual Conference of Hubei Anti-Cancer Society, China, March Prevention of HIV related to Drug Use. January "''%, Goa, India. "''%. Invited Speaker.

page $* Yap SH, Radzio J, Sluis-Cremer N, Tachedjian G. N,$*I in the Crowe SM. Microbes Sans Frontiers. Priscilla Kincaid-Smith Oration connection domain of HIV-# reverse transcriptase confers zidovudine/ and Medal, The Royal Australasian College of Physicians Congress, NNRTI dual resistance. !*th Conference on Retroviruses and Adelaide. Opportunistic Infections, Boston, USA. da Fonseca Pereira C, Ellenberg P, Mak J. Development of a Novel System to Dissect the Early Steps of HIV Infection. Australian Centre for HIV and Hepatitis Virology Research (ACH") Annual Meeting, Adelaide. National Dean J, Boo I, Talbot G, Poumbourios P, Drummer H. Fusion activation Aitken C, Lewis J, Hocking J, Bowden D, Hellard M. Does information triggers of Hepatitis C Virus envelope glycoproteins E# and E!: about drug users’ social networks predict exposure to the hepatitis potential role for thiol disulfide isomerization. ACH" #th National c virus? $th Australasian Viral Hepatitis Conference, "'-"" October Workshop, Barossa Valley, South Australia. "''%. Brisbane. Dowling D, Nasr-Esfahani S, Tan CH, O’Brien K, Howard KL, Jans DA, Aitken C, Lewis J, Tracy S, Spelman T, Bowden D, Bharadwaj M, Purcell DFJ, Stoltzfus CM, Sonza S. HIV-# infection changes the balance Drummer H, Hellard M. High incidence of hepatitis c virus re-infection of cellular splicing factors that regulate alternative viral splicing and in a cohort of injecting drug users. $th Australasian. Viral Hepatitis virus production in macrophages. #th Annual Australian Centre for Conference, "'-"" October "''%. Brisbane. HIV and Hepatitis Virology Research Workshop. Barossa Valley, South Australia. Anderson D. Australasian Viral Hepatitis Conference, Brisbane; Australian Centre for Hepatitis and HIV Virology, Adelaide. Flynn JK, White P, Grebely J, Kaldor J, Hellard M, Dore G, Lloyd AR, Ffrench RA. Immunity to Acute Hepatitis C and the Influence of Early Anderson D. Development of a Rapid, point-of care Therapy. $th Australian Viral Hepatitis Conference, Brisbane, Australia, immunochromatographic test for measurement of CD$ T-cells. "'th -""nd October "''%. Centre for Immunology, Centre for Festschrift for Chris Burrell, Adelaide. Population Health. Anderson D. Interactions of hepatitis viruses with polarized epithelia Gerondakis S. Innate Sculpting of Adaptive Immunity. Hamilton Island, (hepatocytes). $th Australasian Viral Hepatitis Conference, Brisbane. April "''%. Invited Speaker. Anderson D. Novel virus-like particle (VLP) vaccines based on duck Goller J, Guy R, Lim M Gold J, Leslie, D, BK Tee, Roth N, Fairley C, hepatitis B virus. $th Australasian Viral Hepatitis Conference, Brisbane. Higgins N, Hellard M. HIV, syphilis and chlamydia in MSM in Victoria: Novel virus-like particle (VLP) vaccines based on duck Anderson D. risk behaviour and prevalence at clinic Sentinel surveillance sites. hepatitis B virus. Australian Society for Microbiology, Melbourne. ASHM conference !)-"' December "''%. Perth. Anderson D. The vaccine development pathway. UNSW Hepatitis C Goller, J. Syphilis prevalence in Victoria: increased risk in HIV positive vaccine initiative, Sydney. men who have sex with men, (on behalf of the Victorian Primary Care Anderson JL, Tachedjian G, Hope TJ. APOBEC,G restricts early HIV-# Network for Sentinel Surveillance on BBVs and STIs), Population replication primarily in the cytoplasm of target cells. #th Annual Health Conference, "''%. Brisbane. Australian Centre for HIV and Hepatitis Virology Research Workshop. Gray L, Churchill M, Cowley D, Sterjovski J, Ellett E, Saksena N, Barossa Valley, South Australia. Poumbourios P, Wesselingh S, Gabuzda D, Gorry PR. Tissue-specific adaptive changes in R&X$ HIV-# Env variants compartmentalized in Apostolopoulos V. Orphan vaccines – The MUC# Vaccine. "nd brain and lymphoid tissues of individuals with AIDS. #th National Australasian vaccines and immunotherapeutics development (AVID) Scientific Workshop of the Australian Centre for HIV and Hepatitis meeting. Surfers Paradise, Queensland, May "''%. Invited Speaker. Virology Research (ACH"), Barossa Valley, South Australia. , Drummer HE, Poumbourios P. A functional link Bellamy-McIntyre A Greengrass V, Plate M, Steele P, Denholm J, Morris L, Crowe SM. between the CD$ binding domain of gp#!) and the MPER of gp$# in Evaluation of the new version , Cavidi ExaVir™ Load quantitative HIV ! HIV-# ACH . #th National Workshop, Barossa Valley, South Australia. RT load kit as an alternative HIV Viral Load monitoring assay for use Boo I, te Wierek K, Poumbourios P, Drummer HE. Role of Histidine in both resource-constrained and developed countries. Australasian Residues in HCV E! in viral entry. ACH" #th National Workshop, Barossa Society for HIV Medicine (ASHM), "'th Annual Conference, Perth. Valley, South Australia. Greengrass V, Plate M, Steele P, Denholm J, Morris L, Crowe SM. Evaluation of the new version , Cavidi ExaVir™ Load quantitative HIV Brooks N, Pouniotis DS, Apostolopoulos V, Pietersz GA. Delivery RT load kit as an alternative HIV viral load monitoring assay for use in of multiple tumour epitopes by membrane translocating peptides. both resource-constrained and developed countries. Australian Centre Tumour Immunology Workshop, (%th Australasian Society for for HIV and Hepatitis Virology Research (ACH"), #th Annual Workshop, Immunology Canberra, December "''%. Barossa Valley, South Australia. Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S, Price Handoko Y, Grgacic EVL. Role of the endosomal protease cathepin L P, Kamarulzaman A . Predicting neuropathy risk before stavudine in hepadnaviral entry. Australian Centre for HIV and Hepatitis Virology prescription: an algorithm for minimizing neurotoxicity in resource- Research (ACH"), #th Annual Workshop, Barossa Valley, South limited settings. Australasian Society for HIV Medicine Annual Australia. Meeting, Perth. Hearps A, Plate M, Morris L, Greengrass V, Crowe SM. Development Cherry CL, Affandi JS, Yunihastuti E, Imran D, Price P. TNFA genotype, of a low cost HIV genotyping assay to screen for drug resistance patient height and age combine to predict risk of antiretroviral toxic mutations using dried blood spot samples. Australian Centre for HIV neuropathy in HIV patients receiving stavudine. Australian Centre for and Hepatitis Virology Research (ACH"), #th Annual Workshop, Barossa HIV and Hepatitis Research Annual Meeting, Barossa Valley, South Valley, South Australia. Australia. Hellard M, Grebely J, Matthews G, Haber P, Yeung B, Mark P, Chew C, Price P, Affandi JS, Valente F, Imran D, Kamarulzaman A, Petoumenos K, van Beek I, McCaughan G, White P, Ffrench R, Tan HY, Cherry CL. Characterisation of the TNF block haplotypes and Rawlinson W, Lloyd A, Kaldor J, and Dore G on behalf of the ATAHC genotypes that predict an individual’s risk of stavudine-associated Study Group. Impact of illicit drug use on the response to therapy sensory neuropathy. Australasian Society for HIV Medicine Annual during treatment for acute and early chronic hepatitis C infection, Meeting, Perth. $th Australasian. Viral Hepatitis Conference, "'-"" October "''%. Brisbane. Cowieson NP, Hijnen M, Wilce J, Wilce M, Mak J. Structural Analysis of the HIV Gag Polyprotein During Proteolytic Processing. ComBio, Hellard M, Matthews GV, Petoumenos K, Grebely J, Haber P, van Beek I, Canberra. Day C, Mark P, McCaughan G, Rawlinson W, Lloyd A, Kaldor J, and Dore G on behalf of the ATAHC Study Group. Factors associated with uptake Crowe SM. Invited symposium speaker: Clinical viral load testing of treatment for acute and early chronic hepatitis C virus infection, in resource poor settings. "''% Australian Society for Microbiology $th Australasian. Viral Hepatitis Conference, "'-"" October "''%. Conference, Melbourne. Brisbane. page $$ Higgs P, Moneer S, Aitken C, Bharadwaj M, Maher L, Hellard M. Ryan CE, van Rooijen L, Steele P, Morris L, Plate M, Greengrass V, Misclassification bias in a cohort of hepatitis C negative injectors, Crowe SM. The adaptation of the low cost Cavidi ExaVir™ Load assay $th Australasian Viral Hepatitis Conference, "'-"" October "''%. for the use with dried plasma spots to measure HIV-# viral load in Brisbane. resource limited settings. Australian Centre for HIV and Hepatitis Virology Research (ACH"), #th Annual Workshop, Barossa Valley, South Hijnen M, Cowieson NP, Wilce M, Mak J. Solution Structure and Australia. Functional Interactions of the Full Length HIV Gag Proteins. Australian Centre for HIV and Hepatitis Virology Research (ACH") Annual Meeting, Sheng K-C, Kalkanidis M, Pouniotis D, Esparon S, Tang CK, Adelaide. Apostolopoulos V, Pietersz GA. Mannosylated dendrimer modified antigens for immunotherapy. Australian Vaccines and Hogarth PM. Cellular and molecular basis of FcR dependent antibody Immunotherapeutics Development (AVID) Meeting. Gold Coast, induced tissue destruction in induced and spontaneous autoimmune Queensland, May "''%. joint destruction. Garvan Institute International Fellow Symposium, December "''%. Invited Speaker. Sheng K-C, Kalkanidis M, Pouniotis D, Wright MD, Pietersz GA, Apostolopoulos V. The adjuvanticity of a novel mannosylated Holmes W. A novel approach to antenatal risk assessment in very low antigen potentiates immune responses via toll-like receptor $ HIV prevalence settings in resource-poor countries. Oral presentation. modulated dendritic cell functionality. Australian Vaccines and ASHM Conference, September "''%. Perth, Australia. Immunotherapeutics Development (AVID) Meeting, Gold Coast, Queensland, May "''%. Hooker D, Wesselingh S, Cherry CL. Apoptosis is measurable by ligation-mediated polymerase chain reaction. Australian Centre for Sinclair A, Winter R, Jatkar U, Higgs P, Aitken C. Were community HIV and Hepatitis Research Annual Meeting, Barossa Valley, South concerns realized in the establishment of an NSP? Evidence, policy and Australia. practice, APSAD Conference "(-"$ November "''%. Sydney. Abstract ((&, p$). Hooker D, Wesselingh S, Cherry CL. Monitoring and understanding apoptosis in HIV patients by ligation-mediated polymerase chain Smyth RP, Schlub T, Davenport MP, Mak J. HIV Evolution and Its reaction. Australasian Society for HIV Medicine Annual Meeting, Perth. Regulation. Australian Centre for HIV and Hepatitis Virology Research (ACH") Annual Meeting, Adelaide. Jackson DE. Mechanisms of thrombus stability and growth. AIMS National Meeting, Melbourne, Platelet Biology, October "''%. Invited Stoové M, Jenkinson R, Hellard M. Local HIV information, testing Speaker. and support (HITS) program: improving the capacity of general practitioners. Australian Society for HIV Medicine Conference, "''%. Jones KL, Roche M, Gantier M, Williams BRG, Mak J. Uracil DNA Perth. Glycosylase Is Poorly Expressed in the Natural Target Cells of HIV and Is Not Required for HIV Infection. Australian Society for Microbiology Tachedjian G, Tyssen D, Moore K, Treble K, Zanin M, Gray L, Gorry P, Annual Meeting, Melbourne. Sterjovski J, Wesselingh S, Lowe M, Henderson S, Lewis G, Krippner G, McCarthy T, Paull J. In vitro activity of the dendrimer-based microbicide Kong F. Is Khat an emerging practice among regular ecstasy users in SPL()#,. #th Annual Australian Centre for HIV and Hepatitis Virology Melbourne? National Drug Trends Conference, "''%. Sydney. Research Workshop. Barossa Valley, South Australia. Lay C-S, Bellamy-McIntyre A, Talbo G, Drummer HE, Poumbourios P. Tachedjian G. Antivirals and Drug Resistance. Drug resistance in the Terminal interactions in the HIV-# gp$# trimer of hairpins. ACH" #th C-terminal domains of the HIV reverse transcriptase. The Australian National Workshop. Barossa Valley, South Australia. Society for Microbiology Conference, Melbourne. Li S, Loveland BE, Gowans EJ. Regulatory T cells in HCV infection. Tachedjian G. Drug resistance mutations in the HIV reverse Australian Society for Immunology. Annual Meeting. Canberra. transcriptase, Centre for Immunology Research Seminar Series, National Centre for Epidemiology and Clinical Research, Darlinghurst, Lim M, Goller J, Horyniak D, Aitken C, Stoové M, Quinn B, Higgins N, NSW. Hellard M. Victoria’s six hepatitis c surveillance mechanisms – strengths, weaknesses, costs and necessity, $th Australasian Viral Tachedjian G. Preclinical Development of Microbicides. Microbicides Hepatitis Conference, "'-"" Oct "''%. Brisbane. and HIV Biomedical Prevention Symposium: Gender, Vulnerability, University of Sydney, NSW. Loveland BE. Models for Clinical Research. Alfred Medical Research and Education Precinct (AMREP) – the Burnet Institute. Clinical Tachedjian G. Role of HIV)# reverse transcriptase dimerization in Research Excellence (CRX'%), Brisbane. viral replication, Institute for Molecular Bioscience, The University of Queensland. Martyn J, Li S, Gowans EJ. A novel baculovirus which targets IgGR- , McCaffrey K, Boo I, Poumbourios P, Drummer HE. positive cells. ACH" Annual Meeting, Barossa Valley, Australia. TeWierak KT Hypervariable regions of E! modulate E#E! glycoprotein function. ACH" McCaffrey K, Boo I, Vietheer P, Poumbourios P, Drummer HE. #th National Workshop, Barossa Valley, South Australia. Expression and characterization of Hepatitis C virus (HCV) envelope Toole M. Strengthening District and Community Health Services in Lao glycoprotein E! core domains for crystallization trials. ACH" #th PDR. World Health Day Forum. April ), "''%. Melbourne, Australia. National Workshop, Barossa Valley, South Australia. Toole M. Strengthening technical and organisational capacity of local Peel T, McLean C, Cameron P, Hoy J , . Steroid dependent Wright E NGOs in Manica province, Mozambique. Australasian African Studies cryptococcal immune restoration disease in an HIV positive patient. Conference. November "%, "''%. Melbourne, Australia. "'th Annual Conference of the Australasian Society of HIV Medicine, Perth. van de Waarsenburg S. Development of a Rapid Point of Care Test for Estimation of CD$+ T cell counts for use in Resource-Constrained Pietersz GA. Mannosylated dendrimer-modified antigens for settings. Monash Infection and Immunity Network, Melbourne. immunotherapy. (%th Australasian Society for Immunology, Canberra, December "''%. van de Waarsenburg S. Development of a Rapid Point of Care Test for Estimation of CD$+ T cell counts for use in Resource-Constrained Power R, Winter R. Local Solutions to public injecting. APSAD. settings. Australian Centre for Hepatitis and HIV Virology, Adelaide. November "''%. Sydney, Australia. Vietheer, PTK, McCaffrey K, Quinn C, Owczarek C, Hardy M, Walker L, Power R. Reproductive health interventions targeting adolescents in Fabri L, Scotney P, Poumbourios P, Drummer HE. Evaluation of modified " rural Zimbabwe. Australian Society for HIV Medicine. September "''%. E!--# glycoprotein core domain as an HCV vaccine candidate. ACH #th Perth, Australia. National Workshop, Barossa Valley, South Australia. Ryan CE, Kama M, Darcy A, Aleksic E, Mirza, T, Chaudhary A, Rogers Wines B, Ramsland PA, Trist HM, Fraser JD, Hogarth PM. The G, Crowe SM. The Molecular characterization of the HIV-# Epidemic interaction of human, rat and mouse IgA with the staphylococcal decoy in Fiji. Australasian Society for HIV Medicine (ASHM), "'th Annual protein SSL( and the leukocyte IgA receptor. (%th Australasian Society Conference, Perth. for Immunology, Canberra, December "''%.

page $) Wong C, Liu Y, Yip J, Wee JL, Oates L, Beauchemin N, Jackson DE. Gray L, Churchill M, Cowley D, Sterjovski J, Ellett E, Saksena N, Oral presentation, CEACAM# is a negative regulator of platelet-collagen Poumbourios P, Wesselingh S, Gabuzda D, Gorry PR. Tissue-specific interactions and thrombus growth in vivo. Atherothrombosis IVBM adaptive changes in R&X$ HIV-# Env variants compartmentalized in Meeting, Melbourne, June "''%. brain and lymphoid tissues of individuals with AIDS. !*th Conference on Retroviruses and Opportunistic Infections (CROI), February Boston, Yap SH, Radzio RJ, Sluis-Cremer N, Tachedjian G. N,$*I in the MA, USA. connection domain of HIV-# reverse transcriptase confers zidovudine/

NNRTI dual resistance. #th Annual Australian Centre for HIV and Grebely J, Matthews GV, White PA, Renkin M, Flynn J, Ffrench R, Hepatitis Virology Research Workshop, Barossa Valley, South Australia. Kaldor J, Hellard M, Lloyd A, Dore GJ on behalf of the ATAHC Study Group. Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV th POSTER PRESENTATIONS infection. $ Viral Hepatitis Conference, Brisbane, October "''%. Centre for Immunology, Centre for Population Health. Greengrass V, Plate M, Steele P, Denholm J, Morris L, Crowe SM. Aleksic E, Cox H, Ryan C, Globan M, Reiher B, Toatu T, O’Connor J, Evaluation of the new version , Cavidi ExaVir™ Load quantitative HIV Crowe S. Molecular Epidemiology of Mycobacterium tuberculosis in RT load kit as an alternative HIV viral load monitoring assay for use in Kiribati. Australasian Society for HIV Medicine (ASHM), "'th Annual Melbourne. XVII International AIDS Conference, Mexico City, Mexico. Conference, Perth. Higgs P, Aitken C, Hellard M, Maher L. Avoiding hepatitis C infection Benton K, Tin Aung Win. HIV and sexual identity in Myanmar. despite long term injecting: behavioural, social or immunological? (rd International Lesbian and Gay Association (ILGA) Regional Australian Society of HIV Medicine "'th Annual Conference. Conference in Asia ‘Equality in Diversity Now!’ "#-") January "''%, September "''%, Perth. Chiang Mai, Thailand. Higgs P, Kefle Y, Hellard M, Maher L. Factors influencing a self-limiting Brooks N, Pouniotis DS, Apostolopoulos V, Pietersz GA. Delivery of HIV outbreak among ethnic Vietnamese injecting drug users in multiple tumour epitopes by membrane translocating peptides. (%th Melbourne, Australia. !&th International Conference on the Reduction Australasian Society for Immunology, Canberra, December "''%. of Drug-related Harm. May "''%, Barcelona. Day S, Slaats I, Sheng K-C, Apostolopoulos V. Functional Higgs P, Yohannes K, Hellard M, Maher L. Self-limiting HIV outbreak among ethnic Vietnamese injecting drug users in Australia: A characterisation of Muc# on murine lymphocytes. (%th Australasian qualitative study. XVII International AIDS Conference. August "''%, Society for Immunology, Canberra, December "''%. Mexico. Deraos G, Chatzantoni K, Matsoukas M-T, Katsara M, Tselios T, Horyniak D, Higgs P, Lewis J, Winter R, Aitken C, An evaluation of a Deraos S, Papathanasopoulos P, Vynios D, Apostolopoulos V, heroin overdose prevention and education campaign. Australasian Mouzaki A, Matsoukas J. Modifications of the myelin basic protein Professional Society on Alcohol and Other Drugs (APSAD) Conference. epitope MBP*(-'' divert Th! to Th#: immune responses in PBMC from "(rd–"$th November "''%. Sydney. MS patients. ('th European Peptide Symposium (('EPS), Helsinki, Finland, September "''%. Horyniak D, Higgs P, Lewis J, Winter R, Aitken C. An evaluation of a heroin overdose prevention and education campaign. Alfred Week Flynn J, Grgracic E, Anderson D, Ffrench R. HCV E! virus like particles Research Poster Display, Alfred Hospital. "'th–"#th October, "''%, stimulate maturation of human dendritic cells. ISAC XXIV, Budapest, Melbourne. Hungary, !)–"! May "''%. Jenkinson R, Stoové M, Hellard M. Local HIV Information, Testing Flynn J, White P, Grebely J, Hellard M, Kaldor J, Dore G, Lloyd AR, and Support (HITS) Pilot Program: Improving the Capacity of General Ffrench RA. Preservation of effector T cell function in treated acute Practitioners (GPs). Population Health Congress. July "''%, Brisbane. HCV subjects. !*th International Symposium on Hepatitis C Virus Katsara M, Yuriev E, Ramsland P, Deraos G, Matsoukas J, and Related Viruses, Texas, USA, *-&th October "''%. Centre for Apostolopoulos V. Development of a vaccine against Multiple Immunology, Centre for Population Health. Sclerosis. ('th European Peptide Symposium (('EPS), Helsinki, Garcia M. An immunochromatographic test for measurement of CD$ Finland, September, "''%. T- cells at point-of-care. Rapid Diagnostics, Washington DC, USA. Katsara M, Yuriev E, Ramsland P, Deraos G, Tselios T, Deraos S, Garcia M. An immunochromatographic test for measurement of CD$ Matsoukas J, Apostolopoulos V. Linear/cyclic mutant analogues of self T- cells at point-of-care. Alfred Research Week, Melbourne. antigens (MBP and PLP) manipulate immune responses in mice. &th International Conference in Medicinal Chemistry: Drug Discovery and Gold J, Lim M, Aitken C, Hocking J, Hellard M. SMS !))*: Expanding Design. University of Patras, Greece, March "''%. the use of Text Messages for Sexual Health Promotion to Young People. Australasian Sexual Health Conference, September "''%. Perth. Leeansyah E, Crowe SM, Jaworowski A. Poster presentation: ITAM- signalling proteins expression in peripheral blood mononuclear cell Gold J, Lim M, Hocking J, Aitken C, Keogh L, Fairley C, Jordan L, populations of HIV-#-infected individuals. Keystone Symposia in NK Dixon H, Wakefield M, Ferrari G, Johnson E, Hellard M. SMS $ Health and NKT Cell Biology, Colorado, USA. Promotion: Building the Evidence Base. Adolescent Health, November , . The expression "''%, Melbourne. Leeansyah E Paukovics G, Crowe S M, Jaworowski A of ITAM-signalling proteins in peripheral blood mononuclear cell Gowans EJ, Roberts SK, Wall DM, Brown LE, Loveland BE, Hart D, populations of HIV-1-infected individuals. Monash Infection and Jackson DC. Immunotherapy for HCV infection. American Association Immunity Network Young Investigator Symposium, Melbourne. for the Study of Liver Disease. Annual Meeting, San Francisco, USA. Leeansyah E, Zhou J, Paukovics G, Crowe SM, Jaworowski A. Gray L, Churchill M, Cowley D, Sterjovski J, Ellett A, Saksena N, Decreased FcR-gamma Expression in NK cells Isolated from HIV-#- Poumbourios P, Wesselingh S, Gabuzda D, Gorry PR. Tissue-specific infected Individuals receiving antiretroviral therapy. !!th Meeting of the adaptive changes in R&X$ HIV-# Env variants compartmentalized in Society for Natural Immunity, Fremantle, WA. brain and lymphoid tissues of individuals with AIDS. "nd Annual Li S, Loveland BE, Plebanski M, Floess S, Hamann A, Gaudieri S, Monash Immunity & Infection Network, (MIIN). ("''%) Young Lucas A, Hellard M, Roberts S, Paukovics G, Aitken C, Barry S, Investigators Symposium, Monash University, Clayton, Victoria. Schofield L, Gowans EJ. Understanding the role of HCV specific Gray L, Churchill M, Cowley D, Sterjovski J, Ellett A, Saksena N, regulatory T cells. #&th International on HCV and Related Viruses, Poumbourios P, Wesselingh S, Gabuzda D, Gorry PR. Tissue-specific San Antonio, USA. adaptive changes in R&X$ HIV-# Env variants compartmentalized in Lim M, Goller J, Gold J, Samuel-King J, Brown J, Fairley C, Guy R, brain and lymphoid tissues of individuals with AIDS. "'th Alfred Week Henning D, Buchanan A, Hellard M. Hepatitis C Sentinel Surveillance in Research Poster Display, Alfred Hospital, Melbourne. Victoria. Viral Hepatitis Conference, October "''%, Brisbane. page $% Lim M, Goller J, Guy R, Hocking J, McNamee K, Gold J, Fairley C, Sacks-Davis R, Gold J, Hellard M. Hepatitis C treatment outcomes for Kelly N, Henning D, Hellard M. Trends in Chlamydia Testing and Risk injecting drug users: review of the evidence. $th Australasian Viral Factors in Young People: Findings from the Sentinel Surveillance Hepatitis Conference. "'th–""nd October "''%, Brisbane. Network. Adolescent Health November "''%. Melbourne. Sheridan S, Phimphachanh C, Chanlivong N, Manivong S, Lim M, Goller J, Guy R, Hocking J, McNamee K, Gold J, Fairley C, Kelly N, Khamsyvolsvong S, Lattanavong P, Sisouk T, Toledo C, Scherzer Henning D, Timms J, Hellard M. Trends in Chlamydia Prevalence, M, Toole M, van Griensven F. Assessment of HIV infection and risk Testing and Risk Behaviours among Young People: Victorian Sentinel behavior among populations of men who have sex with men in Surveillance. Australasian Sexual Health Conference, September Vientiane Capital, Lao People’s Democratic Republic. XVII International "''%. Perth. AIDS Conference, Mexico City. Poster. Lim M, Goller J, Horyniak D, Aitken C, Stoové M, Quinn B, Samuel-King Snell B. A team approach to strengthening supply of essential J, Brown J, Fairley C, Higgins N, Hellard M. Six current mechanisms medicines in Pacific Island Countries. Population Health Congress July of Hepatitis C surveillance in Victoria: What are the strengths, $-&, "''%, Brisbane, Australia. Poster. weaknesses, costs and necessity of each? Australasian Society for HIV Medicine (ASHM) Conference. !)th–"'th September "''%, Perth. Songbandith T, Sheridan S, Ounaphom P, Chanlivong N, Toole M. Sexual behaviour and vulnerability of young females, Vientiane Lim M, Nguyen O, Walsh N, von Bibra S, Devadason D, Guy R, Capital, Lao PDR. XVII International AIDS Conference, Mexico City. Hellard M. Use of Hepatitus C (HCV) Surveillance System For Poster. Recruitment Of Patients With Newly Aquired HCV Into A Clinical Trial. Australian Society for HIV. "''%, Sydney. Sterjovski J, Churchill MJ, Ellett AM, Gray L, Roche MJ, Dunfee R, Pacific Regional HIV Project team. Let’s talk and walk the talks – Purcell DFJ, Saksena N, Wang B, Sonza S, Wesselingh SL, Karlsson I, a school-based peer education program in Fiji. XVII International Fenyo E-M, Gabuzda D, Cunningham AL, and Gorry PR. Asn ,-! in Conference on AIDS. August "''%, Mexico. Poster. gp#!) contributes to enhanced fusogenicity by CCR&-restricted HIV-# envelope glycoprotein variants from patients with AIDS. Keystone Pacific Regional HIV Project team. Making HIV visible in Fiji – Role of Symposia on HIV Pathogenesis, Banff, Alberta, Canada. People Living with HIV, XVII International Conference on AIDS, August "''%, Mexico. Poster. Tachedjian G, Tyssen D, Moore K, Treble K, Zanin M, Gray L, Gorry P, Wesselingh S, Lowe M, Henderson S, Lewis G, Krippner G, McCarthy T, . Monitoring and evaluating Pacific Regional HIV Project team Paull J. In vitro activity of dendrimer-based microbicides. Microbicides Stepping Stones in the Pacific. XVII International Conference on AIDS. "''%, New Delhi, India. August "''%, Mexico. Poster. Tang CK, Apostolopoulos V, Pietersz GA. Immune responses and Pacific Regional HIV Project team. PRHP Finance Accountability. XVII mechanism of action induced by mannan mediated DNA vaccination. International Conference on AIDS, August "''%. Mexico. Poster. (%th Australasian Society for Immunology, Canberra, December "''%. Pacific Regional HIV Project team. Survey of Female Sex workers in Vanuatu. XVII International Conference on AIDS, August "''%, Mexico. Tang CK, Pietersz GA, Apostolopoulos V. Oxidised mannan potentiates Poster. DNA vaccine for use in cancer immunotherapy. "nd AVID Meeting, Surfers Paradise, May "''%. Parnell BW. Creating conditions for advocacy to shape policy in Myanmar. XVII International AIDS Conference. August "''%. Mexico Toole M, Hughes C, Chanlivong N. A gendered approach to reducing City, Mexico. Poster. the risk of anal sex as a factor in HIV transmission among urban youth in Laos. XVII International AIDS Conference, Mexico City. Poster. Pedrana A, Stoovè M, von Doussa H, Guy R, Hellard M. Estimating HIV prevalence of HIV among men who have sex with men (MSM); a review Toole MJ, Hughes C, Chanlivong N, Khamsyvoravong S, and Vilasack P. of methodological options. Australasian Society for HIV Medicine, Addressing the diversity of male sexual behaviour through research September "''%, Perth. and tailored HIV prevention education in Laos. XVII International AIDS Conference, Mexico City. Poster. Perret J, Apostolopoulos V, McDonald CF, Pouniotis DS. T helper-#( cell responses in chronic obstructive pulmonary disease: a pilot study. The Wapling J, Kuiper M, Tachedjian G. Characterisation of mutations Thoracic society of Australia and New Zealand, Melbourne Convention that prevent and restore HIV-# reverse transcriptase dimerisation. XVII Centre, March, "''%. International AIDS Conference, Mexico City. Perret J, Pouniotis DS, McDonald C, Apostolopoulos V. T helper-#( cell Wapling J, Kuiper M, Tachedjian G. The role of reverse transcriptase responses in chronic obstructive pulmonary disease (COPD): A pilot dimerisation in HIV replication. The #th Australian Health & Medical study. Austin Medical Research Week, Austin Health., Melbourne, Research Congress, Brisbane, Queensland. October, "''%. White PA, Grebely J, Matthews GV, Flynn J, Renkin M, Kaldor J, Lloyd A, Pietersz GA, Mottram PL, van de Velde NC, Tan Sardjono C, Esparon S, Hellard M, Ffrench R, Dore GJ on behalf of the ATAHC Study Ramsland PA, Moloney G, Baell JB, McCarthy TD, Matthews BR, Group. Natural history of HCV reinfection and superinfection. Powell MS, Hogarth PM. Fc Receptors as targets for the treatment $th Viral Hepatitis Conference, Brisbane, October "''%. Centre for of chronic inflammatory disease in mice. Australasian Society for Immunology, Centre for Population Health. Immunology, Canberra, "''%. Whitney R, Brown M, Proto de Souza P. Three simple steps to guided Pouniotis DS, Brooks N, Perret J, Apostolopoulos V, McDonald CF. self-assessment: participatory methodology put into practice in Blood monocytes function from patients with early diagnosed primary Mozambique. XVII International AIDS Conference (–% August "''%, lung cancer. The Thoracic Society of Australia and New Zealand, Mexico City, Mexico. Poster. Melbourne Convention Centre, March, "''%. Woolley IJ, Ayoub S, Crowe SM, Cherry CL, Visvanathan K, Morand Proto de Souza P, Whitney R. How to enhance learning and skills development via planning, review and evaluation. XVII International E. MIF (Macrophage Inhibitory Factor): a potential biomarker for AIDS Conference (–% August "''%, Mexico City, Mexico. Poster. cardiovascular disease in persons with HIV? Lipodystrophy Workshop, London, UK. Renkin L, Hughes C. Altered indigenous decision making structures at community level in Papua New Guinea: enabling genuine youth Yap SH, Radzio J, Sluis-Cremer N, Tachedjian G. N(#%I in the participation in responses to HIV. XVII International AIDS Conference, connection domain of HIV-! reverse transcriptase confers zidovudine/ (–% August "''%, Mexico City. Poster. NNRTI dual resistance. Cold Spring Harbor Retroviruses Meeting, Cold Spring Harbor, New York, USA. Rokhmah Hidayati N, Renkin L. Enabling while rebuilding: facilitating an HIV response in post-tsunami Aceh, Indonesia. XVII International Zhou J, Tippett E, Rogerson SJ, Jaworowski A. HIV alters AIDS Conference, (-% August "''%, Mexico City. Poster. proinflammatory cytokine secretion in response to phagocytosis of malaria infected erythrocytes by monocyte derived macrophages. Sacks-Davis R, Gold J, Hellard M. Treating injecting drug users Australasian Society of Immunology, Canberra. for hepatitis C: myths and reality. $th Australasian Viral Hepatitis Conference. "'th–""nd October "''%. Brisbane.

page $& Awards and prizes Reddy Luthmoodoo, M. Dept. Microbiology Monash University. Telawatte, S. Investigation of the role of SR proteins in HIV-! replication and "kb mRNA expression in macrophages, Monash University. DEGREES AWARDED Wong, CL. (H"A). Investigating virion-associated host cellular factors in retroviruses, Monash University. PhD Yap, ML. BSc (Hons), H! Honours, Department of Pathology, University of Melbourne. Thesis title: Defining mechanisms of immunoreceptor Audsley, J. Alternative approaches in the preparation and growth of binding and modulation of pathogenic Salmonella typhimurium influenza B vaccine viruses. Royal Melbourne Institute of Technology infection. (RMIT). Cook, N. MB BS FRACP. University of Melbourne. Supported by a Postgraduate Medical Research Scholarship from the NHMRC. "''%. DEGREES IN PROGRESS Thesis title: Regulation of the renal sodium co-transporter NKCC! by the AMP-activated protein kinase. Counihan, N. Interactions of hepatitis A virus with polarized epithelia, PhD Monash University. Bellamy-McIntyre, A. Receptor activated conformation of the gp#!)- Dorning, K. Children as Beneficiaries and Participants in Development gp$# glycoprotein complex of HIV-#, Monash University. Programs: A Case Study in Burma (Myanmar), Victoria University. Benton, K. Emotionality and Sexual Scripting, Deakin University Dunstan, K. BSc(Hons), UNSW. Thesis title: Understanding the Early Brooks, N. BSc(Hons), Thesis title: Membrane Permeable Multiple Interactions between Vaccinia virus and Dendritic cells – Towards an Antigen Peptides for the Immunotherapy of Cancer, RMIT Enhanced Vaccine Vector. Bullen, H. The characterisation of a novel family of invasion associated Giles, M. HIV and women in Australia, Monash University. membrane proteins in Apicomplexan parasites with particular focus Guy, R. The use of routine HIV testing data as a basis for planning and on those found in Plasmodium falciparum and Toxoplasma gondii, The evaluating public health interventions, Monash University. University of Melbourne. Higgs, P. Exploring risk: A case study of ethnic Vietnamese heroin Chew, C. Antiretroviral toxic neuropathy in HIV patients: genetic and users, Monash University. other risk factors, University of Western Australia. Jones, K. Early stage of HIV infection, Monash University. Choy, SW. MB BS FRACP. University of Melbourne. Supported by a Postgraduate Medical Research Scholarship from the NHMRC. Katsara, M. Thesis title: Immune responses to myelin peptide analogues conjugated to mannan in animal models of MS University of Cowley, D. Molecular studies of HIV-# infection of the central nervous Patras, Greece. system, Monash University. Leeansyah, E. The effect of HIV-# infection on Fc-gamma receptor Dean, J. Thiol disulfide exchange in HCV glycoproteins E# and E!, signalling and function Department of Medicine, Monash University. Monash University. Neilsen, S. The impact of benzodiazepines on opioid substitution Desmond, M. MB BS FRACP. University of Melbourne. Supported by a treatment, Monash University. Postgraduate Medical Research Scholarship from the NHMRC. Merati, TM. Molecular Epidemiology of HIV infection in Indonesia. Dong, X. Master of Philosophy. Studies of GBV-B infection of Udayana University, Bali. marmosets, Monash University. Warning, J. BSc(Hons), UNSW. Thesis title: Microtransfusion and Viral Fillipas, S. Physical activity and HIV, Monash University. Exposure in Infants Born to HIV-infected Women Flynn, J. BSc(Hons), MBiotech, Monash University. Thesis title: Westhorpe, C. Effects of HIV-# infection in vitro on transendothelial Stimulation and maintenance of T cell responses in acute HCV migration by cells of the macrophage lineage. Monash University. infection. Gold, J. The medium and the message: an investigation of how youth Masters access, interpret and implement sexual health information, Monash University. Naing, KPP. Master of Development Study, Yangon University, Yangon, Myanmar. Gorzin, A. MSc. The role of the HCV p( and NS! proteins in HCV morphogenesis, Monash University. Thein, AM. Master in Public Administration, Yangon University, Yangon, Myanmar. Gouklahni, H. Functional interactions of the structural and nonstructural proteins of HCV, Monash University. van Hoeven, V. (H!). Structural and Biochemical Studies on HIV Assembly Determinants, Utrecht University. Gray, L. Viral determinants in HIV-# neurotropism and neurovirulence, University of Melbourne. Hawkes, D. Rearrangement of the virion plasma membrane in HIV-#, Honours Monash University. Alhammad, Y. Department of Microbiology, Monash University. Khasawneh, A. Studies on the fusion mechanism of the HIV-# Dutkowski, R. BSc(Hons), H"I, Monash University. Thesis title: glycoproteins, Monash University. Investigation of heterosubtypic cellular immune responses to La, J. Small molecule inhibitors targeting HIV-# reverse transcriptase influenza in humans. dimerization. Monash University, Dept of Medicinal Chemistry, Monash Edmunds, M. Department of Microbiology. Monash University. Faculty Scholarship. Gilan, O. (H!). Structural Comparison of Retroviral Gag Proteins, Laslett, A. The role of alcohol in child protection notifications, Monash University. investigations and interventions. Monash University. La, J. BMedChem (Hons), Monash University. Latour, P. BSc(Hons). Optimisation of immunotherapy for HCV infection, Monash University. Orlowski, E. BSc (Hons), H! Honours, Department of Pathology, University of Melbourne.Thesis title: Regulatory mechanisms that Lee, D. MB BS FRACP. University of Melbourne. Supported by a influence blood clot formation. Postgraduate Medical Research Scholarship from the NHMRC. page )' Lichtfuss, G. Immune activation and chronic viral infection, Monash OTHER STUDY IN PROGRESS University. Livingston, M. Alcohol outlets and their relationship to harm, University of Melbourne. Garreffa, D. Certified Practicing Accountant (CPA) Program. McCaffrey, K. Characterization of a novel HCV vaccine candidate. Lwin, A. Certified Accounting Technician, Associate of Chartered Melbourne University. Certified Accountants, London, UK. Pedrana, A. On the Scene: The Epidemiology of HIV among men who Meshkat, Z. Visiting Scientist. have sex with men (MSM) in Victoria, Monash University. Renkin, L. Diploma of Professional Counselling, Australian Institute of Roche, M. HIV-# entry and its inhibition, Monash University. Professional Counsellors Ryan, C. HIV distribution and monitoring in Indonesia, PNG and Fiji, Sanassee, M. Diploma of Community Welfare Work, Swinburne Monash University. University of Technology. Smyth, R. Recombination and the evolution of HIV, Monash University. Schmich, L. Master of Laws Juris Doctor, Monash University. Sterjovski, J. Pathogenesis of CCR&-restricted Human Tey, J. AMS student, University of Melbourne. Immunodeficiency Virus Type #, Monash University. Thwet Aye, N. Diploma in Business Administration, Thames Centre, Taechalertpaisam, T. Investigation of human erythrocyte invasion by Singapore. Plasmodium falciparum, University of Melbourne. Tolstrup, M. Skeiby Hospital, Universitgy of Aahus, Denmark. Tippett, E. The role of CD#-+ monocytes in HIV pathogenesis, Monash Van Rooijen, L. Cavidi assay: Compatibility of blood stabilizers University. and the effect of RT inhibitors and mutations. (Free University, The Tong, YK. Virus-like particle vaccines against HIV/AIDS, Monash Netherlands). University. Wang, J. Trainee of the Australasian Faculty of Public Health Medicine. Wade, J. Mechanisms of direct and bystander cell death by CCR&- ACCA Part ", Associate of Chartered Certified Accountants, restricted HIV-# envelope glycoproteins, University of Melbourne. War Tun, W. London, UK. Wapling, J. Role of highly conserved reverse transcriptase (RT) residues in RT dimerisation, maturation and HIV-# replication, Monash Xiao, K. Certified Practicing Accountant (CPA) Program. University. Wong, SS. BBMedSci, MSc. The function of the M protein of Dengue OTHER AWARDS AND PRIZES virus, University of Melbourne. Wright, E. HIV Neurological Disease: Asia Pacific regional prevalence and response to different antiretroviral treatment strategies across Apostolopoulos, V. Appointed Australia Day Ambassador, January international resource-varied settings, Monash University. "''%. Yap, SH. Role of mutations in the connection domain of the HIV reverse Audsley, J. Young Investigators Award, !*th Conference on transcriptase in drug resistance, Monash University. Opportunistic Infections and Retroviruses, Boston. Barry, A. Ian Alexander Jamieson Travel Award Masters Bellamy-McIntyre, A. Harold Mitchell Award, Burnet Institute. Downing, S. Masters of Applied Epidemiology, National Centre for Cherry, CL. National Health and Medical Research Council (NHMRC) Epidemiology and Population Health, Australian National University. Career Development Award, "''&-"'!". Lau, LM. The role of tetraspanin superfamily members, CD#&# and Crowe, S. Medal, Royal Australian College of Physicians. TSSC- in modulating platelet function, Department of Pathology, da Fonseca Pereira, C. Recipient Roche Travel Award to attend the University of Melbourne. "''% Cold Spring Harbour Laboratory Immunocytochemistry, In Situ Lim, M. Master of Public Health, Monash University. Hybridization and Live Cell Imaging Workshop. van Hoeven, V. (H!). Structural and Biochemical Studies on HIV Dean, J. Melbourne Protein Group. Best Speaker Award. Assembly Determinants, Utrecht University. Gold, J. Australian Postgraduate Award, "''%–"'!'. Winter, R. Latrobe University, School of Public Health. Gold, J. Burnet Institute Public Health Travel Award "''%. Gold, J. Monash University Faculty of Medicine Excellence Award Honours "''%-"'!' Chong, W. HIV in pregnancy. Monash University. Gorry, G. Victorian Young Tall Poppy Science Award; NHMRC Level " Gilan, O. (HI). Structural Comparison of Retroviral Gag Proteins, Career Development Award, "''&–"'!". Monash University. Gray, L. Young Investigator Award. !*th Conference on Retroviruses Santoso, D. BMedSci(Hons) mid-year entry, Monash University. Thesis and Opportunistic Infections ("''%), Boston, MA, USA; Student title: Memory B cell responses in Hepatitis C virus infection. Research Medal (Bronze), Australian Centre for HIV & Hepatitis Virology Research (ACH") #th National Scientific Workshop ("''%), Telawatte, S. Investigation of the role of SR proteins in HIV-# replication Barossa Valley, South Australia; Burnet Prize for Infectious Diseases and !kb mRNA expression in macrophages, Monash University. ("nd Prize), "'th Alfred Week Research Poster Display ("''%), Alfred Wong, CL. (H"A). Investigating virion-associated host cellular factors in Hospital, Melbourne. retroviruses, Monash University. Hijnen, M. Best Young Post-Doctoral Award, Australian Centre for HIV and Hepatitis Research (ACH") Meeting; Recipient of Harold Mitchell Foundation Post-Doctoral Travel Fellowship; The Netherlands Post Graduate Organisation for Scientific Research Rubicon Fellowship, "''$-"''%. O’Neill, S. Masters of Conflict Resolution, La Trobe University Hoare, H. NHMRC Doherty Fellowship, "''&–"'!". Quartermaine, M. Master of Public Health, James Cook University. Katsara, M. Best poster Award, &th International Conference in Whitney, R. Postgraduate Certificate in Assessment and Evaluation, Medicinal Chemistry: Drug Discovery and Design Conference. University of Melbourne. University of Patras, Greece, March, "''%.

page )! Lim, M. Postgraduate Publications Award (Monash University). Cherry, CL. Chair, Toxicology and Pharmacology Working Group of the National Centre for HIV Epidemiology and Clinical Research; Research McCaffrey, K. Virology Travel Award, Burnet Institute. Review Committee, Alfred Health; Models of Care Steering Committee Pedrana, A. Sidney Myer Health Scholarship. member for the Australasian Society for HIV Medicine; Victorian State Representative, Australian Doctors Orchestra National Committee; Power, R. International Health Award, Healthcare Project of the Year Senior Lecturer, Department of Medicine, Monash University, since "''%. Awarded by British Department of Health, Central Asia Regional "''#; Senior Burnet Fellow, since "''*; Member, Asia-Pacific HIV/AIDS Program. NeuroAIDS Consortium; Steering Committee Member, Australian Sheng, K. The McKenzie Travel Award, Burnet Institute, Australia. National NeuroAIDS Brain and Tissue Bank; Member, Data safety and monitoring board for a Biota study being conducted at Nucleus Smyth, R. Outstanding Post-Graduate Student Presentation, "''% Network Clinical Trials Unit. Australian Centre for HIV and Hepatitis Research (ACH") Meeting; Kings College London Northcote Post-Graduated Ph.D. Training Scholarship, Churchill, M. Senior Lecturer, Department of Medicine, Faculty of "''*–"''%. Medicine, Nursing and Health Sciences, Monash University; Burnet Senior Fellow, Burnet Institute, "''$–now; Member, Neurology Stoové, M. Honorary Research Fellow, Department of Epidemiology working Group, National Centre for HIV Epidemiology and Clinical and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University. Research, "''$–now. Stoové, M. Invited to participate in the "''% Theo Murphy High Coghlan, B. Senior lecturer, Department of Epidemiology and Flyers Think Tank on Preventative Health convened by the Australian Preventive Medicine, Monash University. Academy of Science, Sydney. Crabb, B. Adjunct Professor, Faculty of Medicine, The University of Tachedjian, G. Nick Crofts Publication Award for top rated publication, Melbourne; Adjunct Professor, School of Molecular Sciences, La Trobe Burnet Institute. University. Toole, M. Fenner Award "''%. Crowe, S. Member of the Forum International Working Group for HIV Collaborative Research USA; Member of the CD# Initiative Advisory Wapling, W. Travel Award to attend XVII International AIDS conference, Group, UK; Victorian HIV Blood and Tissue Storage Bank Steering Mexico City. Committee; Member, World Health Organisation Working Groups; Yap, SH. Young Investigator Award to present at the !*th Conference Member, Antiretroviral Working Group, NCHECR; Deputy Chairperson, on Retroviruses and Opportunistic Infections, Boston, MA, Feb Board of Australia-India Council, Department of Foreign Affairs and "''%; Bronze award for best oral presentation in HIV/AIDS, #th ACH" Trade; Advisory Panel Member, Medical Services Advisory Committee Workshop, Barossa Valley, South Australia. (MSAC). Dietze, P. Senior Research Associate, University of Melbourne, School of Psychology; Public Health Research Fellow, VicHealth, Public Health Research Fellowship Scheme; Career Development Academic positions Fellowship, National Health and Medical Research Council; Registered and appointments Psychologist, Victoria, Psychologists Registration Board. Dorabjee, J. International Advisory Board Member to the International Harm Reduction Development (IHRD) Program, Open Society Institute Anderson, D. Associate Professor, Department of Microbiology and (OSI), New York, US; Board Member to the Asian Consortium on Immunology, University of Melbourne; Senior Lecturer, Department Drug Use, HIV, AIDS and Poverty (ACDHAP); Board Member to the of Microbiology and Department of Immunology, Monash University; International Network of People who Use Drugs (INPUD); Executive Member of Victorian Government Animal Welfare Advisory Committee; Committee Member to UN Regional Taskforce on Injecting Drug Use Board Member, AMREP AS Ltd; Member, AMREP Scientific Advisory and HIV/AIDS in Asia and the Pacific; Board Member to the Asian Committee; Member, AMREP Monash Micro Imaging committee; Network of People who Use Drugs (ANPUD); Executive Program NHMRC Senior Research Fellow. Committee Member to the "'th International Conference on the Reduction of Drug Related Harm, International Harm Reduction Anderson, J. Convenor of the ‘High Resolution Fluorescence Imaging Association, UK. Workshop featuring DeltaVision Deconvolution Microscopy’ held Nov !!-!#, "''%, Burnet Institute, Melbourne; Burnet Institute Drummer, H. Burnet Principal Fellow; NHMRC RD Wright Fellow; representative, Management and Advisory Committee, Monash Micro- Honorary Fellow; Department of Microbiology; Melbourne University; Imaging; Member, Burnet Imaging Group. Honorary Senior Lecturer; Department of Microbiology; Monash University; Treasurer Australian Centre for Hepatitis Virology. Apostolopoulos, V. Professor, School of Molecular Sciences, Victoria University; Australia Day Ambassador; Associate Professor (Principal Ffrench, R. NHMRC Industry Fellow; Honorary Associate Professor, Research Fellow), Department of Pathology, University of Melbourne; Department of Immunology, Monash University, "''*-"'!"; Secretary, Australian Centre for Hepatitis Virology; Secretary, Immunology Group Chief Scientific Officer, #G Pharmaceutics; Principal Research Fellow, of Victoria; Australian Centre for HIV and Hepatitis Virology Annual Burnet Institute; Patron and Board member, Women’s Wellness Conference Organising Committee; Immunology Group of Victoria West, Victoria University; Adjunct Associate Professor, Department Annual Workshop Organising Committee. of Immunology, Monash University; Scientific Committee, Medicinal Chemistry Postgraduate Program, University of Patras; Scientific Gerondakis, S. NHMRC Principal Research Fellow; Honorary Professor, Advisory Board, ELFAR Pharmaceuticals Ltd, Greece; ELDrug SA, Department of Immunology, Faculty of Medicine, Nursing and Health, Greece; Expert Advisory Committee, "nd Australasian vaccines and Monash University; Honorary Professor, Department of Clinical immunotherapeutics development (AVID) meeting; Conference Hematology, Faculty of Medicine, Nursing and Health, Monash Scientific Committee, Honorary Scientific Committee, International University. Conference, Medicinal Chemistry: Drug Discovery and Design, Gorry, P. Chair, Neurology working Group, National Centre for HIV University of Patras, Greece; Scientific Advisory Board, BIT !st Annual Epidemiology and Clinical Research, "'')–now; Associate Professor, World Vaccine Congress "''%, Guangzhou, China. Department of Medicine, Faculty of Medicine, Nursing and Health Asproloupos, D. Board Member, Medecins Sans Frontieres, Australia; Sciences, Monash University, "'')–now; Associate Professor, Board Member (Chair), Antares Foundation Australia. department of Microbiology and Immunology, University of Melbourne, "''%–now; Burnet Principal Fellow, Burnet Institute, "'')–now; Barry, A. Senior Research Fellow, Burnet Institute; Honourary Senior Member, Asia-Pacific NeuroAIDS Consortium. Lecturer, Monash University. Grgacic, E. Honorary Senior Lecturer, Department of Immunology, Benton, K. Paung Ku Board Member, Myanmar. Faculty of Medicine, Nursing and Health Sciences Central & Eastern Brown, M. Senior Fellow, Centre for International Health; Burnet Clinical School, Monash University, "''*–present; Senior Burnet Principal for Education and Capacity Building. Fellow, "''*–present. page )" Hellard, M. Honorary Associate Professor, Department of Epidemiology Tachedjian, G. Associate Professor, Department of Microbiology, and Preventive Medicine, Monash University; visiting Infectious Monash University and Department of Medicine, Monash University, Diseases Physician, Royal Melbourne Hospital; visiting Infectious Alfred Campus; Principal Burnet Fellow; Member of National Centre Diseases Physician, Alfred Hospital. for HIV Epidemiology and Clinical Research (NCHECR) Antiretroviral Working Group; ASMR’s Liaison to the Premiers Award for Health and Higgs, P. Senior Fellow, Burnet Institute. Medical Research; Member, National Scientific Advisory Committee, Hogarth PM. NHMRC Senior Principal Research Fellow; Honorary Australia Society for Microbiology; Member, Australian Society Professor, Department of Immunology, Monash University; Honorary for Microbiology Research Trust Committee; Convenor of the High Professor, Department of Pathology, University of Melbourne; Acting Resolution Fluorescence Imaging Workshop featuring DeltaVision CEO CRC for Biomarker Translation; Arana Scientific Advisory Board; Deconvolution Microscopy”, Burnet Institute, Melbourne. Board Member Igavax Ltd; Consultant, Option Pharmaceuticals (USA); QLD State Government External Reviewer of Mater Medical Research Tannock, G. WHO consultant NIHR&D, Jakarta Indonesia Institute; Molecular and Cellular Immunology Lecture Program, "''%–present. Australian Influenza Vaccine Committee, !&&)–now. Department of Immunology, Monash University; Member, Victorian Toole, M. Professor, Department of Epidemiology and Preventive Cancer Council Venture Grants Steering Committee; Alfred Centre Stage Medicine, Monash University; Member, Technical Review Panel, Global " Steering Committee. Fund for AIDS, TB and Malaria; Board Member, Three Disease Fund for Jackson, D. NHMRC Senior Research Fellow (SRFB); Honorary Associate Myanmar (Burma). Professor, Department of Pathology, University of Melbourne; Adjunct Wright, E. Chair START Neurology Substudy; Chair Asia-Pacific Associate Professor, Faculty of Medicine, Nursing and Health, Monash NeuroAIDS; Co-Director of the Australian National NeuroAIDS Brain University. and Tissue Bank; Secretary Board of Australasian Society of HIV Jaworowski, A. Senior Lecturer, Department of Medicine, Faculty of Medicine; Chair Neurology Working Group of the National Centre of Medicine, Nursing and Health Sciences, Monash University. HIV Epidemiology and Clinical Research; Chair Asia-Pacific Pediatric HIV/AIDS Consortium, Member; Neurology Working Group, National Loveland, B. Associate Professor, (Honorary), Department of Centre for HIV Epidemiology and Clinical Research; Member Australian Immunology, Central & Eastern Clinical School, Faculty of Medicine, Society of Infectious Diseases; Member, Australian Society of Medical Nursing & Health Sciences, Monash University, "'')–"'!"; Principal Research; Member International Subcommittee ASHM Board; Chair Fellow, Department of Pathology, University of Melbourne, Faculty of Victorian Non-Occupational Postexposure Steering Committee. Medicine, Dentistry & Health Sciences; title of Associate Professor, "''$–now; Principal Fellow, Department of Surgery, University Xing, P. Professor, Victoria University of Technology; Principal Fellow of Melbourne – Austin and Northern Hospitals; title of Associate with the title of Associate Professor Department of Pathology, Professor ("''#); Member, Steering Committee, Research Advisory University of Melbourne; Associate Professor, Monash University; Group, Southern Melbourne Integrated Cancer Service (SMICS), Visiting Professor, Institute of Basic Medical Sciences, Chinese "''$–now; Member of Council, Cancer Council Victoria (CCV), Academy of Medical Sciences, School of Basic Medicine, Peking Union "''"–"'!"; Member, Scientific Committee, Victorian Breast Cancer Medical College; Visiting Professor, Jianghan University, China. Research Consortium (VBCRC), "''"–now. Mak, J. Associate Professor, Departments of Microbiology, Biochemistry and Molecular Biology, Monash University; Member of ACH" and ASHM Annual Meeting Advisory Committee; Member of Editorial boards NHMRC Grant Review Panel Microbiology since "''( (Deputy Chair "''$ and Chair for "'') & "''%); Vice President of Corporate Affairs for the Australian Society for Microbiology since "''%. Apostolopoulos, V. Associate Editor, Immunotherapy (www.future- drugs.com); Editorial Advisory Board, Recent Patent Reviews on Anti- Mottram, P. Honorary Senior Research Fellow, University of Melbourne Cancer Drug Discovery; Current Medicinal Chemistry; Expert Review of and Monash University. Vaccines; Medicinal Chemistry; Acta Biochimica et Biophysica Sinica; Natoli, L. Honorary Lecturer, Department of Epidemiology and Self/Nonself: immune recognition and signaling; Journal Guest Editor Preventive Medicine, Monash University. – Expert Reviews of Vaccines. Special focus issue – Cancer Vaccines. Pietersz, G. Honorary Professor, Department of Pathology, University of Barry, A. The Open Parasitology Journal (International) Melbourne; Honorary Professor, Monash University; Research Advisory Cherry, CL. Basic Science Editor, Australasian Society for HIV Medicine Committee, Avipep Pty Ltd; Board member, #G Vaccines. Journal Club, "''#–now; Open AIDS Journal "''%–now; Journal of the PONJA Assessment Team, Myanmar: International Association of Physicians in AIDS Care "''%–now. ì'U.KLQH1DQGDU6HLQ+WXQ, Field data collector in Training on Village Crabb, B. Editor-in-Chief, International Journal for Parasitology. Tract Assessment (Tripartite Core Group). Crowe, S. Sexual Health, "''(–now; Current HIV Research, "''!–now; ì'U0RQ0RQ, Facilitator in Training on Village Tract Assessment Journal of Infectious Diseases, "''"–now; Current Patents Reviews (Tripartite Core Group). on Anti-Infective Drug Discovery, "''*–now; Future HIV Therapy, ì=LQ0DU7KX, Field data collector in Training on Village Tract "''$–now; Section Editor, Journal of Leukocyte Biology, "''%–now; Assessment (Tripartite Core Group). The Open Infectious Diseases Journal, "''&–now. Poumbourios, P. Honorary Senior Lecturer. Department of Dietze, P. Associate Editor of the International Journal of Drug Policy Microbiology. Monash University. Gorry, P. Retrovirology, "'')–now; Current HIV Research, "''*–now; Ramsland, P. Honorary Senior Fellow, Department of Pathology, The The Open Microbiology Journal, "'')–now; Infectious Disease: University of Melbourne; Honorary Senior Lecturer, Department of Research and Treatment, "''%–now; Immunology and immunogenetic Immunology, Monash University. insights, "''%–now. Reeder, J. Burnet Senior Principal Research Fellow. Burnet Institute, Hogarth, PM. Faculty of #))); Monoclonal Antibodies Journal. Member, Scientific Organising Committee, Molecular Approaches to Jackson, D. Letters in Drug Design and Discovery journal (Bentham Malaria Lorne, Australia, Member, AusAID Malaria Reference Group, Science Publishing; Open Hematology Journal (Bentham Science Member, Malaria Elimination Group, UCSF Global Health Sciences. Publishing). Renkin, L. Honorary Lecturer, Department of Epidemiology and Mak, J. Ad hoc reviews for J Biol Chem, PLoS Med, J Virol, EMBO J, FEBS Preventative Medicine, Monash University. Lett, Trends in Micro, J Leuko Biol, Immuno Cell Biol and Virology; Sonza, S. Senior Lecturer, Department of Microbiology, Monash Assessor for NHMRC & ARC Project Grants, Wellcome Trust Project University. Senior Burnet Fellow; Chair, Burnet Institute Safety Grants, MRC UK Project Grants and Fellowships and the Netherlands Committee. NWO Fellowships.

page )( Power, R. Associate Editor, International Journal of Drug Policy, Centre for International Health events: Editorial Board, International Journal of Drug Policy. Associate Editor, ì 7KH$QQXDO6XH&URFNHWW0HPRULDO/HFWXUH"$ August Harm Reduction Journal. ì 7KH$QQXDO*OREDO+HDOWK)RUXPGlobal Health & Global Crises, Ramsland, P. Associate Editor, Journal of Molecular Recognition, John World Health Day, ) April. In collaboration with other AMREP Wiley & Sons UK, Editorial Board Member, Molecular Biotechnology, partners Humana Press, Springer Verlag GmbH, Germany ì 1RW-XVW7DONâ+RZ&DQ:H+HOS0RWKHUVWR([FOXVLYHO\%UHDVWIHHG" Reeder J. PNG Medical Journal, Scientific Editor. % August Tachedjian, G. Current HIV Research, "''*–now; The Open ì +DUP5HGXFWLRQWKH6KLIWLQJ3DUDGLJP, & September Microbiology Journal, "'')–now; International Journal of Virology, "''*–now. ì 3DWKZD\VWR,QWHUQDWLRQDO+HDOWK, " December Tannock, G. Journal of Med Virology "''!–now; Gene Vaccines and ì :RUOG$,'6'D\'HFHPEHU

Apostolopoulos, V. Australia Day Ambassador Address and Award Presentation. Apollo Bay, Australia. Crowe, S. Invited Judge, Medical and Healthcare Division, Du Pont Australia and New Zealand Innovation Awards, Sydney. Toole, M. World AIDS Day Dinner, December; HIV and AIDS in Asia – where to now? Myanmar.

page )# In appreciation: donations

$*&&,&&&+ Millard, J Bullen, P Glover, J Lush, M Robinson, I Amiet, JW Moore, J Butt, EM Gonshor, M MacDonald, RA Rodgers-Wilson, SJ Moss, RJ & GK Cairns, EJ Goodrich, RA & A Macindoe, A Rogers, DW $-&,&&* 0 $*&&,&&& Murphy, F Cameron, J Gray, YM MacKenzie, KW Rogers, JJ Anonymous Nelson, RE Cannon, M Hagger, M Mair, L Rowley, P Nicholls, P Canty, E Halabut Marek, I Saddington, AR $%&,&&* 0 $-&,&&& Nicholls, S Carroll, J Hall, J Mathison, GR Sanderson, JG Flower, MJ Parker, J Carvell, J Hall, MJ McDougall, M Sawyer, B Paterson, IH Cassidy, A Hamersfeld, A McIntosh, JA Schwab, D $-,&&* 0 $%&,&&& Roach, JA Castles, J Hannagan, C & P McLoughlin, EM Secomb, G Anonymous Roberts-Thomson, P Cattach, K Hannan, S Meredith, E Shearer, VN Anonymous Russell, M Cawthorne, ME Harbig, R Miller, GF Krongold, P Seelenmeyer, DM Chang, M Hargreaves, E & G Miller, RG Shoobridge, MPK Savage, J Semler, R Charleston, P Harris, GA Miller, SP Sime, H Xipell, E Sharpe, KE Charlwood, AC Harrison, L Miller, WH Slade, LJ Yeung, DC Stringer, J Chen, M Harvey, K & J Milne, J Slonim, M Sutton, A Cherry, C Hatch, K Moir, G Slutzkin, J $*,&&* 0 $-,&&& Taylor, RB Cochaud, L Heaviside, J Morgan, T Smart, P Alabaster, RL Tymms, AGM Collier, P Hegarty, VC Morrissey, M Smith, K Allen, D West, A Cousland, P Heitmann, HM Morsby, N Snell, B Anonymous Williams, EM Cowan, F Henderson, ME Morton, LJ Sparling, P & E Blain, RE Crabb, B Herring, ML Moss, LE Spicer, WJ & H Blair, GR $*&* 0 $-&& Crosby, FM Hewett, T Mulder, B Spry, M Bowman, MM Agnew, E Cubbins, JL Hewitt Lees, B Murray, GA & BA Stewart, C & H Cameron, E Aitken, C Davey, G Higgs, P Musgrave, PW Stewart, HB Cherry, E & D Albiston, M Davis, AC Hill, M Nissenbaum, I Stewart, ME Eisner, KR Allison, B Day, ES Hill, R Northend, R Stobart, RF Gantner, N Anderson, MJ de Pury, G Hives, A Northrop, R Strnad, H Gjergja, GS Andrew, M Dennis, P Hogarth, M Nossbaum, R Swain, E Goddard, BH Annand, AS Di Paola, G Hoitinga, EN Nuccio, A Swan, G Kilcullen, M Anonymous Dillon, E Holdsworth, S Oakley, C Syme, JHY Lacey, T Armstrong, EN Dinh, N Hone, RE O’Brien, H Phiddian, H Avery, M Dixon, T Hopkins, J O’Donnell, T Taylor, B Speedy, PM Awburn, V Dowse, B & M Hotton, G O’Halloran, L Taylor, HM Tabak, M & R Bailey, D Drury, JE Hoult, R O’Hara, V Thompson, K Taylor, AG Bailey, LJ Dunn, I Hyams, SH Page, MO Thompson, S & C Wightwick, I Bainbridge, IK Easton, BA & EM Jacka, P Parker, J Turnbull, J Bando, J Emmerson, JM Jackson, F Parnell, B & J Walters, RN & C $-&* 0 $*,&&& Barnes, P Enting, G Jackson, HM Paskos, DB Ward, N Ashcroft, RW Batten, T Fairlie, J Jacoby, R Pelling, W Weller, PH Beever, CJ Batters, P & S Fenner, F, AC CMG Janes, MR Pianko, I Westaway, NM Bourke, J Baulch, AP Fethers, B Jenkins, G Pilley, AB Whitehall, E Brooke, MD, OAM Beecher, D Ffrench, R Johnson, D & L Plunkett, JM Whitney, R Broome, EC Belcher, NC Fischer, M Keir, W Potter, M Wicks, WG Carnegie, L Bender, R Fitzwater, JM Kempson, PC Poulton, S Wilkinson, M Clark, JE & PJ Benjanuvatra, N Foo, T Kimpton, SF Probert, JKS Willis, PG Clarke, RJ Bernhard, WK Ford, D Kimpton, ZM Pryde, AD Wilson, CW Clarridge, F Berryman, N Fowler, EA Kirkpatrick, JN Punshon, KJ Wilson, G Crutch, R Best, J Francis, P Kovacs, J & J Ranken, JB Wilson, M Cumming, J Bishop, EW Franklin, JC Lander, JM Rathbone, P Wilson, MJ Druitt, BL Bland, IW Fung, W Law, J Ray, J Field, J Bockholt, RL Furneaux, C Lawry, B Reid, MC Wilson, R George, L Bouris, A Gabor, S Lazarus, LS Rice, T Wilson, WP Harrison, J Bracher, GHW Gibb, DDV Leitinger, J Riddell, P Wood, FE Heape, WF Bromley, J Gibson, JD Lemon, P Riddiford, ESR Woodside, J Heaton-Harris, D Brooke, DB Giles, J Lesser, EL Riley, GA Wright, C Jennings, M Brown, N Gilfedder, P Linsten, D & BM Roberts, J Yap, SH Kennan, H Brownless, MM Ginns, C Ludbrooke, M Roberts, M McCloskey, J Brownscombe, J Glascodine, BL Lukeis, RM Robertson, JM

page )* In appreciation: donations

ESTATES Harold Mitchell Foundation Federation Square Estate of Dimitra Dimopolous Ian Potter Foundation G.A.P. Adventures Estate of P Campbell Callaway Ivy H Thomas & Arthur A Thomas Trust ‘Go for your life’, Victorian State Government Estate of William Lawrence Anderson Janina and Bill Amiet Foundation Good Afternoon Web Design and Joe White Bequest Development CORPORATE GIFTS Joyce Adelaide Healey Chat Trust Fund Haystac Access Hardware Kel & Rosie Day Foundation KEEN Footwear Delta Sales Pty Ltd Kimberley Foundation Melbourne Camera Club Embelton Limited Lew Foundation Mitchell Communication Group Fleet Plant Hire Pty Ltd Lord Mayor’s Charitable Myer Joondalup Turf Farm Foundation Nova Ken Hands Agencies Pty Ltd Margaret Walkom Bequest Oxygène Branding and Communications Oxygène Branding and Communications Marian and EH Flack Trust Qmani SI Business on Collins Melbourne Community Foundation SecurePay Springwaters Pty Ltd Miller Foundation Sunday Herald Sun Via Architettura Pty Ltd Matsarol Foundation TEAMelbourne W Marshall & Associates Nancy E Pendergast Charitable Trust Fund National Heart Foundation of Australia SPONSORS AND PARTNERS FOR SCHOOLS AND ORGANISATIONS Percy Baxter Charitable Trust THE BRISBANE CITY ROMP All Souls Opportunity Shop Perpetual Foundation – Russell Foundation !',''' Steps Bentleigh RSL – Kilburn Sporting Section Medical Gift Fund ANZ Haileybury College – Aikman, Castlefield & Planet Wheeler Foundation Arnold Bloch Leibler Rendall Houses Robert Christie Foundation Brisbane City Council Methodist Ladies College Snowy Nominees Pty Ltd Brisbane Marketing Tattersall’s George Adams Foundation Channel ) TRUSTS AND FOUNDATIONS The Michael and Andrew Buxton Foundation Good Afternoon Web Design and ANZ Trustees Foundation – Wadham Family William Angliss Charitable Fund Development Gift Account Windermere Foundation Haystac ANZ Trustees Limited Heritage Building Society Bachrach Charitable Trust SUPPORTERS OF THE SIR ZELMAN COWEN Keen Footwear Bell Charitable Fund CANCER FOUNDATION Mitchell Communication Group Bradshaw Foundation Trust Lindsay Fox, AO Myer CASS Foundation Ltd Spotlight Charitable Trust Nova Drakensberg Trust ourbrisbane.com Equity Trustees SPONSORS AND PARTNERS FOR THE ‘GO Oxygène Branding and Communications Equity Trustees FOR YOUR LIFE’ MELBOURNE CITY ROMP Qmani Fonda Family Charitable Foundation ANZ SecurePay Gandel Charitable Trust Arnold Bloch Leibler TRANSLink Goldman Sachs JBWere Foundation Channel ) Harold and Cora Brennen Trust City of Melbourne

page )$ In appreciation: gifts in kind

BOSOM BUDDIES BREAST Hampers Only Scienceworks Museum CANCER FOUNDATION Happy Medium Photo Co. Shane Crawford !(CABS Harding Hardware Sharp Corporation of Australia Adman Odeh Harness Racing Victoria Shiseido Air Pacific Holeproof SKINS Akita IL VICOLO Courtyard Restaurant South Pacific Tyres Alastair Lucas J Lenders Southern Motors Alepat Taylor Jade Princess Restaurant Sports Entertainment Network Applied Climate Control Jamelissa Pty Ltd Sports Image Australia ARMA Jane Art & Design Stay Cool Heating and Airconditioning Austereo Jane Grant Stefano’s Australian Dealer Insurance Jewish Museum of Australia Strategic Interim Management Australian Diamond Company Joy Voice Pty Ltd Swann Insurance Australian Precision Technologies Pty Ltd K Taylor Target Australian Traffic Network Kagan Logistics Territory Discoveries Autobarn Kaye Jones & Ginia Lingerie The Boise Rouge Hotel Restaurant Avis Car Rental Kerry Anne’s Fine Arts The Breakers Apartments Surfers Paradise BACASH Kids Interior Design The Enchanted Maze Garden Barry Cutler Kingston Heath Golf Club The General Trader Beaconsfield Timber and Hardware Kwik Kopy Printing Centre North Melbourne The Heymanson Family Foundation Belgian Beer Café Eureka La Cacciatore Tiger Moth Joy Flights Bendigo Bank Lakelands Golf Club Tobin Brothers Bergerac French Cuisine Lybina Pty Ltd Toolangi Estate Berwick Village Travel and Cruise Matt Cutler Trevor West Formal Wear Bev Brock Max Kirwan Mazda Village Cinemas Bill Jane McLardy McShane Financial Services Woongarra Winery Bob Jane T-Marts Medicare Rosebud Xerox Business Centre Warrigal Body Physics Megabus Pty Ltd Yarrawonga Estate Wines Born Success Melbourne Observation Deck - Rialto Yiannis Tavern Breville Melbourne River Cruises Café AJA Melbourne Short Stay Apartments WORLD AIDS DAY CONCERT Calorex Heat Pumps Limited (UK) Melbourne Sky Dive Centre Alfred Chemist Cannings Outdoor Power Equipment Melbourne Tigers Bikram Yoga Fitzroy Capitol Caretaker Services Melbourne’s Cheapest Cars Cakes by Francesca Carlton Football Club Melway Publishing Eureka Skydeck Castricum Brothers Pty Ltd Miss World Australia Fitzroy Nursery Cell to Cell Mobile Phones Money Online Foodworks East Ivanhoe Channel & Moonah Links The Hon John Howard, AC Chateau Tahbilk National Sports Museum Limited KEEN Footwear Chris Judd New Age Arbor Products Lifestyle Portraits Cinema Haute Couture New Concept Car Sales L’Oréal Computer Initiatives Newmans Holidays Michaels Camera Museum Conley Luff Real Estate Nightingale Electrics Mighty Music Machine Contours Hawthorn Norm Beechey Musiiki Manjaro David Nutter Ford Nutrimetics Nandos Davies Collison Cave Oakfern Tree Care Pacific Brands Di and Geoff Double Paris Go Bistro Paladarr – Thai Restaurant Dynamite Cards, Design and Print Party’s Balloons Everything Parkview Hotel Eric Bana Penguin Group (Australia) Retro Café Fast Track Racing Peter Rowland Catering Werribee Open Range Zoo FCm Travel Solutions Pick Up Truck Pictures Zouki Catering Focus Creative Development Solutions Piper Alderman FOG Bar & Restaurant Plunkett Fowles Wines THOMAS HEYWOOD CONCERT Fruit Only Portsea Golf Club Thomas Heywood Fuji Xerox Puffing Billy Railway Simone O’Loughlin George Donikian Quality Hotel Mildura Grand Toorak Uniting Church GL Catering Revlon Glenmar Cottages REX BUSINESS BREAKFAST Glenmar Financial Services Rio Blake Dawson Glenmar Wines Roadshow Films Professor Tim Flannery Glenn Flowers Robert Piccoli Photography Lynne Haultain Global Ballooning Robert Taylor Zinc, Federation Square Goldman Sachs JBWere Roses Only Golf Australia Rotary Club of Berwick BURNET ORATION Grand Hyatt Melbourne Royal Doulton The Hon Justice Michael Kirby, AC H Hermann Save on Finance

page )) Our organisational structure

One of the major developments over the past year has been a degree the Centre for International Health, which, although substantial restructure of the Burnet’s scientific and public health pre-existing, now incorporates harm reduction into its infectious programs. These changes were made in response to a rapid disease programs. The Centres represent Burnet’s key areas of growth of the Institute, due in part, to the "''$ merger between research and public health strength, and are led by the Institute’s the Burnet and the Austin Research Institutes. most experienced and highly credentialed scientists.

The clarity of purpose and the focus on excellence and high Two new mechanisms have also been created to foster cross- quality outcomes that this new structure provides, lays institute activities and to promote attention to our central a solid foundation for the Institute’s future. A future that themes. The first is the formal recognition of crosscutting themes marries laboratory research, population studies, public health and the appointment of Burnet Principals to represent them. intervention and capacity building programs to address major The second approach to ensuring cross-institute thinking is health problems in Australia and in our region. Our special the creation of the Scientific Advisory Committee (SAC) which emphasis on the specific health needs of disadvantaged comprises Centre Heads and Principals together with the Director communities in Australia and overseas remains the central and Deputy Directors. platform of the Institute. While reform to the scientific leadership has been achieved with With these issues in mind, the Institute has been reorganised the restructure diagrammatically represented below, Burnet into a structure that is appropriate for the effective operation of Institute administration and corporate services will be reviewed an organisation of this scale and complexity. and overseen by the newly created position of Chief Operating Officer with the key purpose of ensuring that the Institute is The cornerstone of this restructure is the creation of four Centres supported in the most efficient and effective manner. of excellence. The Centres – Virology, Immunology, Population Health and International Health – are all new, including to some

Board Board Overseas offices Sub-Committees Alastair Lucas, Chair Burnet Asia Regional Office: Bangkok Burnet China (Tibet): Lhasa Burnet Indonesia: Bali, Lombok, Banda Aceh Director Burnet Lao PDR: Vientiane Brendan Crabb Institute Burnet Mozambique: Chimoio, Maputo Committees Deputy Directors Burnet Myanmar: Yangon Mark Hogarth & David Anderson Burnet Papua New Guinea: Port Moresby, Kokopo

OPERATIONS

Centre for Centre for Centre for Centre for COO Virology Immunology Population Health International Health Geoff Drenkhahn Head: Head: Co-Heads: Head: Suzanne Crowe Mark Hogarth Margaret Hellard Mike Toole & John Reeder CFO Peter Spiller STRATEGIC THEMES ì)DFLOLWLHV0DQDJHPHQW Business Development (Vaccines, Diagnostics & Therapeutics) – Principal: David Anderson Finance & Occupational Health Disease Prevention – Principal: Robert Power & Safety Education & Capacity Building – Principals: Steve Gerondakis & Marion Brown ì+XPDQ5HVRXUFHV Infectious Diseases – Principal: To be appointed ì,QWHOOHFWXDO3URSHUW\  Business Development ì,QIRUPDWLRQ7HFKQRORJ\ ì3XEOLF$İDLUV  Development ì5HVHDUFK$GPLQLVWUDWLRQ Office & Legal

page )% ,S[]SYGERWYTTSVXXLI&YVRIX-RWXMXYXI

;L][IRIIH]SYVLIPT 8]TIWSJ7YTTSVX

The Burnet Institute receives infrastructure funding from the (SREXMSRW government but this only covers a part of our total running costs. All donations over $" to the Burnet Institute are The remainder is made up of funds raised by the Burnet Institute, tax-deductible. competitive grants awarded to our scientists, and competitive contracts won by our public health professionals. &IUYIWXW The Burnet Institute bequest program continues, and as always Each year the generosity of the Australian public greatly assists we are extremely grateful to those individuals who have been kind us in our vital work. enough to remember the Burnet Institute in their Will.

Your contribution enables us to: Please be assured that your bequest, no matter what size or in ì 6WXG\WKHSUHYDOHQFHWUDQVPLVVLRQDQGLPSDFWRIVHULRXV what form, will make a real difference. Below is suggested wording diseases in the community should you wish to leave us a bequest: ì ,QLWLDWHQHZUHVHDUFKSURJUDPVLQWR+,9$,'6KHSDWLWLV$%& I bequeath the sum of $...... (or, part or all of residue of & E, measles, avian influenza, tuberculosis and malaria estate) to the Macfarlane Burnet Institute for Medical Research ì ,QYHVWLJDWHQHZZD\VRIWUHDWLQJDQGSUHYHQWLQJFDQFHUVVXFKDV and Public Health Ltd to be applied for the purposes of the breast, ovarian, prostate and lung cancer Burnet Institute (or as directed by the donor). ì $WWUDFWDQGWUDLQWKHEHVWSHUVRQQHOIURP$XVWUDOLDDQGDURXQG the world +MJXWSJ%WWIXWSV4VSTIVX] ì 3XUFKDVHVWDWHRIWKHDUWPHGLFDOUHVHDUFKHTXLSPHQW We welcome donors who donate property to the Burnet Institute while retaining its use during their lifetime. ì 'HVLJQLPSOHPHQWDQGHYDOXDWHSXEOLFKHDOWKSURJUDPVLQWKH Asia and Pacific regions and Africa 7GLSPEVWLMTW A number of scholarships for Institute staff are available for funding: travel, research scholarships or post graduate scholarships.

)RUYMVMIW 1EMPMRKEHHVIWWJSVEPPHSREXMSRWERHIRUYMVMIW If you require more details on any of the above suggestions, Macfarlane Burnet Institute for would like more information about the Burnet Institute Medical Research and Public Health Ltd or would like to take a tour of our facilities, please call our GPO Box ""%#, Melbourne, Victoria (''!, Australia Community Relations Officer on .'(0 &"%" ""&& or All cheques should be made payable to: Macfarlane Burnet visit www.burnet.edu.au. Institute for Medical Research and Public Health Ltd.

page )& Australia HEAD OFFICE %* Commercial Road, Melbourne, Victoria (''# Tel: + $! ( &"%" "!!! Fax: + $! ( &"%" "!'' Email: [email protected] www.burnet.edu.au A.B.N. #& '') (#& &%#

Overseas Offices The Burnet Institute has offices in Africa, South East Asia, the Pacific region and China (Tibet). For more information about our work overseas or to contact our international offices please email [email protected] or call us on + $! ( &"%" "!!!.

MOZAMBIQUE CHINA (TIBET) LAO PDR Maputo Baofa Hotel, No $ Hong Qi Road, Luangprabang Road, Praceta Tomà Ndude No "" Lhasa %*'''', TAR China Building '$,"A/'(, !st floor, Maputo Mozambique Ban Sihom, Vientiane, Lao PDR Chimoio FIJI Rua !$ de Junho, PO Box "()", MYANMAR ($' Chimoio/Manica, Mozambique Government Building, Suva, Fiji No ""$, #th Floor, ""$ Wizaya Plaza, THAILAND – BURNET INSTITUTE INDONESIA U Wisara Road, Bahan Township, ASIA REGIONAL OFFICE Bali Yangon, Myanmar Bangkok Jalan Raya Bypass Ngurah Rai No."%) United Center, Level #(, Sanur, %'""% Bali PAPUA NEW GUINEA ("( Silom Road, Lombok Port Moresby Bangrak, Bangkok !'*'', Thailand Jalan Swaramahardika IV No. "(B Bank South Pacific (BSP) Building Mataram %(!"! Level ", Tabari Place, Boroko, Port Moresby East New Britain PO Box !#*%, Kokopo Post Office, East New Britain

page %'